UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended February 28,November 30, 2023

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 000-55546

 

CLS HOLDINGS USA, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

45-1352286

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

1800516 S. Industrial Road Suite 100,4th Street, Las Vegas Nevada, 8910289101

(Address of principal executive offices) (Zip Code)

 

(416) 992-4539

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

N/A

N/A

N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☒

Emerging growth company ☐

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

 

State the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date: 72,518,142104,543,141 shares of $0.0001 par value common stock outstanding as of April 5, 2023.January 8, 2024.

 

 

 

 

CLS HOLDINGS USA, INC.

 

FORM 10-Q

Quarterly Period Ended February 28,November 30, 2023

 

TABLE OF CONTENTS

 

 

Page

 

 

FORWARD-LOOKING STATEMENTS

3

 

 

AVAILABLE INFORMATION

3

 

 

PART I. FINANCIAL INFORMATION

 

Item 1.

Financial Statements

4

 

Condensed Consolidated Balance Sheets as of February 28, 2022November 30, 2023 (Unaudited) and May 31, 20222023 (audited)

4

 

Condensed Consolidated Statements of Operations for the Three and NineSix Months ended February 28,November 30, 2023 and 2022 (Unaudited)

5

 

Condensed Consolidated Statements of Stockholders’ Deficit for the NineSix Months ended February 28,November 30, 2023 and 2022 (Unaudited)

6

 

Condensed Consolidated Statements of Cash Flows for the NineSix Months ended February 28,November 30, 2023 and 2022 (Unaudited)

7

 

Notes to the Consolidated Financial Statements (Unaudited)

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

33

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

5044

Item 4.

Controls and Procedures

5044

 

 

PART II. OTHER INFORMATION

 

Item 1.

Legal Proceedings

5145

Item 1A.

Risk Factors

5145

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

5145

Item 3.

Defaults Upon Senior Securities

5145

Item 4.

Mine Safety Disclosures

5145

Item 5.

Other Information

5145

Item 6.

Exhibits

5145

 

 

SIGNATURES

5246

 

 

 

 

 

EXPLANATORY NOTE

 

Unless otherwise noted, references in this report to “CLS Holdings USA, Inc.,” the “Company,” “we,” “our” or “us” means CLS Holdings USA, Inc. and its subsidiaries.

 

FORWARD-LOOKING STATEMENTS

 

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to, among other things, the impact of the COVID-19 virus on our business, the results of our initiatives to retain our employees and strengthen our relationships with our customers and community, the effect of our initiatives to expand market share and achieve growth, the expected development of our business and joint ventures, results of operations and financial performance, liquidity, working capital and capital requirements, the effects of the additional dilution on our common stock that may occur as a result of the amendments to our convertible debentures, and anticipated future events. The continued spread of COVID-19 could have, and in some cases already has had, an adverse impact on our business, operations and financial results, including through disruptions in our cultivation and processing activities, supply chains and sales channels, and retail dispensary operations as well as a deterioration of general economic conditions including a possible national or global recession. These forward-looking statements also relate to our ability to obtain debt or equity capital on reasonable terms, or at all, to finance our operations, and to identify, finance and close potential acquisitions and joint ventures, whether our joint venture partner will make its capital contribution, our ability to comply with applicable cannabis-related regulations and obtain regulatory approvals, market acceptance of our services and product offerings, our ability to protect and commercialize our intellectual property, our ability to use net operating losses to offset certain cannabis-related tax liabilities and our ability to grow our wholesale and processing businesses and joint ventures. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology.

 

These forward-looking statements are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry’s) actual results, levels of activity or performance to be materially different from any expected future results, levels of activity or performance expressed or implied by these forward-looking statements.

 

We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered together with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

 

AVAILABLE INFORMATION

 

We file certain reports under the Securities Exchange Act of 1934 (the “Exchange Act”). Such filings include annual and quarterly reports. The reports we file with the Securities and Exchange Commission (“SEC”) are available on the SEC’s website at (http://www.sec.gov).

 

3

 

Item 1. Financial Statements.

 

CLS HOLDINGS USA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

February 28,

  

May 31,

  

November 30,

  

May 31,

 
 

2023

  

2022

  

2023

  

2023

 
 

(unaudited)

      

(unaudited)

     

ASSETS

                

Current assets

                

Cash and cash equivalents

 $887,812  $2,551,859  $1,759,671  $998,421 

Accounts Receivable

  718,382   618,227   933,011   431,204 

Inventory

  4,349,463   3,417,602   2,641,853   3,012,932 

Prepaid expenses and other current assets

  183,742   295,869   70,188   148,953 

Total current assets

  6,139,399   6,883,557   5,404,723   4,591,510 
                

Property, plant and equipment, net of accumulated depreciation of $2,703,369 and $2,073,449

  3,853,979   4,342,434 

Property, plant and equipment, net of accumulated depreciation of $3,004,396 and $2,687,146

  2,640,075   2,913,077 

Right of use assets, operating leases

  1,938,198   2,154,517   1,680,052   1,641,577 

Intangible assets, net of accumulated amortization of $559,502 and $473,308

  1,104,091   1,190,285 

Intangible assets, net of accumulated amortization of $164,406 and $588,217

  193,587   209,088 

Goodwill

  557,896   557,896   557,896   557,896 

Investments

  590,137   469,575 

Other assets

  198,000   229,500   215,675   157,500 
                

Total assets

 $14,381,700  $15,827,764  $10,692,008  $10,070,648 
                

LIABILITIES AND STOCKHOLDERS' DEFICIT

                

Current liabilities

                

Accounts payable and accrued liabilities

 $3,057,520  $2,317,898   3,724,530  $2,728,572 

Accrued interest, current

  478,472   419,206   850,692   634,594 

Loans payable

  949,902   1,013,073   -   471,380 

Lease liability - operating leases, current

  362,917   309,597   423,925   374,004 

Lease liability - financing leases, current

  80,818   71,813   94,469   86,887 

Taxes Payable

  6,083,810   4,531,782   7,686,021   6,752,457 

Notes payable

  1,250,000   -   2,022,916   1,439,584 

Convertible notes payable - current

  4,003,052   19,448,821 

Convertible notes payable - current, net of discount of $206,400 and $0

  3,749,760   2,952,160 

Convertible notes payable, related party - current

  900,891   900,891 
                

Total current liabilities

  16,266,491   28,112,190   19,453,204   16,340,529 
                

Noncurrent liabilities

                

Lease liability - operating leases, non-current

  1,643,224   1,893,810   1,538,974   1,544,283 

Lease liability - financing leases, non-current

  215,389   277,180   150,767   200,280 

Notes payable, non-current, net of discount of $1,097,113 and $1,681,434

  2,027,887   2,693,566 

Convertible Notes payable, non-current

  3,753,050   - 

Notes payable, non-current, net of discount of $576,903 and $1,291,887

  1,298,097   2,033,077 

Convertible notes payable, non-current

  2,852,159   2,852,159 

Convertible notes payable, related party - non-current

  900,892   900,892 
                

Total Liabilities

  23,906,041   32,976,746   26,194,093   23,871,220 
                

Commitments and contingencies

  -   -   -   - 
                

Stockholder's deficit

                

Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued

  -   -   -   - 

Common stock, $0.0001 par value; 187,500,000 shares authorized at February 28, 2023 and May 31, 2022; 72,518,142 and 32,052,021 shares issued and outstanding at February 28, 2023 and May 31, 2022

  7,253   3,206 

Common stock, $0.0001 par value; 350,000,000 shares authorized at November 30, 2023 and 187,500,000 at May 31, 2023; 72,543,141 shares issued and outstanding at November 30, 2023 and May 31, 2023

  7,255   7,255 

Additional paid-in capital

  96,142,740   77,954,748   96,210,184   96,147,784 

Common stock subscribed

  70,092   70,092   65,702   65,702 

Accumulated deficit

  (105,343,764

)

  (95,079,817

)

  (110,645,559)  (108,879,446)

Stockholder's deficit attributable to CLS Holdings, Inc.

  (9,123,679

)

  (17,051,771

)

  (14,362,418)  (12,658,705)

Non-controlling interest

  (400,662

)

  (97,211

)

  (1,139,667)  (1,141,867)

Total stockholder's deficit

  (9,524,341

)

  (17,148,982

)

  (15,502,085)  (13,800,572)
                

Total liabilities and stockholders' deficit

 $14,381,700  $15,827,764  $10,692,008  $10,070,648 

 

See accompanying notes to these financial statements.

 

4

 

CLS HOLDINGS USA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

For the Three

  

For the Three

  

For the Nine

  

For the Nine

  

For the Three

  

For the Three

  

For the Six

  

For the Six

 
 

Months Ended

  

Months Ended

  

Months Ended

  

Months Ended

  

Months Ended

  

Months Ended

  

Months Ended

  

Months Ended

 
 

February 28, 2023

  

February 28, 2022

  

February 28, 2023

  

February 28, 2022

  

November 30, 2023

  

November 30, 2022

  

November 30, 2023

  

November 30, 2022

 
                                

Revenue

 $5,437,302  $5,588,266  $17,556,406  $16,502,978  $5,197,214  $6,074,177  $10,311,741  $12,119,104 

Cost of goods sold

  2,418,609   2,701,160   8,493,072   7,989,817   3,025,595   3,148,940   5,866,196   6,293,357 

Gross margin

  3,018,693   2,887,106   9,063,334   8,513,161   2,171,619   2,925,237   4,445,545   5,825,747 
                                
                

Selling, general and administrative expenses

  2,860,914   3,492,691   9,568,775   9,440,918   2,606,918   3,428,352   5,336,818   6,488,967 

Total operating expenses

  2,860,914   3,492,691   9,568,775   9,440,918   2,606,918   3,428,352   5,336,818   6,488,967 
                                

Operating income (loss)

  157,779   (605,585

)

  (505,441

)

  (927,757

)

  (435,299)  (503,115)  (891,273)  (663,220)
                                

Other (income) expense:

                                

Interest expense, net

  648,957   589,692   2,024,532   1,416,164   410,841   608,905   868,313   1,375,575 

Employee retention tax credit income

  -   -   (924,862)  - 

Loss on extinguishment of debt

  -   -   6,659,359   -   -   6,659,359       6,659,359 

Loss on equity investment

  22,476   -   176,587   - 

(Gain) Loss on equity investment

  -   (80,319)  -   154,111 

Gain on settlement of debt

  -   -   (2,384

)

  -   -   (2,384)  -   (2,384)

Gain on settlement of accounts payable

  -   -   (4,375)  - 

Gain on settlement of note receivable

  -   (522,246

)

  (348,165

)

  (2,218,574

)

  -   -   -   (348,165)

Total other expense

  671,433   67,446   8,509,929   (802,410

)

Total other (income) expense

  410,841   7,185,561   (60,924)  7,838,496 
                                

Loss before income taxes

  (513,654

)

  (673,031

)

  (9,015,370

)

  (125,347

)

Income (Loss) before income taxes

  (846,140)  (7,688,676)  (830,349)  (8,501,716)
                                

Provision for income tax

  (516,252

)

  (324,265

)

  (1,552,028

)

  (793,322

)

  (456,040)  (516,691)  (933,564)  (1,035,776)
                                

Net loss

  (1,029,906

)

  (997,296

)

  (10,567,398

)

  (918,669

)

  (1,302,180)  (8,205,367)  (1,763,913)  (9,537,492)
                                

Non-controlling interest

  130,391   5,028   303,451   8,528   (92)  (10,587)  (2,200)  173,060 
                                

Net loss attributable to CLS Holdings, Inc.

 $(899,515

)

 $(992,268

)

 $(10,263,947

)

 $(910,141

)

 $(1,302,272) $(8,215,954) $(1,766,113) $(9,364,432)
                                

Net loss per share – basic

 $(0.01

)

 $(0.03

)

 $(0.18

)

 $(0.03

)

Net loss per share - basic

 $(0.02) $(0.12) $(0.02) $(0.20)
                                

Net loss per share – diluted

 $(0.01

)

 $(0.03

)

 $(0.18

)

 $(0.03

)

Net loss per share - diluted

 $(0.02) $(0.12) $(0.02) $(0.20)
                                

Weighted average shares outstanding – basic

  72,518,141   32,039,520   56,657,781   32,024,938 

Weighted average shares outstanding - basic

  72,543,141   65,847,863   72,543,141   48,857,603 
                                

Weighted average shares outstanding – diluted

  72,518,141   32,039,520   56,657,781   32,024,938 

Weighted average shares outstanding - diluted

  72,543,141   65,847,863   72,543,141   48,857,603 

 

See accompanying notes to these financial statements.

 

5

 

CLS HOLDINGS USA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT

(Unaudited)

 

          

Additional

                 
  

Common Stock

  

Paid In

  

Stock

  

Accumulated

  

Non-controlling

     
  

Amount

  

Value

  

Capital

  

Payable

  

Deficit

�� 

interest

  

Total

 
                             

Balance, May 31, 2021

  31,805,354  $3,182  $77,570,934  $65,702  $(92,736,638

)

 $-  $(15,096,820

)

                             

Common stock issued for conversion of debt

  234,167   23   280,977   -   -   -   281,000 

Common stock to be issue to employee

  -   -   -   8,780   -   -   8,780 

Fair value of warrants issued with debenture offering

  -   -   98,448   -   -   -   98,448 

Net loss for the nine months ended February 28, 2022

  -   -   -   -   (910,141

)

  (8,528

)

  (918,669

)

Balance, February 28, 2022

  32,039,521  $3,205  $77,950,359  $74,482  $(93,646,779

)

 $(8,528

)

 $(15,627,261

)

                             

Balance, May 31, 2022

  32,052,021  $3,206  $77,954,748  $70,092  $(95,079,817

)

 $(97,211

)

 $(17,148,982

)

                             

Common stock issued for the conversion of debt

  40,465,546   4,047   11,528,633   -   -   -   11,532,680 

Rounding for reverse split

  575   -   -   -   -   -   - 

Loss on extinguishment of debt

  -   -   6,659,359   -   -   -   6,659,359 

Net loss for the nine months ended February 28, 2023

  -   -   -   -   (10,263,947

)

  (303,451

)

  (10,567,398

)

Balance, February 28, 2023

  72,518,142  $7,253  $96,142,740  $70,092  $(105,343,764

)

 $(400,662

)

 $(9,524,341

)

          

Additional

                 
  

Common Stock

  

Paid In

  

Stock

  

Accumulated

  

Non-controlling

     
  

Amount

  

Value

  

Capital

  

Payable

  

Deficit

  

Interest

  

Total

 
                             

Balance, August 31, 2022

  32,052,021  $3,206  $77,954,748  $70,092  $(96,228,295) $(280,858) $(18,481,107)

Common stock issued for the conversion of debt

  40,465,544   4,047   11,528,633   -   -   -   11,532,680 

Rounding for reverse split

  576   -   -   -   -   -   - 

Loss on extinguishment of debt

  -   -   6,659,359   -   -   -   6,659,359 

Loss for the three months ended November 30, 2022

  -   -   -   -   (8,215,954)  10,587   (8,205,367)

Balance, November 30, 2022

  72,518,141  $7,253  $96,142,740  $70,092  $(104,444,249) $(270,271) $(8,494,435)
                             

Balance, May 31, 2022

  32,052,021   3,206   77,954,748   70,092   (95,079,817)  (97,211)  (17,148,982)

Common stock issued for the conversion of debt

  40,465,544   4,047   11,528,633   -   -   -   11,532,680 

Rounding for reverse split

  576   -   -   -   -   -   - 

Loss on extinguishment of debt

  -   -   6,659,359   -   -   -   6,659,359 

Loss for the six months ended November 30, 2022

  -   -   -   -   (9,364,432)  (173,060)  (9,537,492)

Balance, November 30, 2022

  72,518,141  $7,253  $96,142,740  $70,092  $(104,444,249) $(270,271) $(8,494,435)
                             
                             

Balance, August 31, 2023

  72,543,141  $7,255  $96,147,784  $65,702  $(109,343,287) $(1,139,759) $(14,262,305)

Discount on convertible notes payable

  -   -   62,400   -   -   -   62,400 

Loss for the three months ended November 30, 2023

  -   -   -   -   (1,302,272)  92   (1,302,180)

Balance, November 30, 2023

  72,543,141  $7,255  $96,210,184  $65,702  $(110,645,559) $(1,139,667) $(15,502,085)
                             

Balance, May 31, 2023

  72,543,141   7,255   96,147,784   65,702   (108,879,446)  (1,141,867)  (13,800,572)

Discount on convertible notes payable

  -   -   62,400   -   -   -   62,400 

Loss for the six months ended November 30, 2023

  -   -   -   -   (1,766,113)  2,200   (1,763,913)

Balance, November 30, 2023

  72,543,141  $7,255  $96,210,184  $65,702  $(110,645,559) $(1,139,667) $(15,502,085)

 

See accompanying notes to these financial statements.

 

6

 

CLS HOLDINGS USA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

For the Nine

  

For the Nine

  

For the Six

  

For the Six

 
 

Months Ended

  

Months Ended

  

Months Ended

  

Months Ended

 
 

February 28, 2023

  

February 28, 2022

  

November 30, 2023

  

November 30, 2022

 

CASH FLOWS FROM OPERATING ACTIVITIES

                

Net loss

 $(10,567,398

)

 $(918,669

)

 $(1,763,913) $(9,537,492)

Adjustments to reconcile net loss to net cash used in operating activities:

                

Loss on equity investment

  176,587   -   -   154,111 

Amortization of debt discounts and fees

  597,821   132,735   335,999   394,110 

Loss on extinguishment of debt

  -   6,659,359 

Gain on settlement of note receivable

  (348,165

)

  (2,218,574

)

  -   (348,165)

Fair value of shares vested by officers

  -   8,780 

Loss on extinguishment of debt

  6,659,359   - 

Gain on debt settlement

  (2,384

)

  - 

Gain on settlement of debt

  -   (2,384)

Gain on settlement of accounts payable

  (4,375)  - 

Depreciation and amortization expense

  716,114   535,361   332,748   477,193 

Bad debt expense

  (4,437

)

  2,329   393   - 

Changes in assets and liabilities:

                

Accounts receivable

  (95,718

)

  (160,067

)

  (502,200)  (387,057)

Prepaid expenses and other current assets

  143,627   (6,385

)

  78,765   29,621 

Inventory

  (931,861

)

  (1,114,556

)

  371,079   (1,458,054)

Right of use asset

  263,064   240,736   186,424   174,067 

Accounts payable and accrued expenses

  739,622   266,417   1,000,336   982,209 

Accrued interest

  327,169   95,050   216,098   166,547 

Funds held in escrow

  -   - 

Deferred tax liability

  1,552,028   793,322   933,564   1,035,776 

Operating lease liability

  (244,011

)

  (213,827

)

  (180,287)  (161,153)

Net cash used in operating activities

  (1,018,583

)

  (2,557,348

)

  1,004,631   (1,821,312)
                

CASH FLOWS FROM INVESTING ACTIVITIES

                

Payments to purchase property, plant and equipment

  (141,465

)

  (165,875

)

  (44,248)  (138,476)

Payment for construction security deposit

  (58,175)  - 

Investment in Quinn River

  (297,149

)

  -   -   (242,957)

Cash paid for construction deposit on grow facility

  -   (82,500

)

Proceeds from collection of note receivable

  348,165   2,218,574   -   348,165 

Net cash provided by (used in) investing activities

  (90,449

)

  1,970,199   (102,423)  (33,268)
                

CASH FLOWS FROM FINANCING ACTIVITIES

                

Proceeds from loan payable

  1,717,115   808,800   960,000   1,717,115 

Repayments of loan payable

  (1,869,344

)

  (566,339

)

  (481,943)  (1,371,309)

Proceeds from debenture offering

  -   2,500,000 

Principal payments on notes payable

  -   (365,991

)

  (477,084)  - 

Repayments on convertible debt

  (350,000

)

  -   (100,000)  (200,000)

Principal payments on finance leases

  (52,786

)

  -   (41,931)  (34,493)

Net cash provided by (used in) financing activities

  (555,015

)

  2,376,470 

Net cash used in financing activities

  (140,958)  111,313 
                

Net increase (decrease) in cash and cash equivalents

  (1,664,047

)

  1,789,321 

Net decrease in cash and cash equivalents

  761,250   (1,743,267)
                

Cash and cash equivalents at beginning of period

  2,551,859   1,665,263   998,421   2,551,859 
                

Cash and cash equivalents at end of period

 $887,812  $3,454,584  $1,759,671  $808,592 
                

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

                

Interest paid

 $1,188,397  $1,221,173  $338,529  $894,838 

Income taxes paid

 $-  $-  $-  $- 
                

NONCASH INVESTING AND FINANCING ACTIVITIES:

                

Shares issued for conversion of notes payable

 $11,532,680  $281,000  $-  $11,532,680 
        

Capitalized interest

 $-  $3,283 

Discount on convertible notes payable

 $62,400  $- 

Initial ROU asset and lease liability - operating

 $46,745  $229,412  $224,899  $46,475 

Original issue discount on notes payable

 $-  $1,875,000 

Fair value of warrants issued with debenture offering

 $-  $98,448 

Capitalized Interest

 $3,283  $- 

 

See accompanying notes to these financial statements.

 

7

 

CLS HOLDINGS USA, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

February 28,November 30, 2023

(Unaudited)

 

Note 11: Nature of Business and Significant Accounting Policies

 

Basis of Presentation

 

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in US dollars. The Company has adopted a fiscal year end of May 31st.

 

Principals of Consolidation

 

The accompanying consolidated financial statements include the accounts of CLS Holdings USA, Inc., and; its direct and indirect wholly owned operating subsidiaries, CLS Nevada, Inc., (“CLS Nevada”), CLS Labs, Inc. (“CLS Labs”), CLS Labs Colorado, Inc. (“CLS Colorado”), CLS Massachusetts, Inc. (“CLS Massachusetts”), and Alternative Solutions, LLC (“Alternative Solutions”); and wholly owned inactive subsidiaries CLS Labs Colorado, Inc. (“CLS Colorado”) and CLS Massachusetts, Inc. (“CLS Massachusetts”). Alternative Solutions is the sole owner of the following three entities (collectively, the “Oasis LLCs”): Serenity Wellness Center, LLC (“Serenity Wellness Center”); Serenity Wellness Products, LLC (“Serenity Wellness Products”); and Serenity Wellness Growers, LLC (“Serenity Wellness Growers”). The accompanying consolidated financial statements also include the accounts of CLS CBD in which the company owns a 95% ownership interest and a variable interest entity, Kealii Okamalu, LLC (“Kealii Okamalu”), in which the Company owns a 50% interest. All material intercompany transactions have been eliminated upon consolidation of these entities.

 

Nature of Business

 

CLS Holdings USA, Inc. (the “Company”) was originally incorporated as Adelt Design, Inc. (“Adelt”) on March 31, 2011 to manufacture and market carpet binding art. Production and marketing of carpet binding art never commenced.

 

On November 12, 2014, CLS Labs acquired 2,500,000 shares, or 55.6%,We currently operate a retail marijuana dispensary within walking distance to the Las Vegas Strip and a small-scale cultivation facility, as well as a product manufacturing facility and a wholesale distribution operation in North Las Vegas. The vertically integrated business model drives strong margins to the bottom line on a portion of sales at the dispensary.

Our retail dispensary is a single location operation in Nevada and occupies over 5,000 square feet. This location, which is easily accessible by tourists, is currently open 19.5 hours per day for walk-in service. Curbside and in store express pick up is available between the hours of 8:00am and 12:00am. Oasis dispensary also delivers cannabis to residents between the hours of 8:00 AM and 10:00 PM. The central location provides logistical convenience for delivery to all parts of the outstanding shares of common stock of Adelt from its founder, Larry Adelt. On that date, Jeffrey Binder, the Chairman, President and Chief Executive Officer of CLS Labs, was appointed Chairman, President and Chief Executive Officer of the Company. On November 20, 2014, Adelt adopted amended and restated articles of incorporation, thereby changing its name to CLS Holdings USA, Inc. Effective December 10, 2014, the Company effected a reverse stock split of its issued and outstanding common stock at a ratio of 1-for-0.625 (the “Reverse Split”), wherein 0.625 shares of the Company’s common stock were issued in exchange for each share of common stock issued and outstanding. As a result, 1,562,500 shares of the Company’s common stock were issued to CLS Labs in exchange for the 2,500,000 shares that it owned by virtue of the above-referenced purchase from Larry Adelt.Las Vegas valley.

 

On April 29, 2015, the Company, CLS Labs and CLS Merger Inc., a Nevada corporation and wholly owned subsidiary of CLS Holdings (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) and completed a merger, whereby CLS Merger Inc. merged with and into CLS Labs, with CLS Labs remaining as the surviving entity (the “Merger”). Upon the consummation of the Merger, the shares of the common stock of CLS Holdings owned by CLS Labs were extinguished and the former stockholders of CLS Labs were issued an aggregate of 3,750,000 shares of common stock in CLS Holdings in exchange for their shares of common stock in CLS Labs. As a result of the Merger, the Company acquired the business of CLS Labs and abandoned its previous business.

The Company has been issued a U.S. patent with respect to Its proprietary method of extracting cannabinoids from cannabis plants and converting the resulting cannabinoid extracts into concentrates such as oils, waxes, edibles and shatter. These concentrates may be ingested in a number of ways, including through vaporization via electronic cigarettes (“e-cigarettes”), and used for a variety of pharmaceutical and other purposes. The Company has not commercialized its patented proprietary process or otherwise earned any revenues from it. The Company is currently exploring ways inOur wholesale operations, which to generate revenue from the patent or the sale of the patent.

On December 4, 2017, the Company and Alternative Solutions, entered into a Membership Interest Purchase Agreement (the “Acquisition Agreement”), as amended, for the Company to acquire the Oasis LLCs from Alternative Solutions. Pursuant to the Acquisition Agreement, the Company initially contemplated acquiring all of the membership interests in the Oasis LLCs from Alternative Solutions. Just prior to closing, the parties agreed that the Company would instead acquire all of the membership interests in Alternative Solutions, the parent of the Oasis LLCs, from its members, and the membership interests in the Oasis LLCs owned by members other than Alternative Solutions.

8

Pursuant to the Acquisition Agreement, the Company paid a non-refundable deposit of $250,000 upon signing, which was followed by an additional payment of $1,800,000 paid in February 2018, for an initial 10% of each of the Oasis LLCs. At that time, the Company applied for regulatory approval to own an interest in the Oasis LLCs, which approval was received. On June 27, 2018, the Company made the payments to indirectly acquire the remaining 90% of the Oasis LLCs, which were equal to cash in the amount of $5,995,543, a $4.0 million promissory note due in December 2019 (the “Oasis Note”), and 5,514,706 shares of its common stock (the “Purchase Price Shares”) (collectively, the “Closing Consideration”). The cash payment of $5,995,543 was less than the $6,200,000 payment originally contemplated because the Company assumed an additional $204,457 of liabilities. The Company used the proceeds of a Canadian private securities offering to fund the cash portion of the Closing Consideration. The Company then applied for regulatory approval to own the additional 90% in membership interests in the Oasis LLCs, which it received on December 12, 2018. The Company received final regulatory approval to own its interest in the Oasis LLCs through Alternative Solutions under the revised structure of the transaction on April 26, 2022.

On October 31, 2018, the Company, CLS Massachusetts, Inc., a Massachusetts corporation and a wholly-owned subsidiary of the Company (“CLS Massachusetts”), and In Good Health, Inc., a Massachusetts corporation (“IGH”), entered into an Option Agreement (the “IGH Option Agreement”). Under the terms of the IGH Option Agreement, CLS Massachusetts had an exclusive option to acquire all of the outstanding capital stock of IGH (the “IGH Option”) during the period beginning on the earlier of the date that is one year after the effective date of the conversion and December 1, 2019 and ending on the date that was 60 days after such date. If CLS Massachusetts exercised the IGH Option, the Company, a wholly-owned subsidiary of the Company and IGH would enter into a merger agreement (the form of which had been agreed to by the parties) (the “IGH Merger Agreement”). At the effective time of the merger contemplated by the IGH Merger Agreement, CLS Massachusetts would pay a purchase price of $47,500,000, subject to reduction as provided in the IGH Merger Agreement, payable as follows: $35 million in cash, $7.5 million in the form of a five-year promissory note, and $5 million in the form of restricted common stock of the Company, plus $2.5 million as consideration for a non-competition agreement with IGH’s President, payable in the form of a five-year promissory note. IGH and certain IGH stockholders holding sufficient aggregate voting power to approve the transactions contemplated by the IGH Merger Agreement entered into agreements pursuant to which such stockholders, among other things, agreed to vote in favor of such transactions. On October 31, 2018, as consideration for the IGH Option, the Company made a loan to IGH, in the principal amount of $5,000,000, subject to the terms and conditions set forth in that certain loan agreement, dated as of October 31, 2018 between IGH as the borrower and the Company as the lender. The loan was evidenced by a secured promissory note of IGH, which bore interest at the rate of 6% per annum and was to mature on October 31, 2021. To secure the obligations of IGH to the Company under the loan agreement and the promissory note, the Company and IGH entered into a security agreement dated as of October 31, 2018, pursuant to which IGH granted to the Company a first priority lien on and security interest in all personal property of IGH. If the Company did not exercise the Option on or prior to the date that was 30 days following the end of the option period, the loan amount would be reduced to $2,500,000 as a break-up fee, subject to certain exceptions set forth in the IGH Option Agreement. On August 26, 2019, the parties amended the IGH Option Agreement to, among other things, delay closing until January 2020. By letter agreement dated January 31, 2020, the Company, CLS Massachusetts and IGH extended the IGH Option Agreement to February 4, 2020. On February 4, 2020, CLS Massachusetts exercised the IGH Option and IGH subsequently asserted that CLS Massachusetts’ exercise was invalid. By letter dated February 26, 2020, the Company informed IGH that as a result of its breaches of the IGH Option, which remained uncured, an event of default had occurred under the IGH Note. The Company advised IGH that it was electing to cause the IGH Note to bear interest at the default rate of 15% per annum effective February 26, 2020 and to accelerate all amounts due under the IGH Note. On February 27, 2020, IGH informed CLS Massachusetts that it did not plan to make further payments under the IGH Note on the theory that the break-up excused additional payments. This dispute, including whether IGH breached the IGH Option and whether CLS was entitled to collect default interest, was in litigation. During the twelve months ended May 31, 2021, the Company impaired the remaining amounts due under the IGH Note in the amount of $2,498,706, which included $2,497,884 in principal and $822 in accrued interest.

On June 14, 2021, the parties to the IGH lawsuit entered into a confidential settlement agreement to resolve the action and a secured promissory note dated and executed by IGH in favor of the Company effective on June 11, 2021 (the “IGH Settlement Note”). Pursuant to the IGH Settlement Note, IGH paid the Company $3,000,000, $500,000 of which was paid on or before June 21, 2021. A second payment of $500,000 was paid on or before July 12, 2021. The remaining $2,000,000 and accrued interest was paid in 12 equal monthly installments beginning on August 12, 2021, pursuant to the terms of the promissory note. During the year ended May 31, 2022, the Company received $2,740,820 under the IGH Settlement Note, which included $2,666,670 in principal and $74,150 in accrued interest. During the nine months ended February 28, 2023, the Company received $348,165 under the IGH Settlement Note, which included $333,333 in principal and $14,832 in accrued interest. As of February 28, 2023, the IGH Settlement Note had been repaid in full. The Company records amounts paid under the IGH Settlement Note as gains when payments are received.

9

On October 20, 2021, the Company entered into a management services agreement (the “Quinn River Joint Venture Agreement”) through its 50% owned subsidiary, Kealii Okamalu, LLC (“Kealii Okamalu”), with CSI Health MCD LLC (“CSI”) and a commission established by the authority of the Tribal Council of the Fort McDermitt Paiute and Shoshone Tribe (the “Tribe”). The purpose of the Quinn River Joint Venture Agreement is to establish a business (the “Quinn River Joint Venture”) to grow, cultivate, process and sell cannabis and related products. The Quinn River Joint Venture Agreement has a term of 10 years plus a 10-year renewal term from the date the first cannabis crop produced is harvested and sold; the first sale of product produced by the Quinn River Joint Venture occurred on September 22, 2022. Pursuant to the Quinn River Joint Venture Agreement, Kealii Okamalu leasesoccupies approximately 20-30 acres of the Tribe’s land located along the Quinn River at a cost of $3,500 per quarter and managed the design, finance and construction of a cannabis cultivation facility on such tribal lands (the “Cultivation Facility”). Kealii Okamalu also manages the ongoing operations of the Cultivation Facility and related business, including, but not limited to, cultivation of cannabis crops, personnel staffing, product packaging, testing, marketing and sales. Packaged products are branded as “Quinn River Farms.” The Company has provided up to 10,000 square feet of a 22,000 square foot warehouse, space atbegan sales to third parties in August 2017 and completed construction and received a certificate of occupancy for its Las Vegasstate-of-the-art extraction facility in December of 2019. We have made sales to over 85 external customers as of November 30, 2023. Our existing product line includes vaporizers, tinctures, ethanol produced THC distillate, and live and cured hydrocarbon concentrates. At present, the City Trees cultivation facility only grows breeding stock to preserve valuable genetics and does not offer its crops for the Quinn River product and has preferred vendor status, including the right to purchase cannabis flower and the business’s cannabis trim at favorable prices. Kealii Okamalu is expected to ultimately contribute $6 million towards the construction of the Cultivation Facility and the working capitalsale or processing. As a result, all raw materials for the Quinn River Joint Venture. This amount will be repaidmanufacturing are sourced from a portion of the net income of the Quinn River Joint Venture otherwise payable to CSI and the Tribe at the rate of $750,000 per quarter for eight quarters. After repayment to Kealii Okamalu of the initial investment amount of approximately $6 million, Kealii Okamalu will receive one-third of the net profits of the Quinn River Joint Venture. At February 28, 2023, Kealii Okamalu has contributed approximately $2.95 million to the Quinn River Joint Venture.third parties.

 

On January 4, 2018, the former Attorney General, Jeff Sessions, rescinded the memorandum issued by former Deputy Attorney General James Cole on August 29, 2013 (as amended on February 14, 2014, the “Cole Memo”), the Cole Banking Memorandum, and all other related Obama-era DOJ cannabis enforcement guidance. While the rescission did not change federal law, as the Cole Memo and other DOJ guidance documents were not themselves laws, the rescission removed the DOJ’s formal policy that state-regulated cannabis businesses in compliance with the Cole Memo guidelines should not be a prosecutorial priority. Notably, former Attorney General Sessions’ rescission of the Cole Memo has not affected the status of the U.S. Department of the Treasury’s Financial Crimes Enforcement Network (“FinCEN”) memorandum issued by the Department of Treasury, which remains in effect. This memorandum outlines Bank Secrecy Act-compliant pathways for financial institutions to service state-sanctioned cannabis businesses, which echoed the enforcement priorities outlined in the Cole Memo. In addition to his rescission of the Cole Memo, Attorney General Sessions issued a one-page memorandum known as the “Sessions Memorandum”. The Sessions Memorandum explains the DOJ’s rationale for rescinding all past DOJ cannabis enforcement guidance, claiming that Obama-era enforcement policies are “unnecessary” due to existing general enforcement guidance adopted in the 1980s, in chapter 9.27.230 of the U.A. Attorneys’ Manual (“USAM”). The USAM enforcement priorities, like those of the Cole Memo, are based on the use of the federal government’s limited resources and include “law enforcement priorities set by the Attorney General,” the “seriousness” of the alleged crimes, the “deterrent effect of criminal prosecution,” and “the cumulative impact of particular crimes on the community.” Although the Sessions Memorandum emphasizes that cannabis is a federally illegal Schedule I controlled substance, it does not otherwise instruct U.S. Attorneys to consider the prosecution of cannabis-related offenses a DOJ priority, and in practice, most U.S. Attorneys have not changed their prosecutorial approach to date. However, due to the lack of specific direction in the Sessions Memorandum as to the priority federal prosecutors should ascribe to such cannabis activities, there can be no assurance that the federal government will not seek to prosecute cases involving cannabis businesses that are otherwise compliant with state law.

William Barr served as United States Attorney General from February 14, 2019 to December 23, 2020. The DOJ under Mr. Barr did not take a formal position on federal enforcement of laws relating to cannabis. On March 11, 2021, United States President Biden’s nominee, Merrick Garland was sworn in as the U.S. Attorney General. During his campaign, President Biden stated a policy goal to decriminalize possession of cannabis at the federal level, but he has not publicly supported the full legalization of cannabis. It is unclear what impact, if any, this administration will have on U.S. federal government enforcement policy on cannabis. There is no guarantee that the position of the Department of Justice will change.

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Reclassification

Certain reclassifications, not affecting previously reported net income or cash flows, have been made to the previously issued financial statements to conform to the current period presentation.

108

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. The Company had cash and cash equivalents of $887,812$1,759,671 and $2,551,859$998,421 as of February 28,November 30, 2023 and May 31, 2022,2023, respectively. The reductionincrease in cash and cash equivalents is largely a functionwas primarily the result of the financial demands of the Tribal Joint Venturecash received from notes payable issued during this nine monththe period.

 

Allowance for Doubtful Accounts

 

The Company generates the majority of its revenues and corresponding accounts receivable from the sale of cannabis, and cannabis related products. The Company evaluates the collectability of its accounts receivable considering a combination of factors. In circumstances where it is aware of a specific customer’s inability to meet its financial obligations to it, the Company records a specific reserve for bad debts against amounts due in order to reduce the net recognized receivable to the amount it reasonably believes will be collected. For all other customers, the Company recognizes reserves for bad debts based on past write-off experience and the length of time the receivables are past due. The Company had ($4,437)$93 and $2,329$0 of bad debt expense (recoveries) during the three months ended February 28,November 30, 2023 and 2022, respectively. The Company had ($4,437)$393 and $2,329$0 of bad debt (recoveries) expense during the ninesix months ended February 28,November 30, 2023 and 2022, respectively.

 

Inventory

 

Inventories are stated at the lower of cost or market. Cost is determined using a perpetual inventory system whereby costs are determined by acquisition costs of individual items included in inventory. Market is determined based on net realizable value. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable values. Our cannabis products consist of prepackaged purchased goods ready for resale, along with produced tinctures and extracts developed under our production license.

 

Property, Plant and Equipment

 

Property and equipment is recorded at the lower of cost or estimated net recoverable amount, and is depreciated using the straight-line method over its estimated useful life. Property acquired in a business combination is recorded at estimated initial fair value. Property, plant, and equipment are depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based upon the following life expectancy:

 

Years

Office equipment

3 to 5

Furniture & fixtures

3 to 7

Machinery & equipment

3 to 10

Leasehold improvements

Term of lease

 

Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation are eliminated and any resulting gain or loss is reflected in operations.

 

Long-Lived Assets

 

The Company reviews its property and equipment and any identifiable intangibles including goodwill for impairment on an annual basis utilizing the guidance set forth in the Statement of Financial Accounting Standards Board ASC 350 “Intangibles – Goodwill and Other” and ASC 360 “Property, Plant, and Equipment.” At February 28, 2022,November 30, 2023, the net carrying value of goodwill on the Company’s balance sheet remained at $557,896.

 

Employee Retention Tax Credit

Under the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), the Company was eligible for a refundable employee retention tax credit (the “ERTC”), subject to certain criteria. As ERTCs are not within the scope of ASC 740, Income Taxes, the Company has chosen to account for the ERTCs by analogizing to the International Standard IAS 20, Accounting/or Government Grants and Disclosure of Government Assistance (“IAS 20”). In accordance with IAS 20, an entity recognizes government grants only when there is reasonable assurance that the entity will comply with the conditions attached to them and the grants will be received. During the three and six months ended November 30, 2023, the Company received an aggregate of $0 and $924,862, which was accounted for as other income on the Company’s condensed consolidated statement of operations.

9

Comprehensive Income

 

ASC 220-10-15 “Reporting Comprehensive Income,” establishes standards for reporting and displaying of comprehensive income, its components and accumulated balances. Comprehensive income is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220-10-15 requires that all items that are required to be recognized under current accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The Company does not have any items of comprehensive income in any of the periods presented.

 

11

Non-Controlling Interests

 

The Company reports “non-controlling interest in subsidiary” as a component of equity, separate from parent’s equity, on the Consolidated Balance Sheets. In addition, the Company’s Consolidated Statements of Operations includes “net income (loss) attributable to non-controlling interest.” During the three months ended February 28,November 30, 2023 and 2022, the Company reported a non-controlling interest in the amount of $130,391($92) and $5,028,($10,587), respectively, representing 50% of the (income) lossincome (loss) incurred by its partially owned subsidiary, Kealii Okamalu. During the ninesix months ended February 28,November 30, 2023 and 2022, the Company reported a non-controlling interest in the amount of $303,451($2,200) and $8,528,$173,060, respectively, representing 50% of the lossincome (loss) incurred by its partially owned subsidiary, Kealii Okamalu.

 

Variable Interest Entities

 

The Company’s consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and variable interest entities (“VIE”), where the Company is the primary beneficiary under the provisions of ASC 810, Consolidation (“ASC 810”). A VIE must be consolidated by its primary beneficiary when, along with its affiliates and agents, the primary beneficiary has both: (i) the power to direct the activities that most significantly impact the VIE’s economic performance; and (ii) the obligation to absorb losses or the right to receive the benefits of the VIE that could potentially be significant to the VIE. The Company reconsiders whether an entity is still a VIE only upon certain triggering events and continually assesses its consolidated VIEs to determine if it continues to be the primary beneficiary. See “Note 3 – Joint Ventures” for additional information on the Company’s VIEs.Note 3.

 

Concentrations of Credit Risk

 

The Company maintains its cash in bank deposit accounts and other accounts, the balances of which at times may be uninsured or exceed federally insured limits. From time to time, some of the Company’s funds are also held by escrow agents; these funds may not be federally insured. The Company continually monitors its banking relationships and consequently has not experienced any losses in such accounts.

 

Advertising and Marketing Costs

 

All costs associated with advertising and promoting products are expensed as incurred. Total recognized advertising and marketing expenses were $119,327$103,448 and $299,154$306,189 for the three months ended February 28,November 30, 2023 and 2022, respectively. Total recognized advertising and marketing expenses were $517,452$227,059 and $1,087,692$398,125 for the ninesix months ended February 28,November 30, 2023 and 2022, respectively.

 

Research and Development

 

Research and development expenses are charged to operations as incurred. The Company incurred research and development costs of $196$431 and $1,800$683 for the three months ended February 28,November 30, 2023 and 2022, respectively. The Company incurred research and development costs of $879$1,887 and $12,308$683 for the ninesix months ended February 28,November 30, 2023 and 2022, respectively.

 

Fair Value of Financial Instruments

 

Pursuant to Accounting Standards Codification (“ASC”) No. 825–- Financial Instruments, the Company is required to estimate the fair value of all financial instruments included on its balance sheets. The carrying amounts of the Company’s cash and cash equivalents, notes receivable, convertible notes payable, accounts payable and accrued expenses, none of which is held for trading, approximate their estimated fair values due to the short-term maturities of those financial instruments.

 

10

A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:

 

Level 1–- Quoted prices in active markets for identical assets or liabilities.

 

Level 2–- Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.

 

Level 3–- Significant unobservable inputs that cannot be corroborated by market data.

 

12

Revenue Recognition

 

Revenue from the sale of cannabis products is recognized by Oasis at the point of sale, at which time payment is received, the product is delivered, and the Company’s performance obligation has been met. Management estimates an allowance for sales returns.

 

The Company also recognizes revenue from Serenity Wellness Products LLC and Serenity Wellness Growers LLC, d/b/a City Trees (“City Trees”). City Trees recognizes revenue from the sale of the following cannabis products and services to licensed dispensaries, cultivators and distributors within the State of Nevada:

 

 

Premium organic medical cannabis sold wholesale to licensed retailers

 

 

 

 

Recreational marijuana cannabis products sold wholesale to licensed distributors and retailers

 

 

 

 

Extraction products such as oils and waxes derived from in-house cannabis production

 

 

 

 

Processing and extraction services for licensed medical cannabis cultivators in Nevada

 

 

 

 

High quality cannabis strains in the form of vegetative cuttings for sale to licensed medical cannabis cultivators in Nevada

 

Effective June 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from commercial sales of products and licensing agreements by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied.

 

Disaggregation of Revenue

 

The following table represents a disaggregation of revenue for the three and ninesix months ended February 28,November 30, 2023 and 2022:

 

 

For the Three

  

For the Three

  

For the Three

  

For the Three

 
 

Months Ended

  

Months Ended

  

Months Ended

  

Months Ended

 
 

February 28, 2023

  

February 28, 2022

  

November 30, 2023

  

November 30, 2022

 

Cannabis Dispensary

  3,592,261   3,333,229   3,104,064   3,792,804 

Cannabis Production

  1,908,014   2,255,037   2,093,150   2,281,373 
 $5,437,302  $5,588,266  $5,197,214  $6,074,177 

  

For the Six

  

For the Six

 
  

Months Ended

  

Months Ended

 
  

November 30, 2023

  

November 30, 2022

 

Cannabis Dispensary

  6,412,606   7,681,361 

Cannabis Production

  3,899,135   4,437,743 
  $10,311,741  $12,119,104 

 

  

For the Nine

  

For the Nine

 
  

Months Ended

  

Months Ended

 
  

February 28, 2023

  

February 28, 2022

 

Cannabis Dispensary

  11,210,622   10,670,203 

Cannabis Production

  6,345,784   5,832,775 
  $17,556,406  $16,502,978 
11

 

Basic and Diluted Earnings or Loss Per Share

 

Basic net earnings per share is based on the weighted average number of shares outstanding during the period, while fully diluted net earnings per share is based on the weighted average number of shares of common stock and potentially dilutive securities assumed to be outstanding during the period using the treasury stock method. Potentially dilutive securities consist of options and warrants to purchase common stock, and convertible debt. Basic and diluted net loss per share are computed based on the weighted average number of shares of common stock outstanding during the period. At February 28,November 30, 2023 and 2022, the Company had the following potentially dilutive instruments outstanding: at February 28,November 30, 2023, a total of 42,679,70273,715,637 shares (21,181,449 issuable upon the exercise of warrants, 52,516,688 issuable upon the conversion of convertible notes payable and accrued interest, and 17,500 in stock to be issued); and at November 30, 2022, a total of 42,653,147 shares (21,962,699 issuable upon the exercise of warrants, 256,550 issuable upon the exercise of unit warrants, 20,430,45320,403,898 issuable upon the conversion of convertible notes payable and accrued interest, and 30,000 in stock to be issued); and at February 28, 2022, a total of 19,062,846 shares (1,836,574 issuable upon the exercise of warrants, 760,323 issuable upon the exercise of unit warrants, 16,423,449 issuable upon the conversion of convertible notes payable and accrued interest, and 42,500 in stock to be issued).

 

13

The Company uses the treasury stock method to calculate the impact of outstanding stock options and warrants. Stock options and warrants for which the exercise price exceeds the average market price over the period have an anti-dilutive effect on earnings per common share and, accordingly, are excluded from the calculations.

 

A net loss causes all outstanding stock options and warrants to be anti-dilutive. As a result, the basic and dilutive losses per common share are the same for the three and ninesix months ended February 28, 2023.November 30, 2023 and 2022. For the three and ninesix months ended February 28,November 30, 2023 and 2022, the Company excluded from the calculation of fully diluted earnings per share the following instruments which were anti-dilutive: shares issuable pursuant to the conversion of notes payable and accrued interest, shares issuable pursuant to the exercise of warrants, and 30,000 shares of common stock issuable.

 

Income Taxes

 

The Company accounts for income taxes under the asset and liability method in accordance with ASC 740. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

 

Section 280E of the Internal Revenue Code, as amended, prohibits businesses from deducting certain expenses associated with trafficking controlled substances (within the meaning of Schedule I and II of the Controlled Substances Act). The IRS has invoked Section 280E in tax audits against various cannabis businesses in the U.S. that are permitted under applicable state laws. Although the IRS has issued a clarification allowing the deduction of certain expenses, the bulk of operating costs and general administrative costs are generally not permitted to be deducted. The operations of certain of the Company’s subsidiaries are subject to Section 280E. This results in permanent differences between ordinary and necessary business expenses deemed non-deductible under IRC Section 280E. Therefore, the effective tax rate can be highly variable and may not necessarily correlate with pre-tax income or loss.

 

Commitments and Contingencies

 

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims brought to such legal counsel’s attention as well as the perceived merits of the amount of relief sought or expected to be sought therein.

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

 

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.

 

12

Recent Accounting Pronouncements

 

There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

 

Note 22: Going Concern

 

As shown in the accompanying financial statements, the Company has incurred net losses from operations resulting in an accumulated deficit of $105,343,764$110,645,559 as of February 28,November 30, 2023. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with revenues from operations. The Company has reported positive cash generated from operating incomeactivities for the third quarter oflast four quarters, including the three months ended November 30, 2023.

 

14

Note 3 3: Joint Venture and Options Transaction

 

In Good Health

On October 31, 2018, the Company, CLS Massachusetts, and IGH, which converted to a for-profit corporation on November 6, 2018 (the “Conversion”), entered into the IGH Option Agreement. Under the terms of the IGH Option Agreement, CLS Massachusetts had an exclusive option to acquire all of the outstanding capital stock of IGH (the “IGH Option”) during the period beginning on the earlier of the date that was one year after the effective date of the Conversion and December 1, 2019 and ending on the date that was 60 days after such date (the “Option Period”). If CLS Massachusetts exercised the IGH Option, the Company, a wholly-owned subsidiary of the Company and IGH would enter into the IGH Merger Agreement (the form of which had been agreed to by the parties). At the effective time of the merger contemplated by the IGH Merger Agreement, CLS Massachusetts would pay a purchase price of $47,500,000, subject to reduction as provided in the IGH Merger Agreement, payable as follows: $35 million in cash, $7.5 million in the form of a five-year promissory note, and $5 million in the form of restricted common stock of the Company, plus $2.5 million as consideration for a non-competition agreement with IGH’s President, payable in the form of a five-year promissory note. IGH and certain IGH stockholders holding sufficient aggregate voting power to approve the transactions contemplated by the IGH Merger Agreement entered into agreements pursuant to which such stockholders, among other things, agreed to vote in favor of such transactions.

On October 31, 2018, as consideration for the IGH Option, the Company made a loan to IGH (the “IGH Loan”), in the principal amount of $5,000,000 (the “IGH Loan Amount”), subject to the terms and conditions set forth in that certain Loan Agreement, dated as of October 31, 2018 between IGH as the borrower and the Company as the lender (the “IGH Loan Agreement”). The IGH Loan was evidenced by a secured promissory note of IGH (the “IGH Note”), which bore interest at the rate of 6% per annum and was scheduled to mature on October 31, 2021. The Company recorded interest income in the amounts of $149,972 and $296,450 on the IGH Loan during the twelve months ended May 31, 2021 and 2020, respectively. On March 1, 2020, the Company capitalized interest in the amount of $399,453 into the principal amount due. During the years ended May 31, 2021 and 2020, the Company capitalized interest in the amount of $0 and $399,453, respectively, on the IGH Note. During the year ended May 31, 2021, the Company received payments on the IGH Note in the amount of $1,696,765. The Company applied these payments as follows; $1,544,291 as a repayment of principal and $152,473 as a repayment of accrued interest. During the year ended May 31, 2020, the Company received payments on the IGH Note in the amount of $1,425,000. The Company applied these payments as follows; $1,357,278 as a repayment of principal and $67,722 as a repayment of accrued interest. To secure the obligations of IGH to the Company under the IGH Loan Agreement and the IGH Note, the Company and IGH entered into a Security Agreement dated as of October 31, 2018 (the “IGH Security Agreement”), pursuant to which IGH granted to the Company a first priority lien on and security interest in all personal property of IGH. If the Company did not exercise the IGH Option on or prior to the date that was 30 days following the end of the Option Period, the IGH Loan Amount would be reduced to $2,500,000 as a break-up fee (the “Break-Up Fee”), except in the event of a Purchase Exception (as defined in the IGH Option Agreement), in which case the Break-Up Fee would not apply and there would be no reduction to the Loan Amount. On August 26, 2019, the parties amended the IGH Option to, among other things, extend the Option Period and delay closing until January 2020. By letter agreement dated January 31, 2020, the Company, CLS Massachusetts and IGH extended the IGH Option Agreement to February 4, 2020. On February 4, 2020, CLS Massachusetts exercised the IGH Option and IGH subsequently asserted that CLS Massachusetts’ exercise was invalid. By letter dated February 26, 2020, the Company informed IGH that as a result of its breaches of the IGH Option, which remained uncured, an event of default had occurred under the IGH Note. The Company advised IGH that it was electing to cause the IGH Note to bear interest at the default rate of 15% per annum effective February 26, 2020 and to accelerate all amounts due under the IGH Note. On February 27, 2020, IGH informed CLS Massachusetts that it did not plan to make further payments under the IGH Note on the theory that the Break-Up Fee excused additional payments. This dispute, including whether IGH breached the IGH Option and whether CLS was entitled to collect default interest, was in litigation. During the twelve months ended May 31, 2021, the Company impaired the remaining amounts due under the IGH Note in the amount of $2,498,706, which included $2,497,884 in principal and $822 in accrued interest.

On June 14, 2021, the parties to the IGH lawsuit entered into a confidential settlement agreement to resolve the action and the IGH Settlement Note. Pursuant to the IGH Settlement Note, IGH paid the Company $3,000,000, $500,000 of which was paid on or before June 21, 2021. A second payment of $500,000 was paid on or before July 12, 2021. The remaining $2,000,000 and accrued interest was paid in 12 equal monthly installments beginning on August 12, 2021, pursuant to the terms of the promissory note. During the year ended May 31, 2022, the Company received $2,740,820 under the IGH Settlement Note, which included $2,666,670 in principal and $74,150 in accrued interest. During the nine months ended February 28, 2023, the Company received $348,165 under the IGH Settlement Note, which included $333,333 in principal and $14,832 in accrued interest. As of February 28, 2023, the IGH Settlement Note had been repaid in full. The Company records amounts paid under the IGH Settlement Note as gains when payments are received.

15

Quinn River Joint Venture

On October 20, 2021, the Company entered into a management services agreement (the “Quinn River Joint Venture Agreement”) through its 50% owned subsidiary, Kealii Okamalu, with CSI Health MCD LLC (“CSI”) and a commission established by the authority of the Tribal Council of the Fort McDermitt Paiute and Shoshone Tribe (“Tribe”). The purpose of the Quinn River Joint Venture Agreement iswas to establish a business (the “Quinn River Joint Venture”) to grow, cultivate, process, and sell cannabis and related products. The Quinn River Joint Venture Agreement hashad an initial term of 10 years plus a 10 year10-year renewal option from the date the first cannabis crop produced is harvested and sold. Pursuant to the Quinn River Joint Venture Agreement, Kealii Okamalu is expected to eventually leaseleased approximately 20-305-10 acres of the Tribe’s land located along the Quinn River at a cost of $3,500 per quarter. Additionally, pursuant to the terms of the Quinn River Joint Venture Agreement, Kealii Okamalu hasquarter and managed the design, finance and construction of a cannabis cultivation facility on such tribal lands (“the Cultivation Facility”). Kealii Okamalu also managesmanaged the ongoing operations of the Cultivation Facility and related business, including, but not limited to, the cultivation of cannabis crops, personnel staffing, product packaging, testing, marketing and sales. Packaged products arewere branded as “Quinn River Farms.” The Company will provide up toprovided 10,000 square feet of warehouse space at its Las Vegas facility for the Quinn River Joint Venture product, and hashad preferred vendor status including the right to purchase cannabis flower and the business’s cannabis trim at favorable prices. Kealii Okamalu is expectedwas required to contribute up to $6 million (the “Invested Amount”) towards the construction of the Cultivation Facility and the working capital for the Quinn River Joint Venture. This amount willwas to be repaid from the portion of the net profits of the Quinn River Joint Venture otherwise payable to CSI and the Tribe at the rate of $750,000 per quarter for eight quarters. After repayment of the Invested Amount, Kealii Okamalu willwas to receive one-third of the net profits of the Quinn River Joint Venture.Venture after being repaid its initial contribution.

 

The Company is the manager of and holds a 50% ownership interest in Kealii Okamalu. Kealii Okamalu is a VIE which the Company consolidates. The Quinn River Joint Venture is not a legal entity but rather a business operated by Kealii Okamalu. The Company uses the equity method of accounting to record one-third of the profit or loss generated by the Quinn River Joint Venture, which accrues to Kealii Okamalu. Since the Company is a 50% owner of Kealii Okamalu, 50% of the profit or loss of Kealii Okamalu is recorded as minority interest in the Company’s statement of operations.

 

During the year ended May 31, 2022, Kealii Okamalu made cash investments in the aggregate amount of $581,714 in the Quinn River Joint Venture. The Company also purchased $949,939 of fixed assets for use by the Quinn River Joint Venture which are on the balance sheet of Kealii Okamalu. During the year ended May 31, 2022, the Quinn River Joint Venture recorded a loss in the amount of $336,416. One-third of this amount, or $112,139, was charged to the financial statements of Kealii Okamalu and recorded as a loss on equity investment in the Company’s financial statements for the year ended May 31, 2022, reducing the Company’s equity investment in the Quinn River Joint Venture from $581,714 to $469,575 at May 31, 2022.

 

During the nine monthsyear ended February 28,May 31, 2023, Kealii Okamalu made cash investments in the aggregate amount of $1,249,273$304,145 in the Quinn River Joint Venture; this amount was reduced by $952,125 representing the value of inventory transferred from the Quinn River Joint Venture to the Company. The Company also purchased $84,327 of fixed assets for use by the Quinn River Joint Venture which are on the balance sheet of Kealii Okamalu.Venture. During the nine monthsyear ended February 28,May 31, 2023, the Quinn River Joint Venture recorded a loss in the amount of $529,761.$536,022. One-third of this amount, or $176,587,$178,674, was charged to the financial statements of Kealii Okamalu and recorded as a loss on equity investment in the Company’s financial statements for the nine monthsyear ended February 28,May 31, 2023. The Company additional cash investments, less the loss on the joint venture for the year ended May 31, 2023 resulted in a net increase in the Company’s net equity investment in the Quinn River Joint Venture from $496,575 to $595,046 at May 31, 2023. There was $590,137no additional investment made in the Quinn River Joint Venture during the six months ended November 30, 2023.

13

The Company’s partner in Kealii Okamalu LLC has defaulted on the LLC Operating Agreement and the Quinn River Joint Venture Agreement by failing to make any of its required $3 million capital contribution. As a result of the default by the Company’s partner in Kealii Okamalu LLC, the Tribal Council has formally terminated the Quinn River Joint Venture Agreement. Prior to the termination, the Company removed all of its assets from the tribal land and all of the assets owned by Kealii Okamalu. Although the Company and the Tribal Council have worked over the last few months to explore a new 50/50 partnership with the Tribe, the Company has elected not to continue to pursue an agreement since the economic benefits of doing so are negligible, at February 28, 2023.best, in the current market. The Company does not believe it is likely to recover its investment in Kealii Okamalu and has recorded an impairment charge in the amount of $1,590,742 against the following assets during the year ended May 31, 2023:

Deposits and prepaid expenses

 $33,000 

Fixed assets

  756,808 

Right of use assets

  205,888 

Equity investment in Quinn River

  595,046 

Total impairment

 $1,590,742 

Following the impairment charge the net book value of the Company’s investment in Kealii Okamalu and the Quinn River Joint Venture at November 30, 2023 is $0.

 

Note 44: Accounts Receivable

 

Accounts receivable was $718,382$933,011 and $618,227$431,204 at February 28,November 30, 2023 and May 31, 2022,2023, respectively. The Company had bad debt expense (recoveries) of ($4,437)$93 and $2,329$0 during the three months ended February 28,November 30, 2023 and 2022. The Company had bad debt (recoveries) expense of ($4,437)$393 and $2,329$0 during the ninesix months ended February 28,November 30, 2023 and 2022. No allowance for doubtful accounts was necessary during the three and nine months ended February 28,November 30, 2023 and 2022.

 

Note 55: Inventory

 

Inventory, consisting of material, overhead, labor, and manufacturing overhead, is stated at the lower of cost (first-in, first-out) or market, and consists of the following:

 

 

February 28,

  

May 31,

  

November 30,

  

May 31,

 
 

2023

  

2022

  

2023

  

2023

 

Raw materials

 $487,489  $297,563  $435,777  $399,728 

Finished goods

  3,861,974   3,120,039   2,206,076   2,613,204 

Total

 $4,349,463  $3,417,602  $2,641,853  $3,012,932 

 

16

Raw materials consist of cannabis plants and the materials that are used in our production process prior to being tested and packaged for consumption. Finished goods consist of pre-packaged materials previously purchased from other licensed cultivators and our manufactured edibles and extracts.

 

Note 66: Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets consisted of the following at February 28,November 30, 2023 and May 31, 2022:2023:

 

 

February 28,

  

May 31,

  

November 30,

  

May 31,

 
 

2023

  

2022

  

2023

  

2023

 

Deposits

 $-   2,016 

Prepaid expenses

  183,742   293,853   70,188   147,953 

Employee receivable

  -   1,000 

Total

 $183,742  $295,869  $70,188  $148,953 

 

Deposits consist of amounts paid in advance for the acquisition of property and equipment. Prepaid expenses consist primarily of (i) annual license fees charged by the State of Nevada; these fees are paid in advance(ii) insurance costs; (iii) supplies; (iv) rent; and amortized over the one-year term of the licenses.(v) board fees.

 

Note 7 Notes Receivable

14

 

IGHNote 7: Note Receivable

 

On October 31, 2018, the Company loaned $5,000,000 to In Good Health, Inc. (“IGH”) in connection with an option to purchase transaction (see note 4 for details), the Company loaned $5,000,000 pursuant to the IGH Note to IGH.(the “IGH Option”).

 

By letter dated February 26, 2020, the Company informed IGH that as a result of its breaches of the IGH Option, which remained uncured, an event of default had occurred under the IGH Note. The Company advised IGH that it was electing to cause the IGH Note to bear interest at the default rate of 15% per annum effective February 26, 2020 and to accelerate all amounts due under the Note. This dispute, including whether IGH breached the IGH Option and whether CLS was entitled to collect default interest, was in litigation.

 

On June 14, 2021, the parties to the IGH lawsuit entered into a confidential settlement agreement to resolve the action and the IGH Settlement Note. Pursuant to the IGH Settlement Note, IGH paid the Company $3,000,000, $500,000 of which was paid on or before June 21, 2021. A second payment of $500,000 was paid on or before July 12, 2021. The remaining $2,000,000 and accrued interest was paid in 12 equal monthly installments beginning on August 12, 2021, pursuant to the terms of the promissory note. During the year ended May 31, 2022, the Company received $2,740,820 under the IGH Settlement Note, which included $2,666,670 in principal and $74,150 in accrued interest. During the ninesix months ended February 28, 2023,November 30, 2022, the Company received $348,165 under the IGH Settlement Note, which included $333,333 in principal and $14,832 in accrued interest. As of February 28,May 31, 2023, the IGH Settlement Note had been repaid in full. The Company records amounts paid under the IGH Settlement Note as gains when payments are received.The Company recorded the amount of $348,165 as a gain on settlement of note receivable during the three months ended August 31, 2022.

 

Note 8 8: Property, Plant and Equipment

 

Property, plant and equipment consisted of the following at February 28,November 30, 2023 and May 31, 2022:2023:

 

 

February 28,

2023

  

May 31,

2022

  

November 30,

2023

  

May 31,

2023

 

Office equipment

 $136,476  $132,859  $158,151  $148,243 

Furniture and fixtures

  148,358   148,358   148,358   148,358 

Machinery & Equipment

  2,561,290   2,447,715   2,426,798   2,392,458 

Leasehold improvements

  3,711,224   3,686,951   2,911,164   2,911,164 

Less: accumulated depreciation

  (2,703,369

)

  (2,073,449

)

  (3,004,396

)

  (2,687,146

)

Property, plant, and equipment, net

 $3,853,979  $4,342,434  $2,640,075  $2,913,077 

 

The Company made payments in the amounts of $141,465$44,248 and $165,875$138,476 for property and equipment during the ninesix months ended February 28,November 30, 2023 and May 31, 2022, respectively.

 

Depreciation expense totaled $210,187$158,497 and $150,883$208,190 for the three months ended February 28,November 30, 2023 and 2022, respectively. Depreciation expense totaled $629,920$317,250 and $449,189$208,190 for the ninesix months ended February 28,November 30, 2023 and 2022, respectively.

 

17

Note 9 9: Right of Use Assets and Liabilities Operating Leases

 

The Company has operating leases for offices and warehouses. The Company’s leases have remaining lease terms of 1 year to 10.5 years, some of which include options to extend.

 

The Company’s lease expense for the three months ended February 28,November 30, 2023 and 2022 was entirely comprised of operating leases and amounted to $82,858$123,408 and $73,874,$124,388, respectively. The Company’s lease expense for the ninesix months ended February 28,November 30, 2023 and 2022 was entirely comprised of operating leases and amounted to $244,021$123,408 and $323,218,$124,388, respectively.

The Company’s right of use (“ROU”) asset amortization for the three months ended February 28,November 30, 2023 and 2022 was $88,997$89,736 and $82,479,$86,749, respectively. The Company’s right of use (“ROU”)ROU asset amortization for the threesix months ended February 28,November 30, 2023 and 2022 was $216,319$186,424 and $240,736,$174,067, respectively. The difference between the lease expense and the associated ROU asset amortization consists of interest.

 

The Company has recorded total right of use assets of $4,159,621$4,384,520 and liabilities in the amount of $4,116,221$4,297,720 through February 28, 2022. During the nine months ended February 28, 2023, the Company entered into an agreement to extend the lease term of its property located at 1718 Industrial Road from August 31, 2022 to August 31, 2024, resulting in an increase in right of use assets and lease liabilities in the amount of $46,745.November 30, 2023.

 

On May 17, 2022, pursuant to the Quinn River Joint Venture Agreement (see note 4 for details), the Company, through CLS Nevada, Inc., entered into an agreement (the “Quinn River Lease”) to use approximately 20 acres

15

 

Right of use assets – operating leases are summarized below:

 

 

February 28,

2023

  

November 30,

2023

 

Amount at inception of leases

 $4,159,621  $4,384,520 

Amount amortized

  (2,221,423

)

  (2,498,580

)

Balance – February 28, 2023

 $1,938,198 

Prior Period Impairment of Quinn River Lease

  (205,888

)

Balance – November 30, 2023

 $1,680,052 

 

Operating lease liabilities are summarized below:

 

Amount at inception of leases

 $4,116,221  $4,297,720 

Amount amortized

  (2,110,080

)

  (2,334,821

)

Balance – February 28, 2023

 $2,006,141 

Balance – November 30, 2023

 $1,962,899 

 

Warehouse and offices

 $1,722,874  $1,751,609 

Land

  208,599   205,888 

Office equipment

  6,725   5,402 

Balance – February 28, 2023

 $1,938,198 

Balance – November 30, 2023

 $1,962,899 
        
        

Lease liability

 $2,006,141  $1,962,899 

Less: current portion

  (362,917

)

  (423,925

)

Lease liability, non-current

 $1,643,224  $1,538,974 

 

Maturity analysis under these lease agreements is as follows:

 

Twelve months ended February 28, 2024

 $524,554 

Twelve months ended February 28, 2025

  523,265 

Twelve months ended February 28, 2026

  526,358 

Twelve months ended February 28, 2027

  226,296 

Twelve months ended February 28, 2028

  230,641 

Thereafter

  568,775 

Total

 $2,599,889 

Less: Present value discount

  (593,748

)

Lease liability

 $2,006,141 

Twelve months ended November 30, 2024

 $608,650 

Twelve months ended November 30, 2025

  586,042 

Twelve months ended November 30, 2026

  366,582 

Twelve months ended November 30, 2027

  296,306 

Twelve months ended November 30, 2028

  291,933 

Thereafter

  391,713 

Total

 $2,541,226 

Less: Present value discount

  (578,327

)

Lease liability

 $1,962,899 

 

18

Note 10 10: Intangible Assets

 

Intangible assets consisted of the following at February 28,November 30, 2023 and May 31, 2022:2023:

  

November 30, 2023

 
      

Accumulated

         
  

Gross

  

Amortization

  

Impairment

  

Net

 

License & Customer Relations

 $110,000  $(29,792

)

  -  $80,208 

Tradenames - Trademarks

  222,000   (120,250

)

  -   101,750 

Domain Names

  25,993   (14,364

)

  -   11,629 

Total

 $357,993  $(164,406

)

  -  $193,587 

  

May 31, 2023

 
      

Accumulated

         
  

Gross

  

Amortization

  

Impairment

  

Net

 

Intellectual Property

 $319,600  $(157,137

)

 $(162,463

)

 $- 

License & Customer Relations

  990,000   (243,375

)

  (663,667

)

  82,958 

Tradenames - Trademarks

  301,000   (147,992

)

  (40,158

)

  112,850 

Non-compete Agreements

  27,000   (27,000

)

  -   - 

Domain Names

  25,993   (12,713

)

  -   13,280 

Total

 $1,663,593  $(588,217

)

 $(866,288

)

 $209,088 

 

  

February 28, 2023

 
  

Gross

  

Accumulated

Amortization

  

Net

 

Intellectual Property

 $319,600  $(149,147

)

 $170,453 

License & Customer Relations

  990,000   (231,000

)

  759,000 

Tradenames - Trademarks

  301,000   (140,467

)

  106,533 

Non-Compete Agreements

  27,000   (27,000

)

  - 

Domain Names

  25,993   (11,888

)

  14,105 

Total

 $1,663,593  $(559,502

)

 $1,104,091 
16

 

  

May 31, 2022

 
      

Accumulated

     
  

Gross

  

Amortization

  

Net

 

Intellectual Property

 $319,600  $(125,177

)

 $194,423 

License & Customer Relations

  990,000   (193,875

)

  796,125 

Tradenames - Trademarks

  301,000   (117,892

)

  183,108 

Non-compete Agreements

  27,000   (27,000

)

  - 

Domain Names

  25,993   (9,364

)

  16,629 

Total

 $1,663,593  $(473,308

)

 $1,190,285 

Total amortization expense charged to operations for the three months ended February 28,November 30, 2023 and 2022 was $28,734$7,750 and $28,023,$28,715, respectively. Total amortization expense charged to operations for the ninesix months ended February 28,November 30, 2023 and 2022 was $86,194$15,501 and $86,172,$58,149, respectively.

 

Amount to be amortized during the twelve months ended February 28,

 

 

 

Amount to be amortized during the twelve months ended November 30,

    

2024

 

$

114,896

 

 $31,036 

2025

 

114,896

 

  31,036 

2026

 

114,896

 

  31,036 

2027

 

114,896

 

  29,321 

2028

 

112,321

 

  18,450 

Thereafter

 

 

532,186

 

  52,708 

 

$

1,104,091

 

 $193,587 

 

Note 1111: Goodwill

 

Goodwill in the amount of $557,896 is carried on the Company’s balance sheet at February 28,November 30, 2023 and May 31, 20222023 in connection with the acquisition of Alternative Solutions on June 27, 2018.

 

Goodwill Impairment Test

 

The Company assessed its intangible assets as of May 31, 2022 and 2021 for purposes of determining if an impairment existed as set forth in ASC 350 – Intangibles – Goodwill and Other and ASC 360 – Property Plant and Equipment. Pursuant to ASC 360, the Company determined that the fair value of its intangible assets exceeded the carrying value of goodwill at February 28,November 30, 2023 and May 31, 2022.2023. As a result, no impairment was recorded. At February 28,November 30, 2023 and May 31, 2022,2023, the net amount of goodwill on the Company’s balance sheet was $557,896.

 

19

Note 1212: Other Assets

 

Other assets included the following as of February 28,November 30, 2023 and May 31, 2022:2023:

 

  

February 28,

  

May 31,

 
  

2023

  

2022

 

Security deposits

 $198,000  $229,500 
  $198,000  $229,500 
  

November 30,

  

May 31,

 
  

2023

  

2023

 

Construction deposit

 $58,175  $- 

Security deposits

  157,500   157,500 
  $215,675  $157,500 

During the three months ended November 30, 2023, the Company paid a deposit in the amount of $58,175 for design and architectural work on construction planned for its Las Vegas lounge.

 

Note 1313: Accounts Payable and Accrued Liabilities

 

Accounts payable and accrued liabilities consisted of the following at February 28,November 30, 2023 and May 31, 2022:2023:

  

November 30,

2023

  

May 31,

2023

 

Trade accounts payable

 $3,062,040  $1,793,585 

Accrued payroll and payroll taxes

  353,693   311,505 

Accrued liabilities

  308,797   623,482 

Total

 $3,724,530  $2,728,572 

 

17
  

February 28,

2023

  

May 31,

2022

 

Trade accounts payable

 $2,145,357  $1,414,074 

Accrued payroll and payroll taxes

  272,250   323,254 

Accrued liabilities

  391,882   580,570 

Legal fees in dispute (a)

  248,031   - 

Total

 $3,057,520  $2,317,898 


a.

Amount represents invoices received by the Company from prior legal counsel for services. As of February 28, 2023, the Company has completed its investigation of these invoices and has determined not to approve them for payment. Furthermore, on January 4, 2023, the company filed a Florida Bar Association Complaint against the lawyer who provided the services. The Bar Complaint seeks sanctions for “Excessive and Unreasonable Legal Fees”, “Violation of the Attorney-Client Privilege” and “Intentional Delay and Harm to the Company’s Interest”.

 

Note 14 14: Loans Payable

 

Leaflink Financing Agreement

The Company is a party to an accounts receivable financing agreement with a lender (the “Short Term Financing Agreement”) for two of its subsidiaries. During the three months ended February 28, 2023, the Company received cash proceeds in the amount of $0 from additional loans under the Short-Term Financing Agreement, made payments in the amount of $235,000 and incurred fees in the amount of $0. During the nine months ended February 28, 2022, the Company received cash proceeds in the amount of $650,115 from additional loans under the Short-Term Financing Agreement, made payments in the amount of $1,585,962, and incurred fees in the amount of $75,559. At February 28, 2023, and May 31, 2022, the balance due under the Short Term Financing Agreement was $152,785 and $1,013,073, respectively. The loans are due in 30 days and have a discount fee of 3%.

2022 Financing Agreement CBR

 

Effective September 30, 2022, wethe Company entered into a Business Loan and Security Agreement with CBR Capital LLC to borrow $900,000.$900,000 (the “CBR Loan”). The loanCBR Loan is repayable in 48 weekly installments in the amount of $13,312.50 for weeks 1-8 and $29,287.50 for weeks 9-48. CBR Capital LLC has stated that it is aware of the Canaccord Debentures and the U.S. Convertible Debentures and will agreeagreed to subordinate the CBR security interest to these debenture holders.

 

During the nine monthsyear ended February 28,May 31, 2023, the Company received cash proceeds in the amount of $873,000 from the CBR loan agreement. During the three and nine monthsyear ended February 28,May 31, 2023, the Company made payments in the amount of $364,763 and $457,950, respectively.$838,688. Of these payments $219,159$506,014 was principal and $145,604$332,674 was interest for the three monthsyear ended February 28, 2023. Of these payments $224,811 was principal and $233,139 was interest for the nine months ended February 28,May 31, 2023. At the inception of the loan, the Company recorded a discount in the amount of $27,000 related to prepaid fees. During the three and nine monthsyear ended February 28,May 31, 2023, the Company amortized $7,313 and $11,250, respectively,$18,563 of these fees to interest expense, the balance of the discount remaining at February 22,May 31, 2023 is $15,750.$8,438. During the three months ended November 30, 2023, the Company made payments of principal and interest in the amount of $57,375 and $1,202, respectively, on the CBR Loan. During the six months ended November 30, 2023, the Company made payments of principal and interest in the amount of $393,986 and $45,327, respectively, on the CBR Loan. Also during the three and six months ended November 30, 2023, the Company amortized $1,125 and $8,437, respectively, of prepaid fees to interest expense. At February 28,November 30, 2023 and May 31, 2022,2023, the balance due under the CBR AgreementLoan was $659,439$0 and $0$385,550 net of discount, respectivelyrespectively.

 

2022 Financing Agreement TVT

 

Effective October 21, 2022, we entered into a Purchase and Sale of Future Receipts Agreement with TVT Business Funding LLC to borrow $200,000.$200,000 (the “TVT Loan”). The loan isTVT Loan was repayable in 48 weekly installments in the amount of $5,916.67.

 

During the nine monthsyear ended February 28,May 31, 2023, the Company received cash proceeds in the amount of $194,000 from the loan agreement.TVT Loan. During the three and nine monthsyear ended February 28,May 31, 2023, and 2022, the Company made payments in the amount of $76,917 and $106,500, respectively.$183,417. Of these payments $43,876$112,045 was principal and $33,041$71,372 was interest for the three monthsyear ended February 28, 2023. Of these payments $58,572 was principal and $47,928 was interest for the nine months ended February 28,May 31, 2023. At the inception of the loan, the Company recorded a discount in the amount of $6,000 related to prepaid fees. During the three and nine monthsyear ended February 28,May 31, 2023, the Company amortized $1,625 and $2,250, respectively,$3,875 of these fees to interest expense, the balance of the discount remaining at February 28,May 31, 2023 is $3,750.$2,125. During the three months ended November 30, 2023, the Company made principal and interest payments in the amount of $22,787 and $880, respectively, on the TVT Loan. During the six months ended November 30, 2023, the Company made principal and interest payments in the amount of $87,955 and $12,296, respectively, on the TVT Loan. Also during the three and six months ended November 30, 2023, the Company amortized $500 and $2,126, respectively, of prepaid fees to interest expense. At February 28,November 30, 2023 and May 31, 2022,2023, the balance due under the TVT AgreementLoan was $137,678$0 and $0$85,830 net of discount, respectivelyrespectively.

 

Note 1515: Convertible Notes Payable

  

November 30, 2023

  

May 31, 2023

 
         

Convertible debenture in the principal amount of $1,000,000 (the “U.S. Convertible Debenture 2”) dated October 31, 2018, which bears interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the U.S. Convertible Debenture 2. The U.S. Convertible Debenture 2 was to mature on a date that was three years following issuance. The U.S. Convertible Debenture 2 was convertible into Convertible Debenture Units at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40. On July 26, 2019, U.S. Convertible Debenture 2 was amended such that, should the Company issue or sell common stock or equity securities convertible into common stock at a price less than the conversion price of the U.S. convertible Debenture 2, the conversion price of U.S. Convertible Debenture 2 would be reduced to such issuance price, and the exercise price of the warrant issuable in connection with U.S. Convertible Debenture 2 would be exercisable at a price equal to 137.5% of the adjusted conversion price at the time of conversion. The U.S. Convertible Debenture 2 has other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The U.S. Convertible Debenture 2 is an unsecured obligation of the Company and ranks pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. The Company recorded a discount in the amount of $813,724 on the U.S. Convertible Debenture 2. During the three and six months ended November 30, 2023, the Company accrued interest in the amounts of $9,009 and $18,018 on the U.S. Convertible Debenture 2, respectively. During the three months and six months ended November 30, 2023, the Company made no interest payments on the U.S. Convertible Debenture 2. On April 15, 2021, the U.S. Convertible Debenture 2 was amended as follows: (i) the conversion price of the debentures was reduced to $1.20 per unit; and (ii) the maturity date was extended from October 31, 2021 to October 31, 2022. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $509,700 during the year ended May 31, 2021. On September 15, 2022, the U.S. Convertible Debenture 2 was further amended as follows: (i) the conversion price of debentures with a principal amount of $675,668 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $11,261 were converted to 2,410,279 shares of common stock and warrants to purchase 1,205,140 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $450,446 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $225,223 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $225,223 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable, which the Company believes is unlikely to occur until the conversion price of the debentures is below the market price of the Company’s common stock. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $422,331 was recorded on this transaction. The fair values of the warrants and conversion options included in the calculation of the loss on extinguishment of debt were $223,515 and $198,816, respectively.

  450,446   450,446 

 

  

February 28, 2023

  

May 31, 2022

 

Convertible debenture in the principal amount of $4,000,000 (the “U.S. Convertible Debenture 1”) dated October 31, 2018, which bears interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the U.S. Convertible Debenture 1. The U.S. Convertible Debenture 1 was to mature on a date that was three years following issuance. The U.S. Convertible Debenture 1 was convertible into units (the “Convertible Debenture Units”) at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40. On July 26, 2019, U.S. Convertible Debenture 1 was amended such that, should the Company issue or sell common stock or equity securities convertible into common stock at a price less than the conversion price of the U.S. Convertible Debenture 1, the conversion price of U.S. Convertible Debenture 1 would be reduced to such issuance price, and the exercise price of the warrant issuable in connection with U.S. Convertible Debenture 1 would be exercisable at a price equal to 137.5% of the adjusted conversion price at the time of conversion. The U.S. Convertible Debenture 1 has other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The U.S. Convertible Debenture 1 is an unsecured obligation of the Company and ranks pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. The Company recorded a discount in the amount of $3,254,896 on the U.S. Convertible Debenture 1. During the three and nine months ended February 28, 2023, the Company accrued interest in the amounts of $36,036 and $171,169 on the U.S. Convertible Debenture 1, respectively. During the three and nine months ended February 28, 2023, the Company made interest payments in the amounts of $0 and $90,089, respectively. On April 15, 2021, the U.S. Convertible Debenture 1 was amended as follows: (i) the conversion price of the debenture was reduced to $1.20 per unit; and (ii) the maturity date was extended from October 31, 2021 to October 31, 2022. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $2,038,803 during the year ended May 31, 2021 in connection with the amendment. On September 15, 2022, the U.S. Convertible Debenture 1 was further amended as follows: (i) the conversion price of debentures with a principal amount of $2,702,674 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $45,044 were converted to 9,641,118 shares of common stock and warrants to purchase 4,820,560 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $1,801,783 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $900,891.50 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $900,891.50 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $1,689,368 was recorded on this transaction.

 $1,801,783  $4,504,457 

November 30, 2023

May 31, 2023

Convertible debenture in the principal amount of $532,000 (the “U.S. Convertible Debenture 4”) dated October 25, 2018, which bears interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the U.S. Convertible Debenture 4. The U.S. Convertible Debenture 4 was to mature on a date that was three years following issuance. The U.S. Convertible Debenture 4 was convertible into Convertible Debenture Units at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40. The value of the warrants will be recorded when the issuance becomes probable. On July 26, 2019, U.S. Convertible Debenture 4 was amended such that, should the Company issue or sell common stock or equity securities convertible into common stock at a price less than the conversion price of the U.S. Convertible Debenture 4, the conversion price of U.S. Convertible Debenture 4 would be reduced to such issuance price, and the exercise price of the warrant issuable in connection with U.S. Convertible Debenture 4 would be exercisable at a price equal to 137.5% of the adjusted conversion price at the time of conversion. The U.S. Convertible Debenture 4 has other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The U.S. Convertible Debenture 4 is an unsecured obligation of the Company and ranks pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. The Company recorded a discount in the amount of $416,653 on the U.S. Convertible Debenture 4. During the years ended May 31, 2023 and 2022, the Company accrued interest in the amounts of $41,900 and $47,928 on the U.S. Convertible Debenture 4, respectively. During the years ended May 31, 2023 and 2022, the Company made interest payments in the amounts of $23,964 and $47,928, respectively. On April 19, 2021, the U.S. Convertible Debenture 4 was amended as follows: (i) the conversion price of the debenture was reduced to $1.20 per unit; and (ii) the maturity date was extended from October 25, 2021 to October 25, 2022. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $271,164 during the year ended May 31, 2021. On October 25, 2022, the Company received a notice of demand from the lender, placing the U.S. Convertible Debt 4 into default status. On November 1, 2022, the Company entered into a forbearance agreement with the lender (the “Forbearance Agreement”) with the following terms: (i) the Company will pay the lender the amount of $150,000 on November 2, 2022, and an additional $50,000 each month for the following nine months, or a total of $600,000; (ii) the default interest rate of 12% will be applied on the existing principal balances until paid in full; (iii) lender shall forbear from taking any further action based upon the existing default. As a result of this agreement, the Company capitalized $3,283 of accrued interest. During the three and six months ended November 30, 2023, the Company accrued interest in the amount of $0 and $11,982, respectively, on the U.S. Convertible Debenture 4. The Company recognized a gain in the amount of $2,384 on this transaction during the year ended May 31, 2023. During the three and six months ended November 30, 2023, the Company made payments in the aggregate amount of $0 and $100,000, respectively, pursuant to the Forbearance Agreement. At November 30, 2023 the amount owing under the Forbearance Agreement was $0.

-100,000

  

November 30, 2023

  

May 31, 2023

 
         

Convertible debentures payable in the aggregate principal amount of $12,012,000 (the “Canaccord Debentures”) dated December 12, 2018, which bear interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the Canaccord Debentures. The Canaccord Debentures were to mature on a date that was three years following issuance. The Canaccord Debentures were convertible into Convertible Debenture Units at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40. The Canaccord Debentures have other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The Canaccord Debentures are unsecured obligations of the Company and rank pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. During the three months ended November 30, 2019, in two separate transactions, principal in the aggregate amount of $25,857 was converted into an aggregate of 8,081 shares of the Company’s common stock, and warrants to purchase 4,040 shares of common stock. There were no gains or losses recorded on these conversions because they were done in accordance with the terms of the original agreement. No discount was recorded for the fair value of the warrants issued. Because the market price of the Company’s common stock was less than the conversion price on the date of issuance of the Canaccord Debentures, a discount was not recorded on the Canaccord Debentures. During the three and six months ended November 30, 2023 and 2022, the Company accrued interest in the amounts of $105,077 and $210,155, respectively, on the Canaccord Debentures. During the three and six months ended November 30, 2023, the Company made no interest payments on the Canaccord Debentures. On March 31, 2021, the Canaccord Debentures were amended as follows: (i) the conversion price of the debentures was reduced to $1.20 per unit; (ii) the maturity date was extended from December 12, 2021 to December 12, 2022; (iii) the mandatory conversion threshold was reduced from a daily volume weighted average trading price of greater than $4.80 per share to $2.40 per share for the preceding ten consecutive trading days; and (iv) the exercise price of the warrants issuable upon conversion was reduced from $4.40 to $1.60 and the expiration of the warrants extended until March 31, 2024. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $3,286,012 during the year ended May 31, 2021. During the year ended May 31, 2022, principal In the aggregate amount of $281,000 was converted into an aggregate of 234,167 shares of the Company’s common stock, and warrants to purchase 117,084 shares of common stock. There were no gains or losses recorded on these conversions because they were done in accordance with the terms of the original agreement. On September 15, 2022, the Canaccord Debentures were further amended as follows: (i) the conversion price of debentures with a principal amount of $7,965,278 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $132,755 were converted to 28,414,149 shares of common stock and warrants to purchase 14,207,075 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $52,53,873 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $2,626,936.50 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $2,626,936.50 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable, which the Company believes is unlikely to occur until the conversion price of the debentures is below the market price of the Company’s common stock. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $4,547,660 was recorded on this transaction. The fair values of the warrants and conversion options included in the calculation of the loss on extinguishment of debt were $2,623,852 and $1,923,808, respectively.

  5,253,873   5,253,873 

 

 

  

February 28, 2023

  

May 31, 2022

 

Convertible debenture in the principal amount of $1,000,000 (the “U.S. Convertible Debenture 2”) dated October 31, 2018, which bears interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the U.S. Convertible Debenture 2. The U.S. Convertible Debenture 2 was to mature on a date that was three years following issuance. The U.S. Convertible Debenture 2 was convertible into Convertible Debenture Units at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40. On July 26, 2019, U.S. Convertible Debenture 2 was amended such that, should the Company issue or sell common stock or equity securities convertible into common stock at a price less than the conversion price of the U.S. Convertible Debenture 2, the conversion price of U.S. Convertible Debenture 2 would be reduced to such issuance price, and the exercise price of the warrant issuable in connection with U.S. Convertible Debenture 2 would be exercisable at a price equal to 137.5% of the adjusted conversion price at the time of conversion. The U.S. Convertible Debenture 2 has other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The U.S. Convertible Debenture 2 is an unsecured obligation of the Company and ranks pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. The Company recorded a discount in the amount of $813,724 on the U.S. Convertible Debenture 2. During the three and nine months ended February 28, 2023, the Company accrued interest in the amounts of $9,009 and $42,792 on the U.S. Convertible Debenture 2, respectively. During the three and nine months ended February 28, 2023, the Company made interest payments in the amounts of $0 and $22,522, respectively. On April 15, 2021, the U.S. Convertible Debenture 2 was amended as follows: (i) the conversion price of the debentures was reduced to $1.20 per unit; and (ii) the maturity date was extended from October 31, 2021 to October 31, 2022. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $509,700 during the year ended May 31, 2021. On September 15, 2022, the U.S. Convertible Debenture 2 was further amended as follows: (i) the conversion price of debentures with a principal amount of $675,668 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $11,261 were converted to 2,410,279 shares of common stock and warrants to purchase 1,205,140 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $450,446 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $225,223 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $225,223 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $422,331 was recorded on this transaction.

  450,446   1,126,114 
  November 30, 2023  May 31, 2023 
         

Four unsecured convertible debentures dated November 30, 2023 in the aggregate principal amount of $960,000 (the “November 2023 Debentures”). The November 2023 Debentures bear interest at the rate of 15% per annum and are due on November 30, 2024. A minimum of one year of interest will be due on the November 2023 Debentures regardless of when they are paid; this minimum interest in the amount of $144,000 was recorded as an original issue discount. The Company, at its sole discretion, on or before December 6, 2023, may elect to satisfy the principal and interest due under the November 2023 Debentures by the issuance of shares of common stock at a price of $0.0345 per share; this conversion would result in the issuance of 32,000,000 shares of common stock. The conversion feature of the November 2023 Debentures had an intrinsic value in the amount of $62,400; this amount was recorded as a discount. During the three months ended November 30, 2023, no amortization was recorded on these discounts because the notes were issued on the last day of the period.

 $897,600   - 
         

Convertible Notes Payable

 $6,601,919  $5,804,319 

 

  

November 30, 2023

  

May 31, 2023

 

Total – Convertible Notes Payable, Net of Discounts, Current Portion

 $3,749,760  $2,952,160 

Total – Convertible Notes Payable, Net of Discounts, Long-term Portion

 $2,852,159  $2,852,159 

 

  

February 28, 2023

  

May 31, 2022

 

Convertible debenture in the principal amount of $532,000 (the “U.S. Convertible Debenture 4”) dated October 25, 2018, which bears interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the U.S. Convertible Debenture 4. The U.S. Convertible Debenture 4 was to mature on a date that was three years following issuance. The U.S. Convertible Debenture 4 was convertible into Convertible Debenture Units at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40. The value of the warrants will be recorded when the issuance becomes probable. On July 26, 2019, U.S. Convertible Debenture 4 was amended such that, should the Company issue or sell common stock or equity securities convertible into common stock at a price less than the conversion price of the U.S. Convertible Debenture 4, the conversion price of U.S. Convertible Debenture 4 would be reduced to such issuance price, and the exercise price of the warrant issuable in connection with U.S. Convertible Debenture 4 would be exercisable at a price equal to 137.5% of the adjusted conversion price at the time of conversion. The U.S. Convertible Debenture 4 has other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The U.S. Convertible Debenture 4 is an unsecured obligation of the Company and ranks pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. The Company recorded a discount in the amount of $416,653 on the U.S. Convertible Debenture 4. During the three and nine months ended February 28, 2023, the Company accrued interest in the amounts of $10,500 and $35,009 on the U.S. Convertible Debenture 4, respectively. During the three and nine months ended February 28, 2023, the Company made interest payments in the amounts of $0 and $23,964, respectively. On April 19, 2021, the U.S. Convertible Debenture 4 was amended as follows: (i) the conversion price of the debenture was reduced to $1.20 per unit; and (ii) the maturity date was extended from October 25, 2021 to October 25, 2022. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $271,164 during the year ended May 31, 2021. On October 25, 2022, the Company received a notice of demand from the lender, placing the U.S. Convertible Debt 4 into default status. On November 1, 2022, the Company entered into a forbearance agreement with the lender (the “Forbearance Agreement”) with the following terms: (i) the Company will pay the lender the amount of $150,000 on November 2, 2022, and an additional $50,000 each month for the following nine months, or a total of $600,000; (ii) the default interest rate of 12% will be applied on the existing principal balances until paid in full; (iii) lender shall forbear from taking any further action based upon the existing default. As a result of this agreement, the Company capitalized $3,283 of accrued interest. During the three and nine months ended February 28, 2023, the Company made payments in the aggregate amount of $150,000 and $350,000, respectively, pursuant to Forbearance Agreement. The Company recognized a gain in the amount of $2,384 on this transaction during the nine months ended February 28, 2023.

  250,000   599,101 

Note 16: Convertible Notes Payable Related Party

 

  

November 30, 2023

  

May 31, 2023

 

Convertible debenture in the principal amount of $4,000,000 to a related party (the “U.S. Convertible Debenture 1”) dated October 31, 2018, which bears interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the U.S. Convertible Debenture 1. The U.S. Convertible Debenture 1 was to mature on a date that was three years following issuance. The U.S. Convertible Debenture 1 was convertible into units (the “Convertible Debenture Units”) at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40. On July 26, 2019, U.S. Convertible Debenture 1 was amended such that, should the Company issue or sell common stock or equity securities convertible into common stock at a price less than the conversion price of the U.S. Convertible Debenture 1, the conversion price of U.S. Convertible Debenture 1 would be reduced to such issuance price, and the exercise price of the warrant Issuable in connection with U.S. Convertible Debenture 1 would be exercisable at a price equal to 137.5% of the adjusted conversion price at the time of conversion. The U.S. Convertible Debenture 1 has other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The U.S. Convertible Debenture 1 is an unsecured obligation of the Company and ranks pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. The Company recorded a discount in the amount of $3,254,896 on the U.S. Convertible Debenture 1. During the three and six months ended November 30, 2023, the Company accrued interest in the amounts of $36,036 and $72,072, respectively, on the U.S. Convertible Debenture 1. During the three and six months ended November 30, 2023, the Company made no interest payments on the U.S. Convertible Note 1. On April 15, 2021, the U.S. Convertible Debenture 1 was amended as follows: (i) the conversion price of the debenture was reduced to $1.20 per unit; and (ii) the maturity date was extended from October 31, 2021 to October 31, 2022. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $2,038,803 during the year ended May 31, 2021 in connection with the amendment. On September 15, 2022, the U.S. Convertible Debenture 1 was further amended as follows: (i) the conversion price of debentures with a principal amount of $2,702,674 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $45,044 were converted to 9,641,118 shares of common stock and warrants to purchase 4,820,560 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $1,801,783 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $900,891.50 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $900,891.50 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable, which the Company believes is unlikely to occur until the conversion price of the debentures is below the market price of the Company’s common stock. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $1,689,368 was recorded on this transaction. The fair values of the warrants and conversion options included in the calculation of the loss on extinguishment of debt were $894,090 and $795,278, respectively.

 $1,801,783  $1,801,783 

  

November 30, 2023

  

May 31, 2023

 

Total – Convertible Notes Payable - Related Party, Current Portion

 $900,891  $900,891 

Total – Convertible Notes Payable – Related Party, Long-term Portion

 $900,892  $900,892 

 

  

February 28, 2023

  

May 31, 2022

 

Convertible debentures payable in the aggregate principal amount of $12,012,000 (the “Canaccord Debentures”) dated December 12, 2018, which bear interest, payable quarterly, at a rate of 8% per annum, with interest during the first eighteen months following issuance being payable by increasing the then-outstanding principal amount of the Canaccord Debentures. The Canaccord Debentures were to mature on a date that was three years following issuance. The Canaccord Debentures were convertible into Convertible Debenture Units at a conversion price of $3.20 per Convertible Debenture Unit. Each Convertible Debenture Unit consisted of (i) one share of the Company’s common stock, and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at a price of $4.40. The Canaccord Debentures have other features, such as mandatory conversion in the event the common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The Canaccord Debentures are unsecured obligations of the Company and rank pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. During the three months ended November 30, 2019, in two separate transactions, principal in the aggregate amount of $25,857 was converted into an aggregate of 8,081 shares of the Company’s common stock, and warrants to purchase 4,040 shares of common stock. There were no gains or losses recorded on these conversions because they were done in accordance with the terms of the original agreement. No discount was recorded for the fair value of the warrants issued. Because the market price of the Company’s common stock was less than the conversion price on the date of issuance of the Canaccord Debentures, a discount was not recorded on the Canaccord Debentures. During the three and nine months ended February 28, 2023, the Company accrued interest in the amounts of $105,077 and $501,089 on the Canaccord Debentures, respectively. During the three and nine months ended February 28, 2023, the Company made interest payments in the amounts of $0 and $264,383, respectively. On March 31, 2021, the Canaccord Debentures were amended as follows: (i) the conversion price of the debentures was reduced to $1.20 per unit; (ii) the maturity date was extended from December 12, 2021 to December 12, 2022; (iii) the mandatory conversion threshold was reduced from a daily volume weighted average trading price of greater than $4.80 per share to $2.40 per share for the preceding ten consecutive trading days; and (iv) the exercise price of the warrants issuable upon conversion was reduced from $4.40 to $1.60 and the expiration of the warrants extended until March 31, 2024. This amendment was accounted for as an extinguishment of debt, and the Company recorded a loss in the amount of $3,286,012 during the year ended May 31, 2021. During the year ended May 31, 2022, principal in the aggregate amount of $281,000 was converted into an aggregate of 234,167 shares of the Company’s common stock, and warrants to purchase 117,084 shares of common stock. There were no gains or losses recorded on these conversions because they were done in accordance with the terms of the original agreement. On September 15, 2022, the Canaccord Debentures were further amended as follows: (i) the conversion price of debentures with a principal amount of $7,965,278 was reduced to $0.285 per unit, and these debentures along with accrued interest in the amount of $132,755 were converted to 28,414,149 shares of common stock and warrants to purchase 14,207,075 shares of common stock; (ii) the conversion price of the remaining debentures with a principal amount of $52,53,873 was reduced to $0.40 per share; (iii) the maturity date of 50% of the remaining debentures with a principal amount of $2,626,936.50 was extended to December 31, 2023, and the maturity date of 50% of the remaining debentures with a principal amount of $2,626,936.50 was extended to December 31, 2024; and (iv) the conversion price of the warrants issuable upon conversion of the debentures was reduced to $0.40. The value of the warrants will be determined when the issuance becomes probable. This amendment was accounted for as an extinguishment of debt, and a loss in the amount of $4,547,660 was recorded on this transaction.

  5,253,873   13,219,149 
         

Total - Convertible Notes Payable

 $7,756,102  $19,448,821 

Less: Discount

  (-

)

  (-

)

Convertible Notes Payable, Net of Discounts

 $7,756,102  $19,448,821 

Note 17: Notes Payable

  

November 30, 2023

  

May 31, 2023

 

Debenture in the principal amount of $250,000 (the “Debenture 1”) dated December 1, 2021, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 1 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 75,758 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 1 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $17,223 on Debenture 1. During the three and six months ended November 30, 2023, $1,275 and $2,550, respectively, of this discount was charged to operations. The Company recorded an original issue discount in the amount of $187,500 on Debenture 1. During the three and six months ended November 30, 2023, $13,876 and $27,752, respectively, of this original issue discount was charged to operations. During the three and six months ended November 30, 2023, the Company accrued interest in the amounts of $8,958 and $18,333, respectively, on Debenture 1. During the three and six months ended November 30, 2023, the Company made interest payments in the amounts of $15,208 and $24,583, respectively. During the three and six months ended November 30, 2023, the Company made principal payments in the amounts of $33,333. On May 31, 2023, the Debenture 1 was amended as follows: (1) the maturity date was extended to October 31, 2024; (2) the first payment of principal and interest on June 30, 2023, followed by quarterly payment of principal and interest on September 30, 2023, beginning October 31, 2023, the Company is required to pay the note holder principal and interest monthly through the maturity date.

 $216,667  $250,000 
         

Debenture in the principal amount of $250,000 (the “Debenture 2”) dated December 21, 2021, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 2 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 75,758 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 2 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $10,428 on Debenture 2. During the three and six months ended November 30, 2023, $1,009 and $2,018, respectively, of this discount was charged to operations. The Company recorded an original issue discount in the amount of $187,500 on Debenture 2. During the three and six months ended November 30, 2023, $18,145 and $36,290, respectively, of this original issue discount was charged to operations. During the three and six months ended November 30, 2023, the Company accrued interest in the amounts of $3,516 and $9,740, respectively, on Debenture 2. During the three and six months ended November 30, 2023 and 2022, the Company made interest payments in the amounts of $12,370 and $20,833, respectively. During the three and six months ended November 30, 2023, the Company made principal payments in the amount of $31,250 and $177,083, respectively, on Debenture 2. On May 31, 2023, the Debenture 2 was amended as follows: (1) the first payment of principal and interest on June 30, 2023, followed by quarterly payment of principal and interest on September 30, 2023, beginning October 31, 2023, the Company is required to pay the note holder principal and Interest monthly through the maturity date.

  72,917   250,000 

 

 

  

February 28, 2023

  

May 31, 2022

 

Total - Convertible Notes Payable, Net of Discounts, Current Portion, net of discount

 $4,003,052  $19,448,821 

Total - Convertible Notes Payable, Net of Discounts, Long-term Portion, net of discount

 $3,753,050  $- 

Discounts on notes payable amortized to interest expense – 3 months ended February 28, 2023 and 2022, respectively

$-$-

Discounts on notes payable amortized to interest expense – 9 months ended February 28, 2023 and 2022, respectively

$-$-

Note 16 Notes Payable

  

February 28, 2023

  

May 31, 2022

 

Debenture in the principal amount of $250,000 (the “Debenture 1”) dated December 1, 2021, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 1 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 75,758 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 1 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $17,223 on Debenture 1. During the three and nine months ended February 28, 2023, $1,667 and $5,000 of this discount was charged to operations, respectively. The Company recorded an original issue discount in the amount of $187,500 on Debenture 1. During the three and nine months ended February 28, 2023, $18,145 and $54,435 of this original issue discount was charged to operations, respectively. During three and nine months ended February 28, 2023, the Company accrued interest in the amounts of $9,375 and $28,125 on Debenture 1, respectively. During the three and nine months ended February 28, 2023, the Company made interest payments in the amounts of $9,375 and $40,625, respectively.

 $250,000  $250,000 
         

Debenture in the principal amount of $250,000 (the “Debenture 2”) dated December 21, 2021, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 2 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 75,758 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 2 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $10,428 on Debenture 2. During the three and nine months ended February 28, 2023, $1,009 and $3,027 of this discount was charged to operations, respectively. The Company recorded an original issue discount in the amount of $187,500 on Debenture 2. During the three and nine months ended February 28, 2023, $18,145 and $54,435 of this original issue discount was charged to operations, respectively. During the three and nine months ended February 28, 2023, the Company accrued interest in the amounts of $9,375 and $28,125 on Debenture 2, respectively. During the three and nine months ended February 28, 2023, the Company made interest payments in the amounts of $9,375 and $38,542, respectively.

  250,000   250,000 

  

November 30, 2023

  

May 31, 2023

 

Debenture in the principal amount of $500,000 (the “Debenture 3”) dated December 21, 2021, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 3 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 151,516 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 3 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $19,335 on Debenture 3. During the three and six months ended November 30, 2023, $1,541 and $3,082, respectively, of this discount was charged to operations. The Company recorded an original issue discount in the amount of $375,000 on Debenture 3. During the three and six months ended November 30, 2023, $29,886 and $59,772, respectively, of this original issue discount was charged to operations. During the three and six months ended November 30, 2023, the Company accrued interest in the amounts of $17,917 and $36,667, respectively, on Debenture 3, respectively. During the three and six months ended November 30, 2023, respectively, the Company made interest payments in the amounts of $30,417 and $49,167. During the three and six months ended November 30, 2023, the Company made principal payments in the amount of $66,667 on Debenture 3. On May 31, 2023, the Debenture 3 was amended as follows: (1) the maturity date was extended to October 31, 2024; (2) the first payment of principal and interest on June 30, 2023, followed by quarterly payment of principal and interest on September 30, 2023, beginning October 31, 2023, the Company is required to pay the note holder principal and interest monthly through the maturity date.

  433,333   500,000 
         

Debenture in the principal amount of $500,000 (the “Debenture 4”) dated January 4, 2022, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 4 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 151,516 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 4 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $17,154 on Debenture 4. During the three and six months ended November 30, 2023, $1,413 and $2,826, respectively, of this discount was charged to operations. The Company recorded an original issue discount in the amount of $375,000 on Debenture 4. During the three and six months ended November 30, 2023, $30,882 and $61,764, respectively, of this original issue discount was charged to operations. During the three and six months ended November 30, 2023, the Company accrued interest in the amounts of $17,917 and $36,667, respectively, on Debenture 4. During the three months ended November 30, 2023, the Company made interest payments in the amounts of $30,417 and $49,167, respectively. During the three and six months ended November 30, 2023, the Company made principal payments in the amount of $66,667 on Debenture 4. On May 31, 2023, the Debenture 4 was amended as follows: (1) the maturity date was extended to October 31, 2024; (2) the first payment of principal and interest on June 30, 2023, followed by quarterly payment of principal and interest on September 30, 2023, beginning October 31, 2023, the Company is required to pay the note holder principal and interest monthly through the maturity date.

  433,333   500,000 

 

  

February 28, 2023

  

May 31, 2022

 

Debenture in the principal amount of $500,000 (the “Debenture 3”) dated December 21, 2021, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 3 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 151,516 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 3 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $19,335 on Debenture 3. During the three and nine months ended February 28, 2023, $1,871 and $5,613 of this discount was charged to operations, respectively. The Company recorded an original issue discount in the amount of $375,000 on Debenture 3. During the three and nine months ended February 28, 2023, $36,290 and $108,871 of this original issue discount was charged to operations, respectively. During the three and nine months ended February 28, 2023, the Company accrued interest in the amounts of $18,750 and $56,250 on Debenture 3, respectively. During the three and nine months ended February 28, 2023, the Company made interest payments in the amounts of $18,750 and $76,875, respectively.

  500,000   500,000 
         

Debenture in the principal amount of $500,000 (the “Debenture 4”) dated January 4, 2022, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 4 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 151,516 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 4 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $17,154 on Debenture 4. During the three and nine months ended February 28, 2023, $1,715 and $5,146 of this discount was charged to operations, respectively. The Company recorded an original issue discount in the amount of $375,000 on Debenture 4. During the three and nine months ended February 28, 2023, $37,500 and $112,500 of this original issue discount was charged to operations, respectively. During the three and nine months ended February 28, 2023, the Company accrued interest in the amounts of $18,750 and $56,250 on Debenture 4, respectively. During the three and nine months ended February 28, 2023, the Company made interest payments in the amounts of $18,750 and $74,167, respectively.

  500,000   500,000 
  

November 30, 2023

  

May 31, 2023

 
         

Debenture in the principal amount of $500,000 (the “Debenture 5”) dated January 4, 2022, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 5 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 151,516 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 5 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $17,154 on Debenture 5. During the three and six months ended November 30, 2023, $1,413 and $2,826, respectively, of this discount was charged to operations. The Company recorded an original issue discount in the amount of $375,000 on Debenture 5. During the three and six months ended November 30, 2023, $30,882 and $61,764, respectively, of this original issue discount was charged to operations. During the three and six months ended November 30, 2023, the Company accrued interest in the amounts of $17,917 and $36,667, respectively, on Debenture 5. During the three and six months ended November 30, 2023, the Company made interest payments in the amounts of $30,417 and $49,167, respectively. During the three and six months ended November 30, 2023, the Company made principal payments in the amount of $66,667 on Debenture 5. On May 31, 2023, the Debenture 5 was amended as follows: (1) the maturity date was extended to October 31, 2024; (2) the first payment of principal and interest on June 30, 2023, followed by quarterly payment of principal and interest on September 30, 2023, beginning October 31, 2023, the Company is required to pay the note holder principal and interest monthly through the maturity date.

  433,333   500,000 
         

Debenture in the principal amount of $500,000 (the “Debenture 6”) dated January 4, 2022, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 6 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 151,516 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 6 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $17,154 on Debenture 6. During the three and six months ended November 30, 2023, $1,413 and $2,826, respectively, of this discount was charged to operations. The Company recorded an original issue discount in the amount of $375,000 on Debenture 6. During the three and six months ended November 30, 2023, $30,882 and $61,764, respectively, of this original issue discount was charged to operations. During the three and six months ended November 30, 2023, the Company accrued interest in the amounts of $17,917 and $49,167, respectively, on Debenture 6. During the three and six months ended November 30, 2023, the Company made interest payments in the amounts of $30,417 and $49,167, respectively. During the three and six months ended November 30, 2023, the Company made principal payments in the amount of $66,667 on Debenture 6.On May 31, 2023, the Debenture 6 was amended as follows: (1) the maturity date was extended to October 31, 2024; (2) the first payment of principal and interest on June 30, 2023, followed by quarterly payment of principal and interest on September 30, 2023, beginning October 31, 2023, the Company is required to pay the note holder principal and interest monthly through the maturity date.

  433,333   500,000 
         

Total

  2,022,916   2,500,000 

Original Issue Discount

  1,875,000   1,875,000 

Notes Payable, Gross

  3,897,916   4,375,000 

Less: Discount

  (576,903

)

  (902,339

)

Notes Payable, Net of Discount

  3,321,013   3,472,661 

 

 

  

February 28, 2023

  

May 31, 2022

 

Debenture in the principal amount of $500,000 (the “Debenture 5”) dated January 4, 2022, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 5 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 151,516 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 5 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $17,154 on Debenture 5. During the three and nine months ended February 28, 2023, $1,715 and $5,146 of this discount was charged to operations, respectively. The Company recorded an original issue discount in the amount of $375,000 on Debenture 5. During the three and nine months ended February 28, 2023, $37,500 and $112,500 of this original issue discount was charged to operations, respectively. During the three and nine months ended February 28, 2023, the Company accrued interest in the amounts of $18,750 and $56,250 on Debenture 5, respectively. During the three and nine months ended February 28, 2023, the Company made interest payments in the amounts of $18,750 and $74,167, respectively.

  500,000   500,000 
         

Debenture in the principal amount of $500,000 (the “Debenture 6”) dated January 4, 2022, which bears interest, payable quarterly commencing six months after issuance, at a rate of 15% per annum. Principal on Debenture 6 is due in two equal installments 18 months after issuance and at maturity on July 10, 2024. With the Debenture, the purchaser received warrants to purchase 151,516 shares of common stock at an exercise price of $1.65 per share of common stock. The Company shall make additional quarterly payments under Debenture 6 beginning 90 days after the end of its first fiscal quarter after January 10, 2025, and for the next five years, on an annual basis, equal to the greater of (a) 15% of the original principal amount, or (b) the purchaser’s pro rata portion of 5% of the distributions the Company receives as a result of the Quinn River Joint Venture during the prior fiscal year. The Company recorded a discount in the amount of $17,154 on Debenture 6. During the three and nine months ended February 28, 2023, $1,715 and $5,146 of this discount was charged to operations, respectively. The Company recorded an original issue discount in the amount of $375,000 on Debenture 6. During the three and nine months ended February 28, 2023, $37,500 and $112,500 of this original issue discount was charged to operations, respectively. During the three and nine months ended February 28, 2023, the Company accrued interest in the amounts of $18,750 and $56,280 on Debenture 6, respectively. During the three and nine months ended February 28, 2023, the Company made interest payments in the amounts of $18,750 and $74,167, respectively.

  500,000   500,000 
         

Total

 $2,500,000  $2,500,000 

Original Issue Discount

  1,875,000   1,875,000 

Notes Payable, Gross

  4,375,000   4,375,000 

Less: Discount

  (1,097,113

)

  (1,681,434

)

Notes Payable, Net of Discount

 $3,277,887  $2,693,566 
  

November 30, 2023

  

May 31, 2023

 

Total – Notes Payable, Net of Discounts, Current Portion

 $2,022,916  $1,439,584 

Total – Notes Payable, Net of Discounts. Long Term Portion

 $1,298,097  $2,033,077 

 

Discounts on notes payable amortized to interest expense – 3 months ended February 28, 2023 and 2022, respectively

During the three months ended November 30, 2023 and 2022, the Company amortized discounts to interest expense in the amount of $162,718 and $194,774, respectively. During the six months ended November 30, 2023 and 2022, the Company amortized discounts to interest expense in the amount of $325,436 and $389,547, respectively.

$194,774$-

 

Discounts on notes payable amortized to interest expense – 9 months ended February 28, 2023 and 2022, respectively

$584,321132,735

Aggregate maturities of notes payable and convertible notes payable, and convertible notes payable – related parties as of February 28,November 30, 2023 are as follows:follows (not including unamortized debt discounts in the amount of $783,303):

 

For the twelve months ended February 28,November 30,

 

2024

 

$

5,253,051

 

2025

 

 

5,003,051

 

2026

 

 

375,000

 

2027

 

 

375,000

 

2028

 

 

1,125,000

 

Thereafter

 

 

-

 

Total

 

$

12,131,102

 

During the year ended May 31, 2022, the Company offered for sale a maximum of $5,500,000 of debentures (the “2021 Debentures”) and warrants to purchase shares of the Company’s common stock at a price of $1.65 per share in an aggregate amount equal to one-half of the aggregate purchase price for the 2021 Debentures (the “2021 Debenture Warrants”) (collectively, the “November 2021 Offering”). During the year ended May 31, 2022, the Company received the amount of $2,500,000 pursuant to the November 2021 Offering and issued an aggregate of 757,576 warrants to purchase its common stock at an exercise price of $1.65 per share to the investors.

2024

 $6,879,967 

2025

  4,128,052 

2026

  375,000 

2027

  375,000 

2028

  375,000 

Thereafter

  375,000 

Total

 $12,508,019 

 

Note 17 18: Lease Liabilities - Financing Leases

 

 

February 28,

2023

  

May 31,

2022

  

November 30, 2023

  

May 31, 2023

 
��        

Financing lease obligation under a lease agreement for extraction equipment dated March 14, 2022 in the original amount of $359,900 payable in forty-eight monthly installments of $10,173 including interest at the rate of 15.89%. During the three months ended November 30, 2023, the Company made principal and interest payments on this lease obligation in the amounts of $20,586 and $9,933, respectively. During the six months ended November 30, 2023, the Company made principal and interest payments on this lease obligation in the amounts of $40,377 and $20,660, respectively.

 $236,803  $277,180 
 

(unaudited)

             

Financing lease obligation under a lease agreement for extraction equipment dated March 14, 2022 in the original amount of $359,900 payable in forty-eight monthly installments of $10,173 including interest at the rate of 15.89%. During the three months ended February 28, 2023, the Company made principal and interest payments on this lease obligation in the amounts of $18,292 and $12,227, respectively. During the nine months ended February 28, 2023, the Company made principal and interest payments on this lease obligation in the amounts of $52,786 and $38,771, respectively.

 $296,207  $348,993 

Financing lease obligation under an agreement for equipment dated June 20, 2022 in the original amount of $12,400 payable in forty-eight monthly installments of $350 including interest at a rate of 15.78%. During the three months ended November 30, 2023, the Company made principal and interest payments on this lease obligation in the amounts of $826 and $224, respectively. During the six months ended November 30, 2023, the Company made principal and interest payments on this lease obligation in the amounts of $1,554 and $468, respectively.

 $8,433   9,987 
        

Total

 $245,236  $287,167 
                

Current portion

 $80,818  $71,813  $94,469  $86,887 

Long-term maturities

  215,389   277,180   150,767   200,280 

Total

 $296,207  $348,993  $245,236  $287,167 

 

Aggregate maturities of lease liabilities – financing leases as of February 28,November 30, 2023 are as follows:

 

For the period ended February 28,November 30,

2024

 $94,469 

2025

  110,352 

2026

  40,415 

2027

  - 

2028

  - 

Thereafter

  - 

Total

 $245,236 

 

27

2024

 

$

80,818

 

2025

 

 

94,605

 

2026

 

 

110,744

 

2027

 

 

10,040

 

2028

 

 

-

 

Thereafter

 

 

-

 

Total

 

$

296,207

 


 

Note 1819: Stockholders Equity

 

TheAt the Company's annual meeting of stockholders on November 28, 2023, the Company’s shareholders voted to increase the number of shares of authorized common stock from 187,500,000 shares to 350,000,000 shares. At November 30, 2023, the Company’s authorized capital stock consists of 187,500,000350,000,000 shares of common stock, par value $0.0001 at February 28, 2023 and 2022,per share, and 5,000,000 shares of preferred stock, par value $0.001 per share.

 

On September 15, 2022, the Company effected a reverse stock split of its issued and outstanding common stock (“the “Reverse Split”) at a ratio of 1-for-4, whereby four shares of the Company’s common stock issued and outstanding were exchanged for one share. The number of shares of common stock issued and outstanding immediately before the Reverse Split was 290,070,272; the number of shares outstanding immediately after the reverse split was 72,517,570, a decrease of 217,552,702 shares. All share and per-share information in these financial statements have been adjusted to reflect the effects of the Reverse Split. As a result of the split, an additional 576 shares were issued due to rounding.

 

Common stock transactions for the ninethree months ended February 28,November 30, 2023

 

None.

Common stock transactions for the three months ended November 30, 2022

Common Stock and Warrants Issued upon Conversion of Notes Payable:

 

On September 15, 2022, the Company issued 28,414,149 shares and three-year warrants to acquire 14,207,075 shares of common stock at a price of $0.40 per share as a result of the mandatory conversion provided in the amendments to the Canaccord Debentures. The conversion was for the total amount of $8,098,033, of which $7,965,278 was principal and $132,755 was accrued interest. (See note 15 for details). A loss in the amount of $4,547,660 was recorded in connection with the extinguishment of the Canaccord Debentures. No gain or loss was recorded on the issuance of the shares because the conversion was made pursuant to the terms of the Restructured Canaccord Debenture Agreement.

 

On September 15, 2022, the Company issued 12,051,397 shares and three-year warrants to acquire 6,025,700 shares of common stock at a price of $0.40 per share as a result of the mandatory conversion provided in the amendments to the U.S. Convertible Debenture holders. The conversion was for the total amount of $3,434,647, of which $3,378,342 was principal and $56,305 was accrued interest. (See note 15 for details). A loss in the amount of $2,111,699 was recorded in connection with the extinguishment of the U.S. Convertible Debentures 1 and 2. No gain or loss was recorded on the issuance of the shares because the conversion was made pursuant to the terms of the Restructured U.S. Convertible Debentures 1 and 2 Agreements.

 

Other Warrant Transactions

 

From December 1, 2021, through January 4, 2022, the Company issued $2,500,000 in debentures and issued 757,576 warrants in connection with these debentures. Each warrant allows the holder to purchase one share of the Company’s common stock at an exercise price of $1.65 per share for three years after its date of issuance.

On September 15, 2022, the Company amended $18,846,721 in outstanding debentures to reduce the conversion price of the debentures from $1.20 per unit to $0.40 per unit, increasing the warrants issuable upon conversion of such debentures from 3,400,652 to 6,801,298. As amended, each warrants issuable pursuant to the conversion of such debentures is exercisable for one share of the Company’s common stock at a price of $0.40 per share.

 

Common stock transactions for the nine months ended February 28, 2022

Common Stock and Warrants Issued upon Conversion of Notes Payable:

On June 17, 2021, the Company issued 234,167 shares of common stock and three-year warrants to acquire 117,083 shares of common stock at a price of $1.10 (now $0.40 as a result of the amendment of the Canaccord Debentures) per share to Canaccord Genuity Corp., as nominee, in connection with the conversion of a portion of the Canaccord Debentures in the principal amount of $281,000. No gain or loss was recorded on this transaction because the conversion was made pursuant to the terms of the original agreement.

During the three months ended February 28, 2022, the Company granted 25,000 shares of common stock to an employee. The Company charged the value of these shares $8,780 to common stock subscribed. These shares had not been issued as of February 28, 2022.

Other Warrant transactions

The Company values warrants using the Black-Scholes valuation model utilizing the following variables. On March 31, 2021, the Company reduced the conversion price of the Canaccord Debentures from $3.20 per unit to $1.20 per unit, increasing the warrants issuable upon conversion of the Canaccord Debentures from 2,102,100 to 5,629,094. As amended, each warrant issuable pursuant to conversion of the Canaccord Debentures is exercisable for one share of the Company’s common stock at a price equal to $1.60 per share until March 31, 2024.

In April 2021, the Company amended $6,229,672 in outstanding debentures to reduce the conversion price of the debentures from $3.20 per unit to $1.20 per unit, increasing the warrants issuable upon conversion of such debentures from 973,387 to 2,595,697. As amended, each warrant issuable pursuant to conversion of such debentures is exercisable for one share of the Company’s common stock at a price equal to 137.5% of the conversion price (presently $1.65 per share) until July 14, 2024.

From December 1, 2021, through January 4, 2022, the Company issued $2,500,000 in debentures and issued 757,576 warrants in connection with these debentures. Each warrant allows the holder to purchase one share of the Company’s common stock at an exercise price of $1.65 per share for three years after its date of issuance.

The following table summarizes the significant terms of warrants outstanding at February 28,November 30, 2023. This table does not include the unit warrants. See Unit Warrants section below.

 

Range of

exercise

Prices

Range of

exercise

Prices

 

Number of

warrants

Outstanding

 

Weighted

average

remaining

contractual

life (years)

 

Weighted

average

exercise

price of

outstanding

Warrants

 

Number of

warrants

Exercisable

 

Weighted

average

exercise

price of

exercisable

Warrants

 

Range of

exercise

Prices

  

Number of

warrants

Outstanding

  

Weighted

average

remaining

contractual

life (years)

  

Weighted

average

exercise

price of

outstanding

Warrants

  

Number of

warrants

Exercisable

  

Weighted

average

exercise

price of

exercisable

Warrants

 

 

 

 

 

 

 

 

 

 

 

 

 

                      

$

0.40

 

20,232,775

 

2.55

 

0.40

 

20,232,775

 

0.40

 

0.40   20,232,775   1.79  $0.40   20,232,775  $0.40 
$1.60   191,094   1.79  $1.60   191,094  $1.60 
$1.65   757,580   1.08  $1.65   757,580  $1.65 

1.60

 

191,094

 

2.55

 

$

1.60

 

191,094

 

$

1.60

 

    21,181,449   1.77  $0.46   21,181,449  $0.46 

1.65

 

757,580

 

1.83

 

1.65

 

757,580

 

1.65

 

2.40

 

 

781,250

 

 

0.21

 

 

2.40

 

 

781,250

 

 

2.40

 

 

 

 

21,962,699

 

 

2.44

 

$

0.53

 

 

21,962,699

 

$

0.53

 

 

Transactions involving warrants are summarized as follows. This table does not include the unit warrants. See Unit Warrants section below.

 

 

Number of

Shares

  

Weighted

Average

Exercise

Price

  

Number of

Shares

  

Weighted Average

Exercise Price

 

Warrants outstanding at May 31, 2021

  13,499,411  $2.12 

Granted

  874,666  $1.65 

Exercised

  -  $- 

Cancelled / Expired

  (12,644,153

)

 $2.09 

Warrants outstanding at May 31, 2022

  1,729,924  $1.98   1,729,924  $1.98 

Granted

  20,232,775  $0.40   20,232,775  $0.40 

Exercised

  -  $-   -  $- 

Cancelled / Expired

  -  $-   (781,250

)

 $0.60 

Warrants outstanding at February 28, 2023

  21,962,699  $0.53 

Warrants outstanding at May 31, 2023

  21,181,449  $0.46 

Granted

  -  $- 

Exercised

  -  $- 

Cancelled / Expired

  -  $- 

Warrants outstanding at November 30, 2023

  21,181,449  $0.46 

 

Unit Warrants

 

In February and March 2018, in connection with the Westpark offering, the Company issued five-year warrants to purchase 51,310 of the Company’s units at an exercise price of $5.00 per unit. Each unit consists of four shares of common stock and one warrant to purchase a share of common stock for $3.00

On June 20, 2018, in connection with the special warrant offering, the Company issued Canaccord Genuity Corp. 579,461 three-year broker warrants at an exercise price of C$1.80 per share as compensation. Each warrant entitles the holder to purchase one unit, which consists of one share of common stock and a warrant to purchase one share of common stock, for C$2.60 per share. These warrants were valued at $1,495,373, and this amount was charged to operations during the year ended May 31, 2019.$3.00. These warrants expired on June 20, 2021.in March of 2023.

 

On December 12, 2018, in connection with the issuance of the Canaccord Debentures, the Company issued Canaccord Genuity Corp., as compensation 268,680 three-year agent and advisory warrants. Each warrant entitles the holder to purchase a unit for $3.20, which unit consists of one share of common stock and a warrant to purchase one-half share of common stock at an exercise price of $4.40 per share. The Company, in connection with the issuance of the Canaccord Debentures, also issued to National Bank Financial Inc., as compensation, 67,170 three-year agent and advisory warrants. Each warrant entitles the holder to purchase a unit for $3.20, which unit consists of one share of common stock and a warrant to purchase one-half share of common stock at an exercise price of $4.40 per share. The aggregate value of these warrants was $874,457, which was charged to operations during the year ended May 31, 2019. These warrants expired on December 12, 2021.

Because the unit warrants are exercisable for Common Stock and warrants, they are not included in the warrant tables above.

 

Note 19 20: Related Party Transactions

 

As of February 28,November 30, 2023 and May 31, 2022,2023, the Company had accrued salary due to Michael Abrams, a former officer of the Company prior to his September 1, 2015 termination, in the amount of $16,250.

 

On August 17, 2022, the Company granted 50,000 shares of restricted common stock to Charlene Soco, an officer of the Company, effective February 4, 2022. The shares were fully vested, and the restrictions removed, on December 31, 2022

During the threesix months ended February 28, 2023, the Company made payments of $5,000 to each of its three directors for their participation on the Board, for a total of $15,000. During the nine months ended February 28,November 30, 2023, the Company made payments of $10,000 to each of its three directors for their participation on the Board, for a total of $30,000.

 

AsDuring six months ended November 30, 2023, the Company’s Board of May, 2019Directors authorized a bonus for its Chief Executive Officer in the amount of $50,000; this amount was paid during the sox months ended November 30, 2023.

During the six months ended November 30, 2023, the Company entered intoaccrued interest in the amount of $72,071 on a monthly retainer arrangement with a company called The Workshopconvertible note payable to Navy Capital Green Co-Invest Fund, LLC, located in Miami Florida. The Workshop LLC provided services related to marketing and advertising for the Company and its subsidiaries, including design work for marketing materials. The Workshop LLC is owned by Jordan Binder, the sonan entity that holds greater than 10% of the former CEOCompany’s common stock outstanding. At November 30, 2023, the principal balance of the Company, Jeff Binder. Jeff Binder resigned as CEO effective August 23rd, 2022 after serving seven years in that position. As of December 31, 2022 the retainer agreement between The Workshopconvertible note payable to Navy Capital Green Co-Invest Fund, LLC, and the Company was ended.$1,801,783.

 

Note 20 21: Income Taxes

 

The following table summarizes the Company’s income tax accrued for the three and ninesix and months ended February 28, 2023:November 30, 2023 and 2022:

The Company accounts for income taxes under FASB ASC 740-10, which provides for an asset and liability approach of accounting for income taxes. Under this approach, deferred tax assets and liabilities are recognized based on anticipated future tax consequences, using currently enacted tax laws, attributed to temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts calculated for income tax purposes.

The components of the income tax provision include:

  

Three Months Ended November 30,

 
  

2023

  

2022

 

Revenue

 $5,197,214  $6,074,177 

Directly attributable costs

  (3,025,595

)

  (3,613,744

)

Deferred

  2,171,619   2,460,433 

Tax rate

  21

%

  21

%

Tax expense

 $456,040  $516,691 

 

  

For the Three

Months Ended

February 28, 2023

  

For the Three

Months Ended

February 28, 2022

 

Loss before provision for income taxes

 $(513,654

)

 $(673,031

)

Provision for income taxes

 $(516,252

)

 $(324,265

)

Effective tax rate

  100.5

%

  48.2

%

 

  

For the Nine

Months Ended

February 28, 2023

  

For the Nine

Months Ended

February 28, 2022

 

Loss before provision for income taxes

 $(9,015,370

)

 $(125,347

)

Provision for income taxes

 $(1,552,028

)

 $(793,322

)

Effective tax rate

  17.2

%

  632.1

%

  

Six Months Ended November 30,

 
  

2023

  

2022

 

Revenue

 $10,311,741  $12,119,104 

Directly attributable costs

  (5,866,196

)

  (7,186,837

)

Deferred

  4,445,545   4,932,267 

Tax rate

  21

%

  21

%

Tax expense

 $933,564  $1,035,776 

 

Note: Change in uncertain tax position with all tax expense recorded in current year due to change in estimate. No prior year net operating loss was considered.

Due to the accrual of taxes related to Section 280E of the Internal Revenue Code, as amended, the Company has an uncertain tax accrual that is currently being expensed as a change in estimate. The Company has net operating losses that it believes are available to it to offset this expense; however, there can be no assurance under current interpretations of tax laws for cannabis companies that the Company will be allowed to use these net operating losses to offset Section 280E tax expenses.

 

Note 2122: Commitments and Contingencies

Legal Matters

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of the date of filing of this report, there were no pending or threatened lawsuits.

Integrity Global Security

On October 20, 2022, Integrity Global Security Inc. (“IGS”) filed a Complaint in the Eighth Judicial District Court, Case No. A-22-860152-C, against Serenity alleging Breach of Contract and Breach of Covenant of Good Faith and Fair Dealing. In its Complaint, IGS alleged that Serenity owes IGS the amount of $48,890 for unpaid invoices related to security services performed at Oasis Cannabis Dispensary and City Trees’ locations in Clark County, Nevada. The Company has accrued the amount of $27,314 in connection with this liability of November 30, 2023.

In response to IGS’s Complaint, Serenity filed an Answer on December 8, 2022, and a Countercomplaint against IGS asserting claims for Breach of Contract, Breach of the Implied Covenant of Good Faith and Fair Dealing, Negligence, Respondent Superior, Intentional Interference with Prospective Economic Advantage and Negligent Hiring, Training, and Supervision for actions related to a violent attack by an IGS employee against a Serenity employee. Serenity amended its Counterclaim on January 20, 2023, to include more information related to Serenity’s damages sustained as a result of IGS’s actions.

IGS filed a Motion to Dismiss Serenity’s Counterclaims on February 10, 2023, which Serenity opposed. However, on May 4, 2023, the morning of the Motion to Dismiss oral argument, IGS’s counsel advised Serenity’s counsel and the Court that IGS was voluntarily withdrawing its Motion to Dismiss. The Court granted IGS’s voluntary withdrawal of the Motion to Dismiss and IGS subsequently filed an Answer to Serenity’s Counterclaim on May 18, 2023.

Shortly thereafter the parties’ counsel attended an Early Case Conference on May 18, 2023, and the parties began exchanging information related to relevant witnesses, documents, and computations of damages. IGS served Serenity with Interrogatories, Requests for Admissions, and Requests for Production of Documents on or about July 20, 2023, while Serenity served IGS with their own Interrogatories and Requests for Production of Documents on or about August 11, 2023. Before any of the parties answered the propounded discovery requests served by the other party, the parties agreed to attend a Judicial Settlement Conference with the Eighth Judicial District Court. Accordingly, the parties entered into a Stipulation to Stay Discovery Pending a Judicial Settlement Conference, which was granted and entered by the Eighth Judicial District Court on September 20, 2023.

The parties are awaiting available dates from the Eighth Judicial District Court for the Judicial Settlement Conference. Until the parties attend the Judicial Settlement Conference, this matter is stayed. See note 23.

 

Lease Arrangements

 

Lease Arrangements

The Company leases several facilities for office, warehouse, and retail space. Currently lease commitments are as follows:

 

 

A lease that commenced in February 2019 for 1,400 square feet of office space located at 1718 Industrial Road, Las Vegas, NV 89102, for a term of eighteen months, and for rent of $1,785 per month. In June 2020, this lease was extended to August 31, 2022, with the monthly rent increasing to $1,866.70$1,867 until September 2021, after which time it will be subject to annual increases of 3%. The lease was extended again on April 1, 2022, effective September 1, 2022 until August 31, 2024. The monthly rent will increaseincreased on September 1, 2022 to $2,084.14 with annual increases of 3%. (See Note 23 for details).$2,084.

 

 

 

 

A lease that commenced January 2018 for 1,000 square feet of storefront space plus 5,900 square feet of warehouse space located at 1800 Industrial Road, Suites 102, 160, and 180, Las Vegas, NV 89102, for a term of five years and for initial base rent of $7,500 per month, with annual increases of 3%. In February 2020, this lease was extended to February 28, 2030 and the monthly rent was increased by $600. At November 30, 2023, the monthly rent on this lease was $10,385.

 

 

A lease that commenced in February 2019 for 2,504 square feet of office space located at 1800 Industrial Road, Suite 100, Las Vegas, NV 89102 for a term of eighteen months and for initial rent of $3,210 per month, with annual increases of 4%. In February 2020, this lease was extended to February 28, 2030, and the lease was modified to include annual rent increases of 3%. At November 30, 2023, the monthly rent on this lease was $3,649.

 

 

 

 

A lease that commenced in January 2016 for 22,000 square feet of warehouse space located at 203 E. Mayflower Avenue, North Las Vegas, NV 89030 for a term of five years and initial rent of $11,000 per month, which amount increased to $29,000 per month on January 1, 2020. In June 2020, this lease was extended to February 28, 2026, and the monthly rent was amended as follows: $25,000 for the months of April, May, and June 2020; $22,500 for the months of March 2021 through February 2022; $23,175 for the months of March 2022 through February 2023; 23,870 for the months of March 2023 through February 2024; $24,586 for the months of March 2024 through February 2025; and $25,323 for the months of March 2025 through February 2026.

 

 

 

 

A lease that commenced on May 17, 2022 for approximately 20 acres of land for purposes of developing a cultivation facility along the Quinn River in Nevada at a cost of $3,500 per quarter beginning on or before May 31, 2022 (the “Quinn River Land Lease”). The Quinn River Land Lease hasAs of May 31, 2023 the lease was terminated and will not be renewed by the parties.

A lease that commenced in October 2023 for 2,547 square feet of office space located at 516 S. 4th Street, Las Vegas, NV 89101 for a term of 9five years with two-year renewal options.and initial rent of $5,083 per month through September 30, 2024. The lessee under this Lease is CLS Nevada, Inc. See note 3.monthly rent will increase to $5,236 for the months of October 2024 through September 2025; $5,393 for the months of October 2025 through September 2026; $5,554 for the months of October 2026 through September 2027; and $5,721 for the months of October 2027 through September 2028.

 

In connection with the Company’s planned Colorado operations, on April 17, 2015, pursuant to an Industrial Lease Agreement (the “Lease”), CLS Labs Colorado leased 14,392 square feet of warehouse and office space (the “Leased Real Property”) in a building in Denver, Colorado where certain intended activities, including growing, extraction, conversion, assembly and packaging of cannabis and other plant materials, are permitted by and in compliance with state, city and local laws, rules, ordinances and regulations. The Lease had an initial term of seventy-two (72) months and provided CLS Labs Colorado with two options to extend the term of the lease by up to an aggregate of ten (10) additional years. In August 2017, as a result of the Company’s decision to suspend its proposed operations in Colorado, CLS Labs Colorado asked its landlord to be relieved from its obligations under the Lease, but the parties have not yet reached an agreement on how to proceed.

 

In August 2017, the Company’s Colorado subsidiary received a demand letter from its Colorado landlord requesting the forfeiture of the $50,000 security deposit, $10,000 in expenses, $15,699 in remaining rent due under the lease agreement and $30,000 to buy out the remaining amounts due under the lease. These expenses, which are a liability of the Company’s Colorado subsidiary, have been accrued on the balance sheet as of May 31, 2022.November 30, 2023.

 

Note 22 Subsequent Events

 

Effective March 1,Note 23: Subsequent Events

Conversion of November 2023 Debentures

On December 6, 2023 the Company elected to convert the debt owed under the November 30, 2023 Debentures. As a result of the conversion an additional 32,000,000 shares were issued to four separate parties bringing the outstanding number of issued shares of the Company to 104,543,141.

Amendment to Convertible Debentures and Mr. Glashow entered intoWarrants

On December 28, 2023, the Company executed a three-year employment agreement pursuantSupplemental Indenture (the “December 28, 2023 Indenture Supplement”) to which Mr. Glashow continued servingamend that certain debenture indenture by and between the Company and Odyssey Trust Company, as Trustee, dated as of December 12, 2018, as supplemented March 31, 2021, as further supplemented September 15, 2022 (collectively, the “Debenture Indenture”), in order to amended the terms of its outstanding $5,252,873 principal amount unsecured convertible debentures issued December 12, 2018 to, among other things, (i) decrease the conversion price of the remaining December Debentures to $0.07 per unit; (ii) change the maturity date of the December Debentures so that the December Debentures mature on January 31, 2028; (iii) providing for interest accruing between July 1, 2022 and December 31, 2023 to be added to the principal balance of the December Debentures; (iv) granting debenture holders a put right exercisable to December 29, 2023, granting each debenture holder the right to require the Company to redeem all or any part of such debenture holder’s outstanding December Debenture in cash at a redemption price equal to $600 per $1,000 principal amount of December Debentures elected to be redeemed; any accrued but unpaid interest through to and including the date of the debenture holder’s election shall not be paid and shall be cancelled; (v) granting debenture holders a put right in the event the Company’s Chief Executive Officer and commenced serving ascash available for debt service for any fiscal quarter exceeds $750,000, subject to pro ration, to require the Company’s ChairmanCompany to redeem all or any part of such debenture holder’s outstanding December Debentures in cash at a redemption price equal to the aggregate principal amount of the Board. UnderDecember Debentures being so redeemed, (vi) including a provision providing that the Agreement, Mr. Glashow is entitled to receiveCompany shall redeem on the last day of each calendar month beginning March 31, 2025 an annual salary of $325,000; a monthlyaggregate amount of $1,500 for health insurance and health related expenses; a monthly amount for home office expenses incurred; and an automobile allowance of $1,200 monthly. Further, he is entitled to receive a performance bonusoutstanding December Debentures equal to 2%$108,799 less the amount of interest paid on such date; and (vii) subject to the receipt of regulatory approvals, granting a security interest in certain of the Company’s annual EBITDA upassets (such as licenses, inventory (including work in process), equipment (excluding equipment subject to a maximum annual cash compensationpurchase money financing) and contract rights (excluding investments in entities other than wholly owned subsidiaries)) to the holders of $1 million including Base Salary. Effective March 1, 2023,the December Debentures and to other holders of the Company’s debt, now or in connection with the Agreement, Mr. Glashow entered into an Employee Confidentiality, Invention and Non-Competition Agreement. Pursuant thereto, Mr. Glashow agreed: (i) not to compete withfuture, as the Company duringmay elect.

On December 28, 2023, the termCompany also executed a Notice of his employment and for a periodAmendment to Warrant Terms to extend the terms of one year thereafter; (ii) notthe warrants to release or discloseDecember 28, 2026.

Integrity Global Security Settlement

On January 2, 2024, the Company’s confidential information; and (iii) to assignCompany reached agreements with IGS whereby (i) the rightsCompany will pay the amount of $55,000 in settlement of all work productclaims against the Company, and (ii) IGS will pay the Company $10,000 in settlement of all claims against IGS. The net cost to the Company among other terms.will be $45,000. The date of record of these settlement agreements will be the dates upon which the agreements are signed. At that time, the court will issue an order officially dismissing the case. See note 22.

 

The Company has evaluated events through the date of the financial statements and has determined that there were no additional material subsequent events.

 

 

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations.

 

HISTORY AND OUTLOOKHistory

 

We were incorporated on March 31, 2011 as Adelt Design, Inc. to manufacture and market carpet binding art. Production and marketing of carpet binding art never commenced. On November 20, 2014, we adopted amended and restated articles of incorporation, thereby changing our name to CLS Holdings USA, Inc. Effective December 10, 2014, we effected a reverse stock split of our issued and outstanding common stock at a ratio of 1-for-0.625 (the “Reverse Split”), wherein 0.625 shares of our common stock were issued in exchange for each share of common stock issued and outstanding.

On April 29, 2015, the Company,we entered into a merger agreement with CLS Labs and a newly-formed, wholly owned subsidiary of the Company (the “Merger Sub”) and effected the Merger (the “Merger”). Upon the consummation of the Merger, the separate existence of the Merger Sub consummatedceased and CLS Labs, the surviving corporation in the Merger, wherebybecame a wholly owned subsidiary of the Merger Sub mergedCompany, with and intothe Company acquiring the stock of CLS Labs, with CLS Labs remaining as the surviving entity.Labs. As a result of the Merger, we acquired the business of CLS Labs and abandoned our previous business. As such, only the financial statements of CLS Labs are included herein.

 

CLS Labs was originally incorporated in the state of Nevada on May 1, 2014 under the name RJF Labs, Inc. before changing its name to CLS Labs, Inc. on October 24, 2014. It was formed to commercialize a proprietary method of extracting cannabinoids from cannabis plants and converting the resulting cannabinoid extracts into concentrates such as oils, waxes, edibles and shatter.

 

On April 17, 2015, CLS Labs took its first step toward commercializing its proprietary methods and processes by entering into agreements through its wholly owned subsidiary, CLS Labs Colorado, with certain Colorado entities. During 2017, we suspended our plans to proceed with the Colorado Arrangement due to regulatory delays and have not yet determined if or when we will pursue them again.

We have been issued a U.S. patent with respect to our proprietary method of extracting cannabinoids from cannabis (hemp) plants and converting the resulting cannabinoid extracts into concentrates such as oils, waxes, edibles and shatter. These concentrates may be ingested in a number of ways, including through vaporization via electronic cigarettes, and used for a variety of pharmaceutical and other purposes. Internal testing of this extraction method and conversion process has revealed that it produces a cleaner, higher quality product and a significantly higher yield than the cannabinoid extraction processes currently existing in the marketplace. We have not yet commercialized our proprietary process and due to the current Nevada State laws governing these types of extraction and productionmethods, we do not intend to commercialize the proprietary process utilized in the patentfuture. CLSH is currently prohibitedengaged in Nevada. The Company is currently pursuing optionsattempting to generate revenue fromfind a buyer for the patent including the possible sale of the patent.who may be able to use it in another state or another application.

 

We intend to generate revenues through: (i) the processing of cannabis for others, and (ii) the purchase of cannabis (or cultivation through our joint venture) and the processing and sale of cannabis-related products. We plan to accomplish this through the acquisition of companies, the creation of joint ventures, through licensing agreements, and through fee-for-service arrangements with growers and dispensaries of cannabis products. We believe that we have established a position as one of the premier cannabinoid extraction and processing companies in the industry. We have already created our own brand of concentrates for consumer use, which we sell wholesale to cannabis dispensaries. We believe that we have created a “gold standard” national brand by standardizing the testing, compliance and labeling of our products in an industry currently comprised of small, local businesses with erratic and unreliable product quality, testing practices and labeling. We also plan to offer consulting services through Cannabis Life Sciences Consulting, LLC, which will generate revenue by providing consulting services to cannabis-related businesses, including growers, dispensaries and laboratories, and driving business to our processing facilities. Finally, we intend to grow through select acquisitions in secondary and tertiary markets, targeting newly regulated states that we believe offer a competitive advantage. Our goal at this time is to become a successful regional cannabis company.The Quinn River Joint Venture Agreement

 

On December 4, 2017, we entered into the Acquisition Agreement with Alternative Solutions to acquire the outstanding equity interests in the Oasis LLCs. Pursuant to the Acquisition Agreement, as amended, we paid a non-refundable deposit of $250,000 upon signing, which was followed by an additional payment of $1,800,000 on February 5, 2018, for an initial 10% of Alternative Solutions and each of the subsidiaries. At the closing of our purchase of the remaining 90% of the ownership interests in Alternative Solutions and the Oasis LLCs, which occurred on June 27, 2018, we paid the following consideration: $5,995,543 in cash, a $4.0 million promissory note due in December 2019, and $6,000,000 in shares of our common stock. The cash payment of $5,995,543 was less than the $6,200,000 payment originally contemplated because we assumed an additional $204,457 of liabilities. The Oasis Note, which was repaid in full in December 2019, was secured by all of the membership interests in Alternative Solutions and the Oasis LLCs and by the assets of the Oasis LLCs. At that time, we applied for regulatory approval to own an interest in the Oasis LLCs, which approval was receivedthe CCB Granted on June 21, 2018. Just prior to closing, the parties agreed that we would instead acquire all of the membership interests in Alternative Solutions, the parent of the Oasis LLCs, from its members, and the membership interests in the Oasis LLCs owned by members other than Alternative Solutions. We receivedThe CCB granted final regulatory approval for us to own our interest in the Oasis LLCs through Alternative Solutions under the final structure of the transaction on April 26, 2022.

 

On October 31, 2018, the Company, CLS Massachusetts, Inc., a Massachusetts corporation and a wholly-owned subsidiary of the Company (“CLS Massachusetts”), and In Good Health, Inc., a Massachusetts corporation (“IGH”), entered into an Option Agreement (the “IGH Option Agreement”). Under the terms of the IGH Option Agreement, CLS Massachusetts had an exclusive option to acquire all of the outstanding capital stock of IGH (the “IGH Option”) during the period beginning on the earlier of the date that is one year after the effective date of the conversion and December 1, 2019 and ending on the date that was 60 days after such date. (See Note 3 for more detail).

On October 31, 2018, as consideration for the IGH Option, we made a loan to IGH, in the principal amount of $5,000,000, subject to the terms and conditions set forth in that certain loan agreement, dated as of October 31, 2018 between IGH as the borrower and the Company as the lender. The loan was evidenced by a secured promissory note of IGH, which bore interest at the rate of 6% per annum and was to mature on October 31, 2021.

On February 4, 2020, CLS Massachusetts exercised the IGH Option and IGH subsequently asserted that CLS Massachusetts’ exercise was invalid. By letter dated February 26, 2020, we informed IGH that as a result of its breaches of the IGH Option, which remained uncured, an event of default had occurred under the IGH Note. We advised IGH that we were electing to cause the IGH Note to bear interest at the default rate of 15% per annum effective February 26, 2020 and to accelerate all amounts due under the IGH Note. On February 27, 2020, IGH informed CLS Massachusetts that it did not plan to make further payments under the IGH Note on the theory that the break-up fee excused additional payments.

On June 14, 2021, the parties to the IGH lawsuit entered into a confidential settlement agreement to resolve the action and a secured promissory note dated and executed by IGH in favor of us and effective June 11, 2021 (the “IGH Settlement Note”). Pursuant to the IGH Settlement Note, IGH paid us $3,000,000, $1,000,000 of which was paid on or before July 12, 2021. The remaining $2,000,000 and accrued interest was paid in 12 equal monthly installments, which began on August 12, 2021. During the year ended May 31, 2022, we received $2,740,820 under the IGH Settlement Note, which included $2,666,670 in principal and $74,150 in accrued interest. During the nine months ended February 28, 2023, we received $348,165 was due under the IGH Settlement Note, which included $333,333 in principal and $14,382 in accrued interest. As of February 28, 2023, the IGH Settlement Note has been paid in full. We record amounts paid under the IGH Settlement Note as gains when payments are received.

On October 20, 2021, the Companywe entered into a management services agreement (the “Quinn River Joint Venture Agreement”) through itsour 50% owned subsidiary, Kealii Okamalu LLC, with CSI Health MCD LLC (“CSI”) and a commission established by the authority of the Tribal Council of the Fort McDermitt Paiute and Shoshone Tribe (“Tribe”). The purpose of the Quinn River Joint Venture Agreement iswas to establish a business (the “Quinn River Joint Venture”) to grow, cultivate, process, and sell cannabis and related products. The Quinn River Joint Venture Agreement hashad an initial term of 10 years plus a 10 year10-year renewal option from the date the first cannabis crop produced iswas harvested and sold. Pursuant to the Quinn River Joint Venture Agreement, Kealii Okamalu isLLC was expected to eventually lease approximately 20-30 acres of the Tribe’s land located along the Quinn River at a cost of $3,500 per quarter. Additionally, pursuant to the terms of the Quinn River Joint Venture Agreement, Kealii Okamalu has managedquarter and manage the design, finance and construction of a cannabis cultivation facility on such tribal lands (“the(the “JV Cultivation Facility”). In 2022 and 2023 Kealii Okamalu also managesLLC managed the ongoing operations of the JV Cultivation Facility and related business, including, but not limited to, the cultivation of cannabis crops, personnel staffing, product packaging, testing, marketing and sales. Packaged products arewere branded as “Quinn River Farms.” The Company will provide up toWe provided 10,000 square feet of warehouse space at itsour Las Vegas facility, forand the Quinn River Joint Venture product, and hasgranted us preferred vendor status including the right to purchase cannabis flower and the business’sQuinn River Joint Venture’s cannabis trim at favorable prices. Kealii Okamalu isLLC was expected to contribute up to $6 million (the “Invested Amount”) towards the construction of the JV Cultivation Facility and the working capital for the Quinn River Joint Venture. This amount willwas to be repaid from the portion of the net profits of the Quinn River Joint Venture otherwise payable to CSI and the Tribe at the rate of $750,000 per quarter for eight quarters. After repayment of the Invested Amount, Kealii Okamalu willLLC was to receive one-third of the net profits of the Quinn River Joint Venture.

The Company is We were the manager of and holdsheld a 50% ownership interest in Kealii Okamalu.Okamalu LLC. Kealii Okamalu LLC is a VIEvariable interest entity which the Company consolidates.we consolidate. The Quinn River Joint Venture iswas not a legal entity but rather a business operated by Kealii Okamalu.Okamalu LLC. The Company uses the equity method of accounting to record one-third of the profit or loss generated by the Quinn River Joint Venture which accrues to Kealii Okamalu. Since the Company is a 50% owner of Kealii Okamalu, 50% of the profit or loss of Kealii Okamalu is recorded as minority interest in the Company’s statement of operations.

Duringcompleted its first harvest during the year ended May 31, 2022, Kealii Okamalu made cash investments in2023, from which the aggregate amount of $581,714 in the Quinn River Joint Venture. The Company also purchased $949,939 of fixed assets for use by the Quinn River Joint Venture which are on the balance sheet of Kealii Okamalu. During the year ended May 31, 2022, the Quinn River Joint Venture recorded a lossinventory in the amount of $336,416. One-third of this amount, or $112,139, was charged to the financial statements of Kealii Okamalu and recorded as a loss on equity investment in the Company’s financial statements for the year ended May 31, 2022, reducing the Company’s equity investment in the Quinn River Joint Venture from $581,714 to $469,575 at May 31, 2022.$952,124.

 

 

DuringAs of the nine monthsyear ended February 28,May 31, 2023, the Company’s 50% partner in Kealii Okamalu made investments inLLC had defaulted on its obligations under both the aggregate amount of $1,249,273 in the Quinn River Joint Venture; this amount was reduced by $952,125 representing the value of inventory transferred fromKealii Okamalu LLC Operating Agreement and the Quinn River Joint Venture Agreement by failing to make any of its required capital contribution of $3 million. As a result of the Company. The Company also purchased $84,327 of fixed assets for use bypartner’s breach, the Quinn River Joint Venture which are on the balance sheetAgreement was officially terminated in July of 2023. Kealii Okamalu. During the nine months ended February 28, 2023, the Quinn River Joint Venture recorded a lossOkamalu LLC is no longer an active operating entity. The Company does not believe it is likely to recover its investment in Kealii Okamalu LLC and has made an impairment charge in the amount of $526,761. One-third of this amount, or $176,587, was charged to$1,590,742 against these assets during the financial statements of Kealii Okamalu and recorded as a loss on equity investment in the Company’s financial statements for the nine monthsyear ended February 28,May 31, 2023. The Company’s net equity investment in the Quinn River Joint Venture was $590,137 at February 28, 2023

 

COVID-19 UpdateCurrent Business and Outlook

 

Since mid-2019 there have been many uncertainties regardingWe generate revenues through: (i) our retail dispensary (Oasis), and (ii) our City Trees cultivation and processing of cannabis and wholesale of cannabis-related products for Oasis and third-parties. We continue to explore opportunities for growth through the Novel Coronavirus (“COVID-19”) pandemic, includingacquisition of companies, the scopecreation of scientificjoint ventures, licensing agreements, and health issues, the anticipated durationfee-for-service arrangements with growers and dispensaries of cannabis products. We believe that we can ultimately establish a position as one of the pandemic,premier cannabinoid extraction and processing companies in the extentindustry. We have created our own brand of localconcentrates for consumer use, which we sell wholesale to cannabis dispensaries. We are attempting to create a “gold standard” national brand by standardizing the testing, compliance and worldwide social, political, and economic disruption. The COVID-19 pandemic has had far-reaching impacts on many aspectslabeling of our operations, directlyproducts in an industry currently comprised of small, local businesses with erratic and indirectly, including consumer behavior, customer store traffic, production capabilities, timing ofunreliable product availability, our people,quality, testing practices and the market generally. The COVID-19 pandemic has resulted in regional quarantines, labor stoppages and shortages, changes in consumer purchasing patterns, mandatory or elective shut-downs of restaurants, retail locations and other public gatherings, disruptions to supply chains, including the inability of our suppliers and service providers to deliver materials and services on a timely basis, or at all, severe market volatility, liquidity disruptions, and overall economic instability, which, in many cases, have had adverse impacts on our business, financial condition and results of operations.labeling.

 

In light of the situation relatingFinally, we intend to the COVID-19 pandemic,grow through select acquisitions in secondary and tertiary markets, targeting newly regulated states that we took certain precautionary measures intendedbelieve offer a competitive advantage. Our goal at this time is to help minimize the risk to our Company, employees, and customers, including the following:

We identified safety precautions that we implemented in our facilities from March 2020, and into 2022.

Although our facilities continued to operate, we evaluated their operations in case we had to shut down operations temporarily at any time in the future.

During the year ended December 31, 2022, we made the determination that COVID-19 possessed no continued serious risk to our employees and our business, and we returned to operating under pre-COVID-19 protocols.become a successful regional cannabis company.

 

Results of Operations for the Three Months Ended February 28,November 30, 2023 and February 28, 2022

 

The table below sets forth our select expenses as a percentage of revenue for the applicable periods:

 

 

Three Months

Ended

  

Three Months

Ended

  

Three Months

Ended

  

Three Months

Ended

 
 

February 28, 2023

  

February 28, 2022

  

November 30, 2023

  

November 30, 2022

 

Revenue

  100

%

  100

%

  100

%

  100

%

Cost of Goods Sold

  44

%

  48

%

  58

%

  52

%

Gross Margin

  56

%

  52

%

  42

%

  48

%

Selling, General, and Administrative Expenses

  53

%

  63

%

  50

%

  56

%

Gain on Settlement of Notes Receivable

  -

%

  9

%

  -

%

  (3

)%

Loss on Extinguishment of Debt

  -

%

  110

%

Interest expense

  8

%

  10

%

Provision for Income Tax

  9

%

  6

%

  9

%

  9

%

 

The table below sets forth certain statistical and financial highlights for the applicable periods:

 

  

Three Months

Ended

  

Three Months

Ended

 
  

February 28, 2023

  

February 28, 2022

 

Number of Customers Served (Dispensary)

  77,859   66,016 

Revenue

 $5,437,302  $5,588,266 

Gross Profit

 $3,018,693  $2,887,106 

Gain on Note Receivable

 $-  $522,246 

Net Loss

 $(899,515

)

 $(992,268

)

EBITDA (1)

 $504,615  $100,595 

(1)

EBITDA is a non-GAAP financial performance measures and should not be considered as alternatives to net income(loss) or any other measure derived in accordance with GAAP. This non-GAAP measure has limitations as an analytical tool and should not be considered in isolation or as substitutes for analysis of our financial results as reported in accordance with GAAP. Because not all companies use identical calculations, these presentations may not be comparable to other similarly titled measures of other companies. As required by the rules of the SEC, we provide below a reconciliation of this non-GAAP financial measure contained herein to the most directly comparable measure under GAAP. Management believes that EBITDA provides relevant and useful information, which is widely used by analysts, investors and competitors in our industry as well as by our management. By providing this non-GAAP profitability measure, management intends to provide investors with a meaningful, consistent comparison of our profitability measures for the periods presented.

Reconciliation of net loss for the three months ended February 28, 2023 and 2022 to EBITDA:

  

Three Months

Ended

February 28, 2023

  

Three Months

Ended

February 28, 2022

 

Net Loss attributable to CLS Holdings, Inc.

 $(899,515

)

 $(992,268

)

Add:

        

Interest expense, net

 $648,957  $589,692 

Provision for income taxes

 $516,252  $324,265 

Depreciation and amortization

 $238,921  $178,906 

EBITDA

 $504,615  $100,595 
  

Three Months

Ended

  

Three Months

Ended

 
  

November 30, 2023

  

November 30, 2022

 

Number of Customers Served (Dispensary)

  68,586   83,744 

Revenue

 $5,197,214  $6,074,177 

Gross Profit

 $2,171,619  $2,925,237 

Selling, General, and Administrative Expenses

 $2,606,918  $3,428,352 

 

Revenues

 

We had revenue of $5,437,302$5,197,214 during the three months ended February 28,November 30, 2023, a decrease of $150,964,$876,963, or 3%14%, compared to revenue of $5,588,266$6,074,177 during the three months ended February 28,November 30, 2022. Our cannabis dispensary accounted for $3,529,261,$3,104,064, or 65%60%, of our revenue for the three months ended February 28,November 30, 2023, an increasea decrease of $196,032,$688,740, or 6%18%, compared to $3,333,229$3,792,804 during the three months ended February 28,November 30, 2022. Dispensary revenue increaseddecreased during the thirdsecond quarter of fiscal year 20232024 because our average sales per day increaseddecreased from $37,036$41,679 during the thirdsecond quarter of fiscal year 20222023 to $39,214$34,111 during the thirdsecond quarter of fiscal year 2023.2024. Our cannabis production accounted for $1,908,041,$2,093,150, or 35%40%, of our revenue for the three months ended February 28,November 30, 2023, a decrease of $346,996$188,223 or 15%8%, compared to $2,255,037$2,281,373 for the three months ended February 28,November 30, 2022. The decrease in production revenues for the thirdsecond quarter of fiscal year 20232024 was primarily due to the fact that the overall cannabis market in Nevada has seen a decrease in wholesale pricing, coupled with a slowdown in nonessential expenditures that comes with inflation and an uncertain economy.

 

Cost of Goods Sold

 

Our cost of goods sold for the three months ended February 28,November 30, 2023 was $2,418,609,$3,025,595, a decrease of $282,551,$123,345, or 10%4%, compared to cost of goods sold of $2,701,160$3,148,940 for the three months ended February 28,November 30, 2022. The decrease in cost of goods sold for the three months ended February 28,November 30, 2023 was due primarily due to our ability to leverage partner relationships for better pricing and the overall market’s price contraction.a decrease in sales. Cost of goods sold was 44%58.2% of sales during the three months ended February 28,November 30, 2023 resulting in a gross margin of 56%41.8%. Cost of goods sold was 48% for51.8% of sales during the three months ended February 28,November 30, 2022 resulting in a gross margin of 52%48.2%. Gross margin exceeded our target of 50% for the third quarter of fiscal year 2023. Cost of goods sold during the thirdsecond quarter of the 2024 fiscal year primarily consisted of product cost of $2,478,392, labor and overhead of $417,254, supplies and materials of $121,474, and licenses and fees of $8,475. Cost of goods sold during the second quarter of the 2023 fiscal year primarily consisted of $2,102,515 of product cost $184,288 of state$2,697,590, labor and local fees and taxes, and $131,625overhead of $278,149, supplies and materials.materials of $132,426, and licenses and fees of $40,775.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses, or SG&A, decreased by $631,777,$821,434, or approximately 18%24%, to $2,860,914$2,606,918 during the three months ended February 28,November 30, 2023, compared to $3,492,691$3,428,352 for the three months ended February 28,November 30, 2022. The decrease in SG&A expenses for the three months ended February 28,November 30, 2023 was primarily due to the Company’s efforts to reduce travel, advertising, insurance,payroll, legal and office-related expenses, which included charitable contributions, outsourced IT, repairsoffice related costs, and maintenancesales and equipment expense.marketing expenses.

 

SG&A expense during the three months ended February 28,November 30, 2023 was primarily attributable to an aggregate of $2,388,527$2,205,118 in costs associated with operating the Oasis LLCs, a decrease of $188,419$720,967 compared to $2,576,946$2,926,085 during the third quarter of fiscalthree months ended November 30, 2022. The major components of the $194,385 decrease in SG&A associated with the operation of the Oasis LLCs during the three months ended February 28, 2023 compared to the three months ended February 28, 2022 were as follows: sales and marketing costs of $115,214$103,048 compared to $299,154; lease, facilities, and office costs of $576,493$525,014 compared to $662,294; and insurancepayroll and related costs of $82,299$1,170,765 compared to $100,112. Sales and marketing$1,220,960. The reductions in costs decreased due to a concerted effort to reduce professional outsourced marketing programs.were primarily the result of our cost cutting efforts. The decrease in SG&A expense for the thirdsecond quarter was partially offset by increases in payroll and related costs of $1,412,706 compared to $1,220,960; depreciation and amortization of $163,837 compared to $104,396; and professional fees of $96,952 compared to $68,714. Payroll costs increased during the third quarter of fiscal 2023 primarily due to increases in salaries of our employees related to the national labor shortage and due to an increase in professional fees to $186,144 compared to $68,714 and a decrease in the numberabsorption of employeescosts into cost of goods sold and inventory in our manufacturing division as we planned for the rolloutamount of our pre-roll division.$677,311.

 

Finally, SG&A decreased by $442,923$100,467 during the three months ended February 28,November 30, 2023 as a result of aan decrease in the expenses associated with the ongoing implementation of other aspects of our business plan and our general corporate overhead to $472,387$401,800 from $915,310$502,267 during the three months ended February 28,November 30, 2022. The major components of this decrease compared to the third quarter of fiscal 2022 was a decrease in expenses related to the November 2021 Debenture Offering of $411,298, there is no comparable expense in the current period.

Gain on Settlement of Note Receivable

During the three months ended February 28, 2023, we recorded a gain on the settlement of the IGH Settlement Note in the amount of $0 compared to $522,246 for the third quarter of 2022. This gain on the settlement arose after IGH notified us on February 27, 2021, that it did not plan to make further payments in accordance with the terms of the IGH Note on the theory that the Break-Up Fee excused such additional payments. We vehemently disagreed and litigation ensued. On June 14, 2021, the parties to the IGH lawsuit entered into a confidential settlement agreement to resolve the action and executed the $3,000,000 IGH Settlement Note. Pursuant to the IGH Settlement Note, IGH paid us $1,000,000 on or before July 21, 2021. The remaining $2,000,000 and accrued interest was paid in 12 equal monthly installments, and the final installment was paid in July 2022.

Loss on Equity Investment

During the three months ended February 28, 2023, we had income on equity investment in the amount of $22,476; there was no comparable transaction in the prior period. The Company, through its 50% owned subsidiary Kealii Okamalu, owns a one-third interest in the Quinn River Joint Venture. The second quarter of fiscal 2023 loss represents our sharewas a decrease in payroll and related costs to $106,354 during the current period from $165,488 during the comparable period of the results of the Quinn River Joint Venture.prior year.

 

Interest Expense, Net

 

Our interest expense was $648,957$410,841 for the three months ended February 28,November 30, 2023, an increasea decrease of $59,265,$198,064, or 10%33%, compared to $589,692$608,905 for the threesix months ended February 28,November 30, 2022. The increase in interest expense wasdecrease consisted primarily due to the original issue discount associated with the 2021 Debenturesof a decrease in the amount of $185,081 which was amortized to interest expense during the three months ended February 28, 2023 compared to $93,145 charged during the third quarter of the prior fiscal year. The increase in net interest expense for the third quarter of fiscal 2023 was partially offset by a net decrease in interest expense of $38,270$102,286 in connection with the Company’s loanspayment of principal due on our short-term financing arrangements, and a decrease of $59,947 in connection with our convertible debentures due primarilyrelated to the conversion of $11,343,619 inof principal of convertible debentures. In addition, the increase in net interestto equity on September 15, 2022. Interest expense for the third quarter of fiscal 2023 was partially offsetalso decreased by $32,056 due to a decrease in the amortization of discounts on our notes payable.

Loss on Extinguishment of Debt

During the three months ended November 30, 2022, certain of our convertible debentures were amended to (i) permit mandatory conversion of $11,343,619 in principal plus $189,061 in accrued interest into units at a reduced rate of $0.285 per unit; (ii) decrease the conversion price of the remaining debentures to $0.40 per unit; (iii) reduce the mandatory conversion VWAP provision from $2.40 to $0.80; and (iv) change the maturity date so that half of the remaining balance matures on December 31, 2023 and the remaining on December 31, 2024. We recognized a loss on the amendment of the debt in the amount of $11,720.$6,659,359 in connection with these amendments during the second quarter of fiscal 2023. There was no comparable transaction in the current period.

Gain on Equity Investment

During the three months ended November 30, 2022, we had income on equity investment in the amount of $80,319 in connection with our interest in the Quinn River Joint Venture; there was no comparable transaction in the current period.

Gain on Settlement of Debt

During the three months ended November 30, 2022, our U.S. Convertible Debenture 4 in the amount $599,101 in principal and accrued interest in the amount of $3,283, went into default. We entered into a forbearance agreement with the lender, whereby we would pay the amount of $600,000 in installments beginning in November of 2022 through August of 2023. As a result of this agreement, we recognized a gain on the settlement of debt in the amount of $2,384. There was no comparable transaction in the current period.

 

Provision for Income Taxes

 

We recorded a provision for income taxes in the amount of $516,252$456,040 during the three months ended February 28,November 30, 2023 compared to $324,265$516,691 during the three months ended February 28,November 30, 2022. Although we have net operating losses that we believe are available to us to offset this entire tax liability, which arises under Section 280E of the Code because we are a cannabis company, as a conservative measure, we have accrued this liability.

 

Net Loss

 

For the reasons above, our net loss for the three months ended February 28,November 30, 2023 was $1,029,906$1,302,180 compared to a net loss of $997,296$8,215,954 for the three months ended February 28,November 30, 2022, an increasea decrease of $32,610,$6,903,187, or 3%84%.

 

Non-Controlling Interest

 

During the three months ended February 28,November 30, 2023 and 2022, the lossincome (loss) associated with the non-controlling interest in Kealii Okamalu was $130,391($92) and $5,028,($10,587), respectively. This amount is comprised of the third-party portion of the operating loss of the Quinn River Joint Venture and our loss on equity investment.

 

Net Loss Attributable to CLS Holdings USA, Inc..

 

Our net loss attributable to CLS Holdings USA, Inc. for the three months ended February 28,November 30, 2023 was $899,515$1,302,272 compared to a net loss of $992,268$8,215,954 for the three months ended February 28,November 30, 2022, a decrease of $92,753$6,913,682 or 9%84%.

Non-GAAP Measures

EBITDA and Adjusted EBITDA are non-GAAP financial performance measures and should not be considered as alternatives to net income(loss) or any other measure derived in accordance with GAAP. These non-GAAP measure have limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of our financial results as reported in accordance with GAAP. Because not all companies use identical calculations, these presentations may not be comparable to other similarly titled measures of other companies. As required by the rules of the SEC, we provide below a reconciliation of these non-GAAP financial measures contained herein to the most directly comparable measure under GAAP. Management believes that EBITDA provides relevant and useful information, which is widely used by analysts, investors and competitors in our industry as well as by our management. Management also believes that adjusting EBITDA for the effects of non-recurring transactions may provide insight into the nature of the core business. By providing these non-GAAP profitability measure, management intends to provide investors with a meaningful, consistent comparison of our profitability measures for the periods presented.

  

Three Months Ended

November 30, 2023

  

Three Months Ended

November 30, 2022

 

Net Loss attributable to CLS Holdings, Inc.

 $(1,302,272

)

 $(8,215,954

)

Add:

        

Interest expense, net

  410,841   608,905 

Provision for taxes

  456,040   516,691 

Depreciation and amortization

  165,874   240,258 

EBITDA (1)

 $(269,517

)

 $(6,850,100

)

Less non-recurring gains and losses:

        

Gain on settlement of debt

 $-  $(2,384)

Loss on extinguishment of debt

      6,659,359 

Gain on equity investment

  -   (80,319

)

Adjusted EBITDA (2)

 $(269,517

)

 $(273,444

)

(1)

Net loss plus interest, taxes, depreciation, and amortization.

(2)

EBITDA adjusted for non-recurring gains, losses, and impairments.

 

Results of Operations for the NineSix Months Ended February 28,November 30, 2023 and February 28, 2022

 

The table below sets forth our select expenses as a percentage of revenue for the applicable periods:

 

 

Nine Months Ended

  

Nine Months Ended

  

Six Months

Ended

  

Six Months

Ended

 
 

February 28, 2023

  

February 28, 2022

  

November 30, 2023

  

November 30, 2022

 

Revenue

  100

%

  100

%

  100

%

  100

%

Cost of Goods Sold

  48

%

  48

%

  57

%

  52

%

Gross Margin

  52

%

  52

%

  43

%

  48

%

Selling, General, and Administrative Expenses

  55

%

  57

%

  52

%

  54

%

Employee Retention Tax Credit

  (9

)%

  -

%

Gain on Settlement of Notes Receivable

  2

%

  13

%

  -

%

  (3

)%

Loss on Extinguishment of Debt

  38

%

  -   -

%

  55

%

Interest expense

  8

%

  11

%

Provision for Income Tax

  9

%

  5

%

  9

%

  9

%

 

The table below sets forth certain statistical and financial highlights for the applicable periods:

 

  

Nine Months Ended

  

Nine Months Ended

 
  

February 28, 2023

  

February 28, 2022

 

Number of Customers Served (Dispensary)

  244,547   195,994 

Revenue

 $17,556,406  $16,502,978 

Gross Profit

 $9,063,334  $8,513,161 

Gain on Note Receivable

 $(348,165

)

 $(2,218,574

)

Net (Loss) Income

 $(10,263,947

)

 $(910,141

)

Loss on Extinguishment of Debt

 $6,659,359  $- 

EBITDA (1)

 $(5,971,273

)

 $1,834,706 

(1)

EBITDA is a non-GAAP financial performance measures and should not be considered as an alternative to net income(loss) or any other measure derived in accordance with GAAP. This non-GAAP measure has limitations as an analytical tool and should not be considered in isolation or as substitutes for analysis of our financial results as reported in accordance with GAAP. Because not all companies use identical calculations, these presentations may not be comparable to other similarly titled measures of other companies. As required by the rules of the SEC, we provide below a reconciliation of this non-GAAP financial measure contained herein to the most directly comparable measure under GAAP. Management believes that EBITDA provides relevant and useful information, which is widely used by analysts, investors and competitors in our industry as well as by our management. By providing this non-GAAP profitability measure, management intends to provide investors with a meaningful, consistent comparison of our profitability measures for the periods presented.

Reconciliation of net loss for the nine months ended February 28, 2023 and 2022 to EBITDA:

  

Nine Months Ended

February 28, 2023

  

Nine Months Ended

February 28, 2022

 

Net Loss attributable to CLS Holdings, Inc.

 $(10,263,947

)

 $(909,141

)

Add:

        

Interest expense, net

 $2,024,532  $1,416,164 

Provision for income taxes

 $1,552,028  $792,322 

Depreciation and amortization

 $716,114  $535,361 

EBITDA

 $(5,971,273

)

 $1,834,706 
  

Six Months

Ended

  

Six Months

Ended

 
  

November 30, 2023

  

November 30, 2022

 

Number of Customers Served (Dispensary)

  140,152   166,688 

Revenue

 $10,311,741  $12,119,104 

Gross Profit

 $4,445,545  $5,825,747 

Selling, General, and Administrative Expenses

 $5,336,818  $6,488,967 

 

Revenues

 

We had revenue of $17,556,406$10,311,741 during the ninesix months ended FebruaryNovember 30, 2032, an increase2023, a decrease of $1,053,428,$1,807,363, or 6%15%, compared to revenue of $16,502,978$12,119,104 during the ninesix months ended February 28,November 30, 2022. Our cannabis dispensary accounted for $11,210,622,$6,412,606, or 64%62%, of our revenue for the ninesix months ended February 28,November 30, 2023, an increasea decrease of $540,419,$1,268,755, or 5%17%, compared to $10,670,203$7,681,361 during the ninesix months ended February 28,November 30, 2022. Dispensary revenue increaseddecreased during the first nine monthssecond quarter of fiscal year 20232024 because our average sales per day increaseddecreased from $39,085$41,975 during the first nine monthssecond quarter of fiscal year 20222023 to $41,065$35,042 during the first nine monthssecond quarter of fiscal year 2023.2024. Our cannabis production accounted for $6,345,784,$3,899,135, or 36%38%, of our revenue for the ninesix months ended February 28,November 30, 2023, an increasea decrease of $513,009$568,608 or 9%12%, compared to $5,832,775$4,437,743 for the ninesix months ended February 28,November 30, 2022. The increasedecrease in production revenues for the first nine monthssecond quarter of fiscal year 20232024 was primarily due to the fact that the overall cannabis market in Nevada has seen a decrease in wholesale pricing, coupled with a slowdown in nonessential expenditures that comes with inflation and an increase in our THC distillate sales of almost $1,000,000, as well as sales to 10 new dispensaries and significant increases in existing customer order size and frequency. These improvements occurred as a result of our addition of a new sales director, an improvement in our product mix, the introduction of new products, and the procurement of higher quality materials. The increase was also due to greater revenue from third parties for whom we manufactured and processed their products.uncertain economy.

 

Cost of Goods Sold

 

Our cost of goods sold for the ninesix months ended February 28,November 30, 2023 was $8,493,072, an increase$5,866,196, a decrease of $503,255,$427,161, or 6%7%, compared to cost of goods sold of $7,989,817$6,293,357 for the ninesix months ended February 28,November 30, 2022. The increasedecrease in cost of goods sold for the ninesix months ended February 28,November 30, 2023 was due primarily due to an increasea decrease in revenue and more aggressive competitive discounts.sales. Cost of goods sold was 48%56.9% of sales during the ninesix months ended February 28,November 30, 2023 resulting in a gross margin of 52%43.1%. Cost of goods sold was 48% for51.9% of sales during the ninesix months ended February 28,November 30, 2022 resulting in a gross margin of 52%48.1%. Costs of goods sold as a percentage of revenue remained the same as the prior period. Gross margin exceeded our target of 50% for the first nine months of fiscal year 2023. Cost of goods sold during the first nine monthssecond quarter of the 2024 fiscal year primarily consisted of product cost of $4,878,402, labor and overhead of $748,381, supplies and materials of $222,463, and licenses and fees of $16,950. Cost of goods sold during the second quarter of the 2023 fiscal year primarily consisted of $7,436,279 of product cost $583,491 of state$5,333,849, labor and local fees and taxes, and $415,558overhead of $618,097, supplies and materials.materials of $283,933, and licenses and fees of $57,478.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses, or SG&A, increaseddecreased by $127,857,$1,112,149, or approximately 1%18%, to $9,568,775$5,336,818 during the ninesix months ended February 28,November 30, 2023, compared to $9,440,918$6,488,967 for the ninesix months ended February 28,November 30, 2022. The increasedecrease in SG&A expenses for the ninesix months ended February 28,November 30, 2023 was primarily due to increases inthe Company’s efforts to reduce payroll, legal and office related costs, associated with operating the Oasis LLCs.and sales and marketing expenses.

 

SG&A expense during the ninesix months ended February 28,November 30, 2023 was primarily attributable to an aggregate of $7,877,316$4,410,998 in costs associated with operating the Oasis LLCs, an increasea decrease of $459,663$858,867 compared to $7,417,653$5,269,865 during the first ninesix months of fiscalended November 30, 2022. The major components of the $459,663 increase in SG&A associated with the operation of the Oasis LLCs during the nine months ended February 28, 2023 compared to the nine months ended February 28, 2022decrease were as follows: payroll and related costs of $4,239,052$2,342,484 compared to $3,363,573; professional fees of $488,778 compared to $215,227; depreciation and amortization of $491,354 compared to $309,684;$2,826,346; lease, facilities, and office costs of $1,948,396$1,075,350 compared to $1,819,549; and taxes and licensure of $143,358 compared to $62,309. Payroll costs increased during the first nine months of fiscal 2023 primarily due to increases in salaries of our employees related to the national labor shortage and due to an increase in the number of employees in our manufacturing division as we planned for the rollout of our pre-roll division. Professional fees increased primarily due to legal fees related to the restructuring of debt and the implementation of a reverse stock split. Lease, facilities and office costs increased due to our efforts to prepare our facilities for the new pre-roll division by purchasing equipment and implementing compliance procedures applicable to this new division. These increases were partially offset by a decrease in$1,373,874; sales and marketing costs of $581,388 due$218,509 compared to a concerted effort$391,090; and depreciation and amortization of $225,882 compared to reduce professional outsourced marketing programs.

our cost cutting efforts. The decrease in SG&A expense for the second quarter was partially offset by an increase in taxes and licenses to $369,043 compared to $130,212 and an increase in travel and related costs to $231,796 from $176,970.

 

Finally, SG&A decreased by $331,242$293,382 during the ninesix months ended February 28,November 30, 2023 as a result of a decrease in the expenses associated with the ongoing implementation of other aspects of our business plan and our general corporate overhead to $1,691,460$925,821 from $2,022,702$1,219,103 during the ninesix months ended February 28,November 30, 2022. The major componentcomponents of this decrease compared to the second quarter of fiscal 2023 was a decrease in expenses relatedprofessional fees to the November 2021 Debenture Offering of $411,298, there is no comparable expense in$475,903 during the current period. Payroll costs also decreased by $213,689period from $795,591 during the nine months ended February 28, 2023 compared tocomparable period of the prior period. Theyear. This decrease in SG&A expenses for the first nine months of fiscal 2023 was partially offset by an increase in professional feespayroll and related costs to $297,833 during the six months ended November 30, 2023 compared to $187,065 during the comparable period of the prior year.

Interest Expense, Net

Our interest expense was $868,313 for the six months ended November 30, 2023, a decrease of $507,262, or 37%, compared to $1,375,575 for the six months ended November 30, 2022. The decrease in interest expense consisted primarily of a decrease in the amount of $292,232 associated$323,703 in connection with former counsel’s last seriesour convertible debentures related to conversion of invoices before termination. The Company is actively disputing$11,343,619 of principal to equity on September 15, 2022, and a decrease in the amount of fees charged$113,409 in connection with the payment of principal due on our short-term financing arrangements, Interest expense also decreased by $64,110 due to a decrease in the amortization of discounts on our notes payable.

Employee Retention Tax Credit

During the six months ended November 30, 2023, the Company received the amount of $924,862 Under the provisions of the extension of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). This amount was recorded as other income. There was no comparable transaction in the prior legal counsel.period.

Loss on Extinguishment of Debt

During the six months ended November 30, 2022, certain of our convertible debentures were amended to (i) permit mandatory conversion of $11,343,619 in principal plus $189,061 in accrued interest into units at a reduced rate of $0.285 per unit; (ii) decrease the conversion price of the remaining debentures to $0.40 per unit; (iii) reduce the mandatory conversion VWAP provision from $2.40 to $0.80; and (iv) change the maturity date so that half of the remaining balance matures on December 31, 2023 and the remaining on December 31, 2024. We recognized a loss on the amendment of the debt in the amount of $6,659,359 in connection with these amendments during the second quarter of fiscal 2023. There was no comparable transaction in the current period.

 

Loss on Equity Investment

 

During the ninesix months ended February 28, 2023,November 30, 2022, we had a loss on equity investment in the amount of $176,587;$154,111 in connection with our interest in the Quinn River Joint Venture; there was no comparable transaction in the priorcurrent period. The Company, through its 50% owned subsidiary Kealii Okamalu, owns a one-third interest

Gain on Settlement of Debt

During the six months ended November 30, 2022, our U.S. Convertible Debenture 4 in the Quinn River Joint Venture. The Quinn River Joint Venture completed its first harvest during the nine months ended February 28, 2023,amount $599,101 in principal and the Company purchased inventoryaccrued interest in the amount of $952,124 from$3,283, went into default. We entered into a forbearance agreement with the Quinn River Joint Venture.lender, whereby we would pay the amount of $600,000 in installments beginning in November of 2022 through August of 2023. As a result of this agreement, we recognized a gain on the settlement of debt in the amount of $2,384. There was no comparable transaction in the current period.

Gain on Settlement of Accounts Payable

During the six months ended November 30, 2023, we settled an outstanding vendor account in the amount of $8,375 for a cash payment of $4,000 representing a gain in the amount of $4,375. There was no comparable transaction in the prior period.

 

Gain on Settlement of Note Receivable

 

During the ninesix months ended February 28, 2023,November 30, 2022, we recorded a gain on the settlement of the IGH Settlement Note in the amount of $348,165$0 compared to $2,218,574$522,246 for the first nine monthshalf of fiscal 2022. This gain on the settlement arose after IGH notified us on February 27, 2021, that it did not plan to make further payments in accordance with the terms of the IGH Note on the theory that the Break-Up Fee excused such additional payments. We vehemently disagreed and litigation ensued. On June 14, 2021, the parties to the IGH lawsuit entered into a confidential settlement agreement to resolve the action and executed the $3,000,000 IGH Settlement Note. Pursuant to the IGH Settlement Note, IGH paid us $1,000,000 on or before July 21, 2021. The remaining $2,000,000 and accrued interest was paid in 12 equal monthly installments, and the final installment was paid in July 2022.

Loss on Extinguishment of Debt

During the nine months ended February 28, 2023, certain of our convertible debentures were amended to: (i) permit mandatory conversion of $11,343,619 in principal plus $189,061 in accrued interest into units at a reduced rate of $0.285 per unit; (ii) decrease the conversion price of the remaining debentures to $0.40 per unit; (iii) reduce the mandatory conversion VWAP provision from $2.40 to $0.80; (iv) change the maturity date so that half of the remaining balance matures on December 31, 2023 and the remaining on December 31, 2024. We recognized a loss on the amendment of the debt in the amount of $6,659,359 in connection with these amendments during the first half of fiscal 2023. There was no comparable transaction in the prior year.

Gain on Settlement of Debt

During the nine months ended February 28, 2023, our U.S. Convertible Debenture 4 in the amount $599,101 in principal and accrued interest in the amount of $3,283, went into default. We entered into a forbearance agreement with the lender, whereby we would pay the amount of $600,000 in installments beginning with a $150,000 payment on November 2, 2022 and $50,000 payments each month thereafter through August of 2023. As a result of this agreement, we recognized a gain on the settlement of debt in the amount of $2,384. There is no comparable transaction in the priorcurrent period.

Interest Expense, Net

Our interest expense was $2,024,532 for the nine months ended February 28, 2023, an increase of $608,368, or 43%, compared to $1,416,164 for the nine months ended February 28, 2022. The increase in interest expense was primarily due to the original issue discount associated with the 2021 Debentures in the amount of $555,243 which was amortized to interest expense during the nine months ended February 28, 2023 compared to $91,936 charge during the first nine months of the prior fiscal year. In addition, the increase in net interest expense for the first nine months of fiscal 2023 was also attributable to a net increase in interest expense of $156,781 in connection with the Company’s loans and convertible debentures, driven by an increase in interest expense and financing fees associated with short-term loan in the amount of $370,126. The increase in net interest expense for the first nine months of fiscal 2023 was partially offset by a decrease in the amortization of discounts on debentures in the amount of $11,720.

 

Provision for Income Taxes

 

We recorded a provision for income taxes in the amount of $1,552,028$933,564 during the ninesix months ended February 28,November 30, 2023 compared to $793,322$1,035,776 during the ninesix months ended February 28,November 30, 2022. Although we have net operating losses that we believe are available to us to offset this entire tax liability, which arises under Section 280E of the Code because we are a cannabis company, as a conservative measure, we have accrued this liability.

 

Net Loss

 

OurFor the reasons above, our net loss for the ninesix months ended February 28,November 30, 2023 was $10,567,398$1,763,913 compared to a net loss of $918,669$9,537,492 for the ninesix months ended February 28,November 30, 2022, an increasea decrease of $9,648,729$7,773,579, or 1,050%82%. The net loss amount was primarily due to the loss on extinguishment of debt in the amount of $6,659,359 and interest expense in the amount of $2,024,532.

 

Non-Controlling Interest

 

During the ninesix months ended February 28,November 30, 2023 and 2022, lossthe income (loss) associated with the non-controlling interest in Kealii Okamalu was $303,451($2,200) and $8,528,$173,060, respectively. This amount is composedcomprised of the third-party portion of the operating loss of the Quinn River Joint Venture and our loss on equity investment.

 

Net Loss Attributable to CLS Holdings USA, Inc..

 

Our net loss attributable to CLS Holdings USA, Inc. for the ninesix months ended February 28,November 30, 2023 was $10,263,947$1,766,113 compared to a net loss of $910,141$9,364,432 for the ninesix months ended February 28,November 30, 2022, an increasea decrease of $9,353,806,$7,598,319 or 1,028%81%. The

Non-GAAP Measures

EBITDA and Adjusted EBITDA are non-GAAP financial performance measures and should not be considered as alternatives to net loss amount was primarily dueincome(loss) or any other measure derived in accordance with GAAP. These non-GAAP measure have limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of our financial results as reported in accordance with GAAP. Because not all companies use identical calculations, these presentations may not be comparable to other similarly titled measures of other companies. As required by the rules of the SEC, we provide below a reconciliation of these non-GAAP financial measures contained herein to the loss on extinguishmentmost directly comparable measure under GAAP. Management believes that EBITDA provides relevant and useful information, which is widely used by analysts, investors and competitors in our industry as well as by our management. Management also believes that adjusting EBITDA for the effects of debt innon-recurring transactions may provide insight into the amountnature of $6,659,359 and interest expense in the amountcore business. By providing these non-GAAP profitability measure, management intends to provide investors with a meaningful, consistent comparison of $2,024,532.our profitability measures for the periods presented.

  

Six Months Ended

November 30, 2023

  

Six Months Ended

November 30, 2022

 

Net Loss attributable to CLS Holdings, Inc.

 $(1,766,113

)

 $(9,364,432

)

Add:

        

Interest expense, net

  868,313   1,375,575 

Provision for taxes

  933,564   1,035,776 

Depreciation and amortization

  332,748   477,193 

EBITDA (1)

 $368,512  $(6,475,888

)

Less non-recurring gains and losses:

        

Gain on settlement of accounts payable

 $(4,375

)

 $- 

Gain on settlement of debt

  -   (2,384

)

Gain on settlement of notes receivable

  -   (348,165

)

Employee retention tax credit

  (924,862

)

  - 

Loss on extinguishment of debt

  -   6,659,359 

Loss on equity investment

  -   154,111 

Adjusted EBITDA (2)

 $(560,725

)

 $(12,967

)

(1)

Net loss plus interest, taxes, depreciation, and amortization.

(2)

EBITDA adjusted for non-recurring gains, losses, and impairments.

 

Liquidity and Capital Resources

 

The following table summarizes our total current assets, liabilities and working capital at February 28,November 30, 2023 and May 31, 2022:2023:

 

 

February 28,

  

May 31,

  

November 30,

  

May 31,

 
 

2023

  

2022

  

2023

  

2023

 

Current Assets

 $6,139,399  $6,883,557  $5,404,723  $4,591,510 

Current Liabilities

 $16,266,491  $28,112,190  $19,453,205  $16,340,529 

Working Capital (Deficit)

 $(10,127,092

)

 $(21,228,633

)

 $(14,048,482

)

 $(11,749,019

)

 

At February 28,November 30, 2023, we had a working capital deficit of $10,127,092, an improvement$14,048,482, a decline in our working capital position of $11,101,541$2,299,463 compared to the working capital deficit of $21,228,633$11,749,019 we had at May 31, 2022.2023. Our working capital increaseddecreased primarily due to the restructuring of debenture agreements whereby (i) the current principalan increase in accounts payable and interestaccrued liabilities in the aggregate amount of $11,532,679 was converted$995,958 and a shift of notes payable from long term to common stock, and (ii) the principalcurrent classification in the aggregate amount of $3,753,052 was converted to long term liabilities.$577,084. Our working capital was also negatively impacted by an increase in our accrued potential tax liability in the amount of $1,552,028$933,564 as a result of the calculation of our tax liability under 280E, which can change based on the deductibility of applicable expenses and is not necessarily tied to operating income. Our potential tax liability under Section 280E was $7,686,021 at November 30, 2023, representing 40% of total current liabilities.

 

We have a 50% ownership of Kealii Okamalu which in turn has a 1/3 interest in the Quinn River Joint Venture. We recently completed the first harvest of the Quinn River Joint Venture and have been selling the products derived from that initial harvest since October of 2022. Our partner in Kealii Okamalu has not yet contributed its capital contribution and we have advanced additional amounts to cover this cash need. We received inventory with a value of $952,125 from this initial crop. As of the initial crop fromyear ended May 31, 2023, the Company’s 50% partner in Kealii Okamalu LLC had defaulted on its obligations under both the Kealii Okamalu LLC Operating Agreement and the Quinn River Joint Venture. We believe this sourceVenture Agreement by failing to make any of inventory will continue to improve our liquidity. We cannot yet estimate when, or if, our partner will make theits required capital contributions. If our partner failscontribution of $3 million. As a result of the partner’s breach, the Quinn River Joint Venture Agreement was officially terminated in July of 2023. Kealii Okamalu LLC is no longer an active operating entity. The company does not believe it is likely to make the required capital contributions we will take control and ownership of our partners interestrecover its investment in Kealii Okamalu (among other remedies)LLC and has made an impairment charge in lieuthe amount of $1,590,742 against these assets during the contributions that should have been made byyear ended May 31, 2023. There was no comparable transaction in the partner. Until these issues are resolved, we may utilize short-term financing through the 2022 Financing Agreement and our Short-Term Financing Agreement. Although we have been able to secure such financing so far, there can be no assurance that we will be able to continue to secure such financing if we continue to need it.prior period.

 

In September 2022, we successfully refinanced all but one of the U.S. Convertible Debentures and all of the Canaccord Debentures so that 60% of them were converted into equity and the balance of them mature in equal portions in December 2023 and December 2024.

 

We have recently taken significant actions to improve our liquidity and reduce our debt:

On November 30, 2023, we completed a private placement of $960,000 original principal amount of Unsecured Debentures (the “November 2023 Debentures”). The November 2023 Debentures bear interest at 15%, and are convertible to the Company’s Common Stock, par value $0.0001 per share, at the option of the Company on or before December 6, 2023, at a conversion price of $0.0345 per share. A minimum of one year of interest is required to be converted as well.

On December 6, 2023 we elected to convert the debt owed under the November 2023 Debentures. As a result of the conversion an additional 32,000,000 shares were issued to four separate parties bringing the outstanding number of issued shares of the Company to 104,543,141.

On December 28, 2023, we executed a Supplemental Indenture (the “December 28, 2023 Indenture Supplement”) to, among other things, (i) decrease the conversion price of the remaining December Debentures to $0.07 per unit; (ii) change the maturity date of the December Debentures to January 31, 2028; (iii) provide interest accruing between July 1, 2022 and December 31, 2023 to be added to the principal balance of the December Debentures; (iv) grant the debenture holders a put right (the “Put Options”) exercisable to December 29, 2023, grant each debenture holder the right to require the Company to redeem all or any part of such debenture holder’s outstanding December Debenture in cash at a redemption price equal to $600 per $1,000 principal amount of December Debentures elected to be redeemed; any accrued but unpaid interest through to and including the date of the debenture holder’s election shall not be paid and shall be cancelled; (v) granting debenture holders a put right in the event the Company’s cash available for debt service for any fiscal quarter exceeds $750,000, subject to pro ration, to require the Company to redeem all or any part of such debenture holder’s outstanding December Debentures in cash at a redemption price equal to the aggregate principal amount of the December Debentures being so redeemed, (vi) including a provision providing that the Company shall redeem on the last day of each calendar month beginning March 31, 2025 a portion of the outstanding December Debentures less the amount of interest paid on such date; and (vii) subject to the receipt of regulatory approvals, granting a security interest in certain of the Company’s assets (such as licenses, inventory (including work in process), equipment (excluding equipment subject to purchase money financing) and contract rights (excluding investments in entities other than wholly owned subsidiaries)) to the holders of the December Debentures and to other holders of the Company’s debt, now or in the future, as the Company may elect.

We expect a significant number of debenture holders to exercise the Put Options pursuant to the terms of the December 28, 2023 Indenture Supplement. As of January 3, 2024, we have received a total of $3,841,308 in principal amount of debentures that have exercised their Put Options. We obtained the November 30, 2023 loan in order to facilitate the payment of these Put Options. Additionally, we are currently in negotiations to obtain an additional $2,000,000 in loans, of which we expect $1,050,000 to be converted into equity at $0.033 per share and $950,000 of which will be in the form of a conventional debenture at 16% interest payable quarterly over 18 months. We will utilize the proceeds of the November 2023 Debentures to complete these put transactions, which will satisfy these debentures in cash at a 40% discount to principal. These transactions have not been completed as of January 3, 2024, and there can be no assurance the they will be completed at the terms which we currently anticipate, if at all.

Although our revenues are expected to grow as we expand our operations, we only achieved net income for the first time during our first quarter of fiscal 2022 and we have experienced net losses since such time. Nonetheless, asDue to our cost control efforts, we have generated positive cash flow from operating activities in the amounts of $223,618. $783,250, $788,724, and $802,729 for the three months ended November 30, 2023, May 31, 2023, February 28, 2023 and May 31, 2023, respectively. As a result of thethis improved operational performance and our debt restructuring and the competition of the first harvest of the Quinn River Joint Venture, we believe we will have funds sufficient to sustain our operations at their current level, or if we require additional cash, we expect to obtain the necessary funds as described above;through short-term financing agreements; however, our prospects must be considered in light of the risks, expenses and difficulties frequently encountered by companies in the cannabis business. To address these risks, we must, among other things, seek growth opportunities through investments and acquisitions in our industry, successfully execute our business strategy and successfully navigate the COVID-19 business environment in which we currently operate as well as any changes that may arise in the cannabis regulatory environment. We cannot assure that we will be successful in addressing such risks, and the failure to do so could have a material adverse effect on our business prospects, financial condition and results of operations.

 

Cash flows used inprovided by operating activities were $1,018,583$1,004,631 during the ninesix months ended February 28,November 30, 2023, an improvement of $1,538,795$2,825,943, or approximately 60%155%, compared to $2,557,348($1,821,312) during the ninesix months ended February 28,November 30, 2022. In deriving cash flows used in operating activities from the net losses for the first ninethree months of fiscalended November 30, 2023 and the first nine months of fiscal 2022, certain non-cash items were (deducted from)deducted from or added back to the net loss for each such period. These amounts were $7,794,895$664,765 and $(1,539,369)$7,334,224 for the ninesix months ended February 28,November 30, 2023 and 2022, respectively. For the first ninesix months of fiscal yearended November 30, 2023, the most significant item deducted fromitems added back to net income were $335,999 of amortization of debt discounts and fees, and $332,748 of depreciation and amortization. For the netsix months ended November 30, 2022, this included adding back the loss was $348,165 related toon extinguishment of debt in the amount of $6,659,359, depreciation and amortization in the amount of $477,193, the loss on equity investment of $154,111, and amortization of debt discounts and fees of $394,110; these items were partially offset by the deduction of the gain on settlement of note receivable in the IGH Settlement Note; compared to $2,218,574 during the first nine monthsamount of fiscal 2022. For the first nine months$348,165.

 

Finally, our cash used inprovided by operating activities was affected by changes in the components of working capital. The amounts of the components of working capital fluctuate for a variety of reasons, including management’s expectation of required inventory levels; the amount of accrued interest, both receivable and payable; the amount of prepaid expenses; the amount of accrued compensation and other accrued liabilities; our accounts payable and accounts receivable balances; and the capitalization of right of use assets and liabilities associated with operating leases. The overall net change in the components of working capital resulted in an increase in cash from operating activities in the amount of $1,1,753,920$2,103,779 during the ninesix months ended February 28,November 30, 2023, compared to a decreasean increase in cash from operating activities of $99,310$381,956 during the first ninesix months of fiscalended November 30, 2022. The more significant changes for the first ninesix months ended November 30, 2023 which were added back to the net loss in deriving cash generated by in operating activities were the changes in accounts payable and accrued liabilities of fiscal 2023$1,000,336, accrual for taxes in the amount of $933,564, and inventory in the amount of $371,079. These increases were as follows: inventory increased during first ninepartially offset by a reduction in the amount of $502,200 related to accounts receivable. The more significant changes for the six months of fiscal 2023ended November 30, 2022 which were added back to the net loss in deriving cash generated by $931,861, compared to an increase of $1,114,556 duringoperating activities were the first nine months of the prior fiscal year because of increased inventory levels necessary to support increased sales;deferred tax liability increasedof $1,035,776 and accounts payable and accrued expenses of $982,209, offset by $1,552,028 duringreductions related to inventory in the first nine monthsamount of fiscal 2023, compared to $793,322 during the first nine months of the prior year as we accrued potential taxes in connection with Section 280E of the tax code;$1,458,054 and accounts receivable increased by $95,718 duringin the first nine monthsamount of fiscal 2023 compared to an increase of $160,067 during the first nine months of prior fiscal year due to an increase in revenue; and operating lease liability decreased by $244,011 during the first nine months of fiscal 2023 compared to $213,827 during the first nine months of prior fiscal year as certain leases were renegotiated resulting in lower monthly amortization.$387,057.

 

Cash flows used by investing activities were $90,449$102,423 for the ninesix months ended February 28,November 30, 2023, a decreasean increase in cash used of $2,060,648,$69,155 or 105%208%, compared to cash flow provided byused in investing activities of $1,970,199$33,268 during the ninesix months ended February 28,November 30, 2022. This decreaseincrease was primarily due to payments for our investmenta decrease in proceeds from the Quinn River Joint Venturecollection of $297,149, and payments to acquire property, plant and equipment of $141,465, all of which occurred in the first nine months of fiscal 2023. The decrease was partially offset by our receipt of principal payments received on the IGH Settlement Note in the amount of $348,165 during the nine months ended February 28, 2023,a note receivable compared to our receipt of $2,218,574 during the nine months ended February 28, 2022.prior period.

 

Cash flows used by financing activities were $555,015$140,958 for the ninesix months ended February 28,November 30, 2023, an increasea decrease in the amount of $2,931,485, or 1,239%,$252,271 compared to cash flow provided by financing activities of $2,376,470$111,313 in the prior period. We received proceeds in the amount of $960,000 from the issuance of convertible notes payable during the nine months ended February 28, 2022. This increase was primarily dueperiod, compared to proceeds from loans payable in the amount of $1,717,115. This increase was offset by principal payments made on loans payable$1,717,115 in the amount $1,869,344,prior period. During the six months ended November 30, 2023, we made principal payments on notes, leases, and convertible notes payabledebt in the aggregate amount of $350,000, and principal$1,100,958 compared to $1,605,802 during the prior year period. These payments onrepresent our equipment financing lease obligations of $52,786.continued effort to reduce our debt from internal cash flow.

 

Third Party Debt and Related Party Debt

 

The table below summarizes the status of our third partythird-party debt, excluding our short termshort-term receivables-based debt facilitiesfacility and reflects whether such debt remains outstanding, has been repaid, or has been converted into or exchanged for our common stock:

 

Name of Note

 

Original

Principal Amount

 

Outstanding

 

Payment Details

 

Original

Principal Amount

 

Outstanding

 

Payment Details

U.S. Convertible Debentures 1 and 2

 

$

2,252,229

 

Outstanding

 

Half due on December 31, 2023 and half due on December 31, 2024

U.S. Convertible Debentures 1 – Related Party

 

$

1,801,783

 

Outstanding

 

Half due on December 31, 2023 and half due on December 31, 2024

 

 

 

 

 

 

U.S. Convertible Debentures 2

 

$

450,446

 

Outstanding

 

Half due on December 31, 2023 and half due on December 31, 2024

 

 

 

 

 

 

 

 

 

 

 

 

Canaccord Debentures

 

$

5,253,872

 

Outstanding

 

Half due December 31, 2023 and half due December 31, 2024

 

$

5,253,873

 

Outstanding

 

Half due December 31, 2023 and half due December 31, 2024

 

 

 

 

 

 

 

 

 

 

 

 

Debentures1,2,3,4,5 and 6*

 

$

2,500,000

 

Outstanding

 

Due July 10, 2024

Debentures 1,2,3,4,5 and 6*

 

$

2,022,916

 

Outstanding

 

Due July 10, 2024

 

 

 

 

 

 

 

 

 

 

 

 

2022 Financing Agreement

 

$

675,189

 

Outstanding

 

Due September 2023

 

$

0

 

Paid

 

Due September 2023

      

November 2023 Convertible Notes

 

$

960,000

 

Outstanding

 

Due October 2024

 

* The terms of the 6 Debentures provide for additional payments in the aggregate amount of not less than $375,000 per year beginning in 2025, for five years.

 

We have generated positive cash flow from operating activities in the amounts of $223,618, $783,250, $788,724, and $802,729 for the three months ended November 30, 2023, May 31, 2023, and February 28, 2023 and May 31, 2023. We believe that we will have sufficient capital to satisfy our obligations through the use of internally generated cash, the sale of debt and or equity, and the conversion of debt to equity, though there can be no assurance that this will be the case.

U.S. Convertible Debentures 1 and 2

Between October 22, 2018 and November 2, 2018, we entered into six subscription agreements, pursuant to which we agreed to sell, $5,857,000 in original principal amount of convertible debentures in minimum denominations of $1,000 each for an aggregate purchase price of $5,857,000.

Under the original terms, the debentures bear interest, payable quarterly, at a rate of 8% per annum, with capitalization of accrued interest on a quarterly basis for the first 18 months, by increasing the then-outstanding principal amount of the debentures. The debentures originally matured on a date that was three years following their issuance. The debentures were convertible into units at a conversion price of $3.20 per unit. Each unit consists of (i) one share of our common stock, par value $0.001 and (ii) one-half of one warrant, with each warrant exercisable for three years to purchase a share of common stock at an initial price of $1.10. The warrants also provided that we could force their exercise at any time after the bid price of our common stock exceeds $2.20 for a period of 20 consecutive business days. The debentures include a provision for the capitalization of accrued interest on a quarterly basis for the first 18 months. After capitalizing accrued interest in the aggregate amount of $738,663, the aggregate principal amount of the debentures increased to $6,595,663.

The debentures have other features, such as mandatory conversion in the event our common stock trades at a particular price over a specified period of time and required redemption in the event of a “Change in Control” of the Company. The debentures are unsecured obligations of the Company and rank pari passu in right of payment of principal and interest with all other unsecured obligations of the Company. The warrants have anti-dilution provisions that provide for an adjustment to the exercise price in the event of a future sale of our common stock at a lower price, subject to certain exceptions as set forth in the warrant.

On July 26, 2019, we entered into amendments to the debentures with four of the purchasers, pursuant to which we agreed to reduce the conversion price of the original debentures if, in general, we issue or sell common stock, or warrants or options exercisable for common stock, or any other securities convertible into common stock, in a capital raising transaction, at a consideration per share, or exercise or conversion price per share, as applicable, less than the conversion price of the original debentures in effect immediately prior to such issuance. In such case, the conversion price of the original debentures will be reduced to such issuance price. The amendments also provided that, if a dilutive issuance occurs, the warrant to be issued upon conversion will be exercisable at a price equal to 137.5% of the adjusted conversion price at the time of conversion of the debenture. If a dilutive issuance occurs, the form of warrant attached to the subscription agreement would be amended to change the Initial Exercise Price, as defined therein, to be the revised warrant exercise price.

On March 31, 2021, we amended the Canaccord Debentures. This Debenture Amendment (as hereafter defined) was a dilutive issuance. As a result, the conversion price of the convertible debentures was automatically reduced from $3.20 per unit to $1.20 per unit and the form of warrant attached to the subscription agreement will be amended to reduce the exercise price from $4.40 per share of common stock to 137.5% of the debenture conversion price (presently $1.65 per share of common stock).

On April 15, 2021 and April 19, 2021, we amended three of the purchasers’ debentures and subscription agreements in order to (i) reduce the conversion price of the debentures from $3.20 per unit to $1.20 per unit, and (ii) extend the maturity date of the debentures by one year to four (4) years from the execution date of the debentures. The subscription agreements, as amended, also provide that we will file a registration statement to register for resale all of the shares of common stock issuable to these three purchasers upon conversion of the debentures and the exercise of the warrants issuable upon conversion of such debentures. Each warrant issuable pursuant to the debentures is exercisable for one share of common stock at a price equal to 137.5% of the conversion price (presently $1.65 per share) for a period of three years from the earlier of the date of issuance of the warrant or the effectiveness of a registration statement registering the warrant shares.

On October 25, 2021, we repaid three of the debentures at maturity, which comprised $365,991 of principal and $2,065 of interest.

Effective September 15, 2022, we entered into agreements with the holders of two of the debentures to make the following changes to these debentures and the related subscription agreements: (i) to permit the mandatory conversion, in our discretion, of an aggregate of $3,378,342 in principal amount plus $56,307 in accrued interest into units at the reduced conversion price of $0.285 per unit; (ii) to decrease the conversion price of the remaining amount due under these debentures (following the mandatory conversion) to $0.40 per unit; (iii) to reduce the mandatory conversion VWAP provision in the debentures from $2.40 to $0.80; (iv) to provide for a reduced conversion price to holders of these debentures who elect to covert more than the mandatory conversion amount on or prior to September 15, 2022; (v) to change the maturity date so that half of the remaining amounts due of $2,252,229.00 mature on December 31, 2023 and the remaining amounts due mature on December 31, 2024; (vi) to provide for the payment of interest accruing between July 1, 2022 and December 31, 2024 so that one-third of the total scheduled interest is paid on December 31, 2023 and the balance of the accrued interest is paid on December 31, 2024; and (vii) subject to the receipt of regulatory approvals, to grant a security interest in certain of our assets (such as licenses, inventory (including work in process), equipment (excluding equipment subject to purchase money financing) and contract rights (excluding investments in entities other than wholly owned subsidiaries)) to the holders of these debentures and to other holders of our debt, now or in the future, as we may elect. Following execution of the amendments to these two debentures and the related subscription documents, the Company elected to affect the mandatory conversion provided for in the amended documents.

Canaccord Debentures

On December 12, 2018, we entered into an agency agreement with two Canadian agents regarding a private offering of up to $40 million of convertible debentures of the Company at an issue price of $1,000 per debenture (the “Canaccord Debentures”). The agents sold the convertible debentures on a commercially reasonable efforts private placement basis. Each debenture was convertible into units of the Company at the option of the holder at a conversion price of $3.20 per unit at any time prior to the close of business on the last business day immediately preceding the maturity date of the debentures, being the date that is three (3) years from the closing date of the offering (the “2018 Convertible Debenture Offering”). Each unit will be comprised of one share of common stock and a warrant to purchase one-half of a share of common stock. Each warrant was initially exercisable for one share of common stock at a price of $4.40 per warrant for a period of 36 months from the closing date.

We closed the 2018 Convertible Debenture Offering on December 12, 2018, issuing $12,012,000 million in 8% senior unsecured convertible debentures at the initial closing. At the closing, we paid the agents: (A)(i) a cash fee of $354,000 for advisory services provided to us in connection with the offering; (ii) a cash commission of $720,720, equivalent to 6.0% of the aggregate gross proceeds received at the closing of the offering; (B)(i) an aggregate of 46,094 units for advisory services; and (ii) a corporate finance fee equal to 93,844 units, which is the number of units equal to 2.5% of the aggregate gross proceeds received at the closing of the offering divided by the conversion price; and (C)(i) an aggregate of 110,625 advisory warrants; and (ii) 225,225 broker warrants, which was equal to 6.0% of the gross proceeds received at the closing of the offering divided by the conversion price. During the year ended May 31, 2020, principal in the amount of $25,856 was converted into 8,080 shares of common stock. The debentures include a provision for the capitalization of accrued interest on a quarterly basis for the first 18 months. Accrued interest in the amount of $1,514,006 was capitalized, and the principal amount of the debentures is $13,500,150.

The debentures are unsecured obligations of the Company, rank pari passu in right of payment of principal and interest and were issued pursuant to the terms of a debenture indenture, dated December 12, 2018, between the Company and Odyssey Trust Company as the debenture trustee. The debentures bear interest at a rate of 8% per annum from the closing date, payable on the last business day of each calendar quarter.

Beginning on the date that is four (4) months plus one (1) day following the closing date, we could force the conversion of all of the principal amount of the then outstanding debentures at the conversion price on not less than 30 days’ notice should the daily volume weighted average trading price, or VWAP, of our common stock be greater than $1.20 per share for the preceding 10 consecutive trading days.

Upon a change of control of the Company, holders of the debentures have the right to require us to repurchase their debentures at a price equal to 105% of the principal amount of the debentures then outstanding plus accrued and unpaid interest thereon. The debentures also contain standard anti-dilution provisions.

On March 31, 2021, the holders of the Canaccord Debentures approved the amendment of the indenture related to the Canaccord Debentures (the “Debenture Amendment”) to: (i) extend the maturity date of the Canaccord Debentures from December 12, 2021 to December 12, 2022; (ii) reduce the conversion price from $3.20 per unit (as such term is defined in the indenture) to $1.20 per unit; (iii) reduce the mandatory conversion VWAP threshold from $1.20 to $0.60 per share; and (iv) amend the definitions of “Warrant” and “Warrant Indenture” (as such terms are defined in the indenture), to reduce the exercise price of each warrant to $1.60 per share of our common stock. Simultaneously, we amended the warrant indenture to make conforming amendments and extend the expiration date of the warrants to March 31, 2024.

Effective September 15, 2022, we entered into agreements with the holders of the Canaccord Debentures to restructure the debentures as follows: (i) $7,931,490 in principal amount of the Canaccord Debentures plus $132,192 in accrued interest on the Canaccord Debentures were converted into units at the reduced conversion price of US$0.285 per unit; (ii) to decrease the conversion price of the remaining Canaccord Debentures (following the mandatory conversion) to $0.40 per unit; (iii) to reduce the mandatory conversion VWAP provision in the Canaccord Debentures from $2.40 to $0.80; (iv) to provide for a reduced conversion price to holders of Canaccord Debentures who elect to covert more than the mandatory conversion amount of Canaccord Debentures on or prior to the date of the meeting of debenture holders; (v) to change the maturity date so that half of the remaining amount due of $5,253,872 matures on December 31, 2023 and the remaining amounts due mature on December 31, 2024; (vi) to provide for the payment of interest accruing between July 1, 2022 and December 31, 2024 so that one-third of the total scheduled interest is paid on December 31, 2023 and the balance of the accrued interest is paid on December 31, 2024; and (vii) to grant a security interest in certain of our assets (such as licenses, inventory (including work in process), equipment (excluding equipment subject to purchase money financing) and contract rights (excluding investments in entities other than wholly owned subsidiaries)) to the holders of the Canaccord Debentures and to other holders of debt of ours now or in the future, as we may elect, provided that we are able to secure all regulatory approvals required to make such a grant. Following the meeting, we elected to affect the mandatory conversion provided for in the amendments to the Canaccord Debentures and received an additional voluntary conversion of $33,787 in principal and $563 in accrued interest of the Canaccord Debentures.

If, at the time of exercise of any warrant in accordance with the warrant indenture, there is no effective registration statement under the Securities Act covering the resale by the holder of a portion of the shares of common stock to be issued upon exercise of the warrant, or the prospectus contained therein is not available for the resale of the shares of common stock by the holder under the Securities Act by reason of a blackout or suspension of use thereof, then the warrants may be exercised, in part for that portion of the shares of common stock not registered for resale by the holder under an effective registration statement or in whole in the case of the prospectus not being available for the resale of such shares of common stock, at such time by means of a “cashless exercise” in which the holder shall be entitled to receive a number of shares of common stock equal to the quotient obtained by dividing [(A-B) (X)] by (A), where: A = the last volume weighted average price, or VWAP, for the trading day immediately preceding the time of delivery of the exercise form giving rise to the applicable “cashless exercise”; B = the exercise price of the warrant; and X = the number of shares of common stock that would be issuable upon exercise of the warrant in accordance with the terms of such warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

Pursuant to the agency agreement, we granted the agents an option to increase the offering by an additional $6 million in principal amount of debentures, which option was not exercised by the agents prior to the closing date of the offering.

Pursuant to the agency agreement and the subscription agreements signed by investors in the offering, we granted certain registration rights to the holders of the debentures pursuant to which we agreed to prepare and file a registration statement with the SEC to register the resale by the original purchasers of the debentures of the shares of common stock issuable upon conversion of the debentures or exercise of the warrants.

Debentures 1,2,3,4,5 and 6

During November 2021, we commenced an offering of a maximum of $5,500,000 of 2021 Debentures and warrants to purchase shares of our common stock at an exercise price of $1.65 per share in an aggregate amount equal to one-half of the aggregate purchase price for the 2021 Debentures The proceeds of the November 2021 Debenture Offering were used to fund our investment in the Quinn River Joint Venture.

On March 9, 2022, we conducted the final closing of the November 2021 Debenture Offering. Between December 1, 2021 and January 4, 2022, we completed multiple closings of the November 2021 Debenture Offering in which we sold an aggregate of $2,500,000 in 6 debentures and issued an aggregate of 757,576 Debenture Warrants to the investors. Debenture Number 1 was in the principal amount of $250,000; Debenture Number 2 was in the principal amount of $250,000; Debenture Number 3 was in the principal amount of $500,000; Debenture Number 4 was in the principal amount of $500,000; Debenture Number 5 was in the principal amount of $500,000; and Debenture Number 6 was in the principal amount of $500,000. The 6 Debentures bear interest at the rate of 15% per annum calculated on the basis of a 360-day year and mature with 50% due on dates ranging from May 31 to July 4 2023 and the remaining 50% due all on July 10, 2024. Commencing in 2025, and for a period of 5 years thereafter, all note holders of the 6 Debentures shall receive, on an annual basis, cash payments equal to the greater of (i) 15% of the principal amount of the notes they purchased, or (ii) such purchaser’s pro rata portion of 5% of the distributions we receive for the prior fiscal year pursuant to the terms of the Quinn River Joint Venture Agreement. This will result in additional payments in the aggregate amount of not less than $375,000 per year beginning in 2025, for five years, to the 6 Debenture holders.

Leaflink Financing Agreement

We maintain an accounts receivable financing agreement (the “Short Term Financing Agreement”) with LeafLink Financial whereby we can sell certain of our accounts receivable for a discount of 3%. In April 2022, the discount rate decreased to 2.5% Loans under the facility cannot exceed an aggregate of $1,500,000 and are payable within 30 days.

2022 Financing Agreement CBR

Effective September 30, 2022, we entered into a Business Loan and Security Agreement with CBR Capital LLC to borrow $900,000. The loan is repayable in 48 weekly installments in the amount of $13,312.50 for weeks 1-8 and $29,287.50 for weeks 9-48. CBR Capital LLC has stated that it is aware of the Canaccord Debentures and the U.S. Convertible Debentures and has agreed to subordinate the CBR security interest to these debenture holders. During the nine months ended February 28, 2023, the Company received cash proceeds in the amount of $873,000 from the loan agreement and made payments in the amount of $457,950.

2022 Financing Agreement TVT

Effective October 21, 2022, we entered into an Agreement for the Purchase and Sale of Future Receipts with TVT Business Funding LLC to borrow $200,000. The loan is prepayable in future receipts until the amount of $284,000 has been repaid. During the nine months ended February 28, 2023, the Company received cash proceeds in the amount of $194,000 from the loan agreement and made payments in the amount of $106,500.

Sales of Equity

The Canaccord Special Warrant Offering

On June 20, 2018, we executed an agency agreement with Canaccord Genuity Corp. and closed on a private offering of our Special Warrants for aggregate gross proceeds of CD$13,037,859 (USD$9,785,978). In connection therewith, we also entered into a Special Warrant Indenture and a Warrant Indenture with Odyssey Trust Company, as special warrant agent and warrant agent.

Pursuant to the offering, we issued 7,243,014 special warrants at a price of CD$1.80 (USD$1.36) per Special Warrant. Each Special Warrant was automatically exercised, for no additional consideration, into Units on November 30, 2018.

Each Unit consisted of one Unit Share and one warrant to purchase one share of common stock. Each warrant was to be exercisable at a price of CD$2.60 for three years after our common stock was listed on a recognized Canadian stock exchange, subject to adjustment in certain events. The warrants expired on January 7, 2022. Because we did not receive a receipt from the applicable Canadian securities authorities for the qualifying prospectus by August 20, 2018, each Special Warrant entitled the holder to receive 1.1 Units (instead of one (1) Unit); provided, however, that any fractional entitlement to penalty units was rounded down to the nearest whole penalty unit.

In connection with the Special Warrant Offering, we paid a cash commission and other fees equal to CD$1,413,267 (USD$1,060,773), a corporate finance fee equal to 362,163 Special Warrants with a fair value of USD$1,413,300, and 579,461 Broker Warrants. Each Broker Warrant entitles the holder thereof to acquire one unit at a price of CD$1.80 per unit for a period of 36 months from the date that our common stock is listed on a recognized Canadian stock exchange, subject to adjustment in certain events. Our common stock commenced trading on the Canadian Stock Exchange on January 7, 2019. During the year ended May 31, 2020, we also issued investors 760,542 Special Warrants with a fair value of $7,142,550 as a penalty for failure to timely effect a Canadian prospectus with regard to the securities underlying the Special Warrants.

The Navy Capital Investors

Effective July 31, 2018, we entered into a subscription agreement with Navy Capital Green International, Ltd., a British Virgin Islands limited company (“Navy Capital”), pursuant to which we agreed to sell to Navy Capital, for a purchase price of $3,000,000, 1,875,000 units ($1.60 per unit), representing (i) 1,875,000 shares of our common stock, and (ii) three-year warrants to purchase an aggregate of 1,875,000 shares of our common stock (the “Navy Warrant Shares”) at an exercise price of $2.40 per share of common stock (the “Navy Capital Offering”). We valued the warrants using the Black-Scholes valuation model, and allocated gross proceeds in the amount of $1,913,992 to the common stock and $1,086,008 to the warrants. The closing occurred on August 6, 2018. In the subscription agreement, we also agreed to file, on or before November 1, 2018, a registration statement with the SEC registering the shares of common stock and Navy Warrant Shares issued to Navy Capital. If we failed to file the registration statement on or before that date, we were required to issue to Navy Capital an additional number of units equal to ten percent (10%) of the units originally subscribed for by Navy Capital (which would include additional warrants at the original exercise price). On August 29, 2019, we filed a registration statement with the SEC which included the shares of common stock and Navy Warrant Shares issued to Navy Capital. The warrant was exercisable from time to time, in whole or in part for three years. The warrant had anti-dilution provisions that provided for an adjustment to the exercise price in the event of a future issuance or sale of common stock at a lower price, subject to certain exceptions as set forth in the warrant. The warrant also provided that it is callable at any time after the bid price of our common stock exceeds 120% of the exercise price of the warrant for a period of 20 consecutive business days. This warrant expired on July 31, 2021.

Between August 8, 2018 and August 10, 2018, we entered into five subscription agreements, pursuant to which we sold, for an aggregate purchase price of $2,750,000, 1,718,750 units ($1.60 per unit), representing (i) 1,718,750 shares of our common stock, and (ii) three-year warrants to purchase an aggregate of 1,718,750 shares of our common stock at an exercise price of $2.40 per share of common stock. We valued the warrants using the Black-Scholes valuation model, and allocated gross proceeds in the amount of $1,670,650 to the common stock and $1,079,350 to the warrants. These warrants expired on August 7, 2021. The balance of the terms set forth in the subscription agreements are the same as the terms in the Navy Capital subscription agreement summarized above.

Oasis Cannabis Transaction

On December 4, 2017, we entered into the Acquisition Agreement, with Alternative Solutions for us to acquire all of the outstanding equity interests in Alternative Solutions and the Oasis LLCs. Pursuant to the Acquisition Agreement, we paid a non-refundable deposit of $250,000 upon signing, which was followed by an additional payment of $1,800,000 approximately 45 days thereafter and were to receive, upon receipt of applicable regulatory approvals, an initial 10% of each of the Oasis LLCs. Regulatory approvals were received and the 10% membership interests were transferred to us.

On June 27, 2018, we closed on the purchase of the remaining 90% of the membership interests in Alternative Solutions and the Oasis LLCs from the owners thereof (excluding Alternative Solutions). The closing consideration was as follows: $5,995,543 in cash, a $4.0 million promissory note due in December 2019, known as the Oasis Note, and $6,000,000 in shares of our common stock. The cash payment of $5,995,543 was less than the $6,200,000 payment originally contemplated because the Company assumed an additional $204,457 of liabilities.

The number of shares to be issued was computed as follows: $6,000,000 divided by the lower of $1.00 or the conversion price to receive one share of our common stock in our first equity offering of a certain minimum size that commenced in 2018, multiplied by 80%. This price was determined to be $0.272 per share. The Oasis Note was secured by a first priority security interest over our membership interests in Alternative Solutions and the Oasis LLCs, and by the assets of each of the Oasis LLCs and Alternative Solutions. We also delivered a confession of judgment to a representative of the former owners of Alternative Solutions and the Oasis LLCs (other than Alternative Solutions) that would generally become effective upon an event of default under the Oasis Note or failure to pay certain other amounts when due. We repaid the Oasis Note in full in December 2019.

At the time of closing of the Acquisition Agreement, Alternative Solutions owed certain amounts to a consultant known as 4Front Advisors, which amount was in dispute. In August 2019, we made a payment to this company to settle this dispute and the Oasis Note was reduced accordingly.

The former owners of Alternative Solutions and the Oasis LLCs (other than Alternative Solutions) became entitled to a $1,000,000 payment from us because the Oasis LLC maintained an average revenue of $20,000 per day during the 2019 calendar year. We made a payment in the amount of $850,000 to the sellers on May 27, 2020. We deposited the balance due to sellers of $150,000 with an escrow agent to hold pending the outcome of a tax audit. During the year ended May 31, 2020, the State of Nevada notified the Oasis LLCs that it would be conducting a tax audit for periods both before and after the closing of the sale to CLS. In February 2021, we finalized the tax audit, used approximately $43,000 of the escrowed amount to reimburse ourselves for the portion of the tax liability properly payable by the sellers, and returned approximately $107,000 of the escrowed amount to the sellers.

We received final regulatory approval to own the membership interests in the Oasis LLCs on December 12, 2018. We received final regulatory approval to own our interest in the Oasis LLCs through Alternative Solutions under the revised structure of the transaction on April 26, 2022.

Consulting Agreements

We periodically use the services of outside investor relations consultants. During the year ended May 31, 2016, pursuant to a consulting agreement, we agreed to issue 2,500 shares of common stock per month, valued at $11,600 per month, to a consultant in exchange for investor relations consulting services. The consulting agreement was terminated during the first month of its term. The parties are in discussions regarding whether any shares of our common stock have been earned and it is uncertain whether any shares will be issued. As of February 28, 2023, we included 5,000 shares of common stock, valued at $23,200 in stock payable on the accompanying balance sheets. The shares were valued based on the closing market price on the grant date.

On December 29, 2015, pursuant to a consulting agreement, we agreed to issue 6,250 shares of common stock per month, valued at $21,250, to a consultant in exchange for investor relations consulting services. The consulting agreement was terminated during the first month of its term. The parties are in discussions regarding whether any shares of our common stock have been earned and it is uncertain whether any shares will be issued. As of February 28, 2023, we had 12,500 shares of common stock, valued at $42,500 included in stock payable on the accompanying balance sheet. The shares were valued based on the closing market price on the grant date.

 

Going Concern

 

Our financial statements were prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. With the exception of the first quarter of fiscal 2022, we have incurred losses from operations since inception, and have an accumulated deficit of $105,343,764$110,645,559 as of February 28,November 30, 2023, compared to $95,079,817$108,879,446 as of May 31, 2022.2023. We had a working capital deficit of $10,127,092$14,048,482 as of February 28,November 30, 2023, compared to a working capital deficit of $21,228,633$11,749,019 as of May 31, 2022.2023. The report of our independent auditors for the year ended May 31, 20222023 contained a going concern qualification.

 

Our ability to continue as a going concern must be considered in light of the problems, expenses, and complications frequently encountered by early-stage companies.

 

Our ability to continue as a going concern is dependent on our ability to generate sufficient cash from operations to meet our cash needs and finance our ongoing operations. There can be no assurance that cash generated by our future operations will be adequate to meet our needs.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

Critical Accounting Estimates

 

Management uses various estimates and assumptions in preparing our financial statements in accordance with generally accepted accounting principles. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Accounting estimates that are the most important to the presentation of our results of operations and financial condition, and which require the greatest use of judgment by management, are designated as our critical accounting estimates. We have the following critical accounting estimates:

 

Estimates and assumptions regarding the deductibility of expenses for purposes of Section 280E of the Internal Revenue Code: Management evaluates the expenses of its manufacturing and retail operations and makes certain judgments regarding the deductibility of various expenses under Section 280E of the Internal Revenue Code based on its interpretation of this regulation and its subjective assumptions about the categorization of these expenses.

Estimates and assumptions used in the valuation of derivative liabilities: Management utilizes a lattice model to estimate the fair value of derivative liabilities. The model includes subjective assumptions that can materially affect the fair value estimates.

Estimates and assumptions used in the valuation of intangible assets. In order to value our intangible assets, management prepares multi-year projections of revenue, costs of goods sold, gross margin, operating expenses, taxes and after tax margins relating to the operations associated with the intangible assets being valued. These projections are based on the estimates of management at the time they are prepared and include subjective assumptions regarding industry growth and other matters.

 

Recently Issued Accounting Standards

 

Accounting standards promulgated by the Financial Accounting Standards Board (the “FASB”) are subject to change. Changes in such standards may have an impact on our future financial statements. The following are a summary of recent accounting developments.

 

In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment, which simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, current U.S. GAAP requires the performance of procedures to determine the fair value at the impairment testing date of assets and liabilities (including unrecognized assets and liabilities) following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, the amendments under this ASU require the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The ASU became effective for us on January 1, 2020. The amendments in this ASU were applied on a prospective basis. During the year ended May 31, 2020, the Company recorded an impairment of goodwill in the amount of $25,185,003 pursuant to ASU No. 2017-04.

 

In May 2017, the FASB issued ASU No. 2017-09, Stock Compensation - Scope of Modification Accounting, which provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The ASU requires that an entity account for the effects of a modification unless the fair value (or calculated value or intrinsic value, if used), vesting conditions and classification (as equity or liability) of the modified award are all the same as for the original award immediately before the modification. The ASU became effective for us on January 1, 2018 and is applied to an award modified on or after the adoption date. Adoption of ASU 2017-09 did not have a material effect on the Company’s financial statements.

 

In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception.

 

These amendments do not have an accounting effect. For public business entities, the amendments in Part I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period.

 

There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows.

 

49

Item 3. Quantitative and Qualitative Disclosure about Market Risk.

 

This item is not applicable as we are currently considered a smaller reporting company.

 

Item 4. Controls and Procedures.

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit pursuant to the requirements of the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, among other things, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file under the Securities Exchange Act is accumulated and communicated to our management, including our principal executive and financial officers, as appropriate, to allow timely decisions regarding required disclosure.

 

Evaluation of Disclosure Controls and Procedures

 

Andrew Glashow, our Chief Executive Officer, and Principal Financial and Accounting Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. The Company believes it now has an adequate number of trained personnel to resolve any segregation of duties deficiencies. Based on the evaluation, Mr. Glashow concluded that our disclosure controls and procedures are not effective in timely alerting him to material information relating to us that is required to be included in our periodic SEC filings and ensuring that information required to be disclosed by us in the reports we file or submit under the Act is accumulated and communicated to our management, including our Chief Financial Officer, or person performing similar functions, as appropriate to allow timely decisions regarding required disclosure, for the following reasons:that:

 

We do not have adequate segregation of duties;

 

We do not have an independent body to oversee our internal controls over financial reporting and lack segregation of duties due to our limited resources.

 

We plan to rectify these weaknesses by hiring additional accounting personnel once we have additional resources to do so.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal controls over financial reporting that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

PART II OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

None.

 

Item 1A. Risk Factors.

 

The Effects of Climate Change Could Adversely Affect the Quantity and Quality of Our Crops and the Cost and Availability of Energy to Our Dispensary Operations.

 

We are feeling the effects of climate change in terms of the temperatures in the areas where we maintain our joint venture cultivation facilities. The high temperatures are higher than in previous years and the impact of the additional heat is adversely affecting both the yield of our harvest and the quality of our crop. Rising temperatures could also cause us to reduce our growing season in the future. In addition, the effect of climate change is causing an increase in the cost of electricity to operate our dispensary operation and if temperatures remain high, could result in rationing of electricity, which could necessitate a reduction in operating hours at our dispensary.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

None.

 

Item 5. Other Information.

 

Item 6. Exhibits.

 

31.1

Certification by the Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

32.1

Certification by the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

101.INS

Inline XBRL Instance Document

 

 

101.SCH

Inline XBRL Taxonomy Extension Schema

 

 

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase

 

 

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase

 

 

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase

 

 

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase

 

 

104

Cover Page Interactive Data File (formatted as Inline XBRL)

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

CLS HOLDINGS USA, INC.

 

 

 

 

 

Date: April 10, 2023January 11, 2024

By:

/s/ Andrew Glashow

 

 

 

Andrew Glashow

President and Chief Executive Officer

 

 

 

(Principal Executive, Financial and Accounting Officer)

 

 

 

 

 

 

5246
iso4217:CAD xbrli:shares